An immunogenetic study of psoriatic arthritis by Korendowych, Eleanor
        
University of Bath
PHD








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.






for the degree of PhD 
at the University of Bath
2004
COPYRIGHT
Attention is drawn to the fact that copyright of this thesis rests with the author.
This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise 
that its copyright rests with the author and that no quotation from the thesis and no information derived from 
it may be published without the prior written consent of the author.
This thesis may be made available for consultation within the University Library and may be photocopied or 
lent to other libraries for the purposes of consultation.
UMI Number: U601600
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U601600
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 







? I j a a t hi » - c. . . . *
* !»•;£. - , A
S g o  2 0 <>*>£03
PkX).» « 9  * <■ 9 » T < ,  < -
agssstfl
CONTENTS
List of Tables 7




Publications arising from the work of this thesis 18
Conference contributions arising from the work of this thesis 20
CHAPTER 1 INTRODUCTION__________________________________________ 21
1.1 Introduction 22
1.2 PsA -  background 22
1.3 Psoriasis - background 26
1.4 Genetics of psoriasis 27
1.4.1 The PSORS1 locus 28
1.4.2 Candidate gene analysis in psoriasis 29
1.5 Immunology of psoriasis 30
1.6 Genetics of PsA 31
1.6.1 HLA studies in PsA 31
1.6.2 Candidate gene analysis in PsA 32
1.7 Environmental factors in PsA 33
1.7.1 Infection 33
1.7.2 Trauma 34
1.8 Immunology of PsA 35
1.9 Immunogenetic studies of PsA 36
1.9.1 Patient selection 36
1.9.2 The MICA gene 37
1.9.3 HLA associations of PsA 3 8
1.9.4 Anti-CCP antibodies 38
1.10 Aims 40
CHAPTER 2 MATERIALS AND METHODS_______________________________43
2.1 Materials 44




2.1.5 Buffers and Solutions 45
2.1.6 Equipment 51
2.1.7 Commercial kits 51
2.2 Patient recruitment and clinical data 52
2.2.1 Ethics approval 52
2.2.2 Recruitment of subjects 52
2.2.2.1 Controls 52
2.2.2.2 Patients with Psoriatic Arthritis (PsA) 52
2.2.2.3 Patients with Psoriasis 53
1
22.2A  Reference samples 54
2.2.3 The Psoriasis Area Severity Index 55
2.2.4 Psoriasis Nail Score 55
2.2.5 Modified Ritchie tender and swollen joint counts 55
2.2.6 Health Assessment Questionnaire 56
2.2.7 Radiology 56
2.2.8 Laboratory tests 57
2.3 Serum and DNA collection 57
2.3.1 Collection of whole blood 57
2.3.2 Extraction of serum 57
2.3.3 Extraction of DNA 57
2.3.4 Labelling and storage of the DNA samples 58
2.3.5 Quantification of DNA by spectrophotometry 58
2.3.6 Purification of DNA 59
2.4 Genetic analysis 60
2.4.1 MICA exon 5 microsatellite typing 60
2.4.1.1 PCR Conditions 60
2.4.1.2 Preparation of the gel 61
2.4.1.3 Analysis of the gel 63
2.4.2 Typing exons 2,3 and 4 of MICA 63
2.4.2.1 Background 63
2.4.2.2 Phylogenetic analysis 63
2.4.2.3 Selection of Primers 64
2.4.2.4 PCR conditions 65
2.4.2.5 Agarose Gel Electrophoresis 66
2.4.2.6 Preparation of the gel 66
2.4.2.7 Loading the gel 67
2.4.2.8 Running the gel 67
2.4.2.9 Interpretation of the gel 67
2.4.3 HLA-DRB1 ‘shared epitope’ typing 67
2.4.3.1 Primers 67
2.4.3.2 PCR conditions 68
2.4.4 HLA Class I typing 69
2.4.5 Analysis of Genetic data 69
2.4.5.1 Basic statistics 69
2.4.5.2 Haplotype analysis 70




2.6 Anti-CCP antibodies 73
2.6.1 Collection of serum 73
2.6.2 Anti-CCP ELISA 73
2.6.3 Rheumatoid Factor ELISA 74
CHAPTER 3 MICROSATELLITE POLYMORPHISM OF THE MICA GENE 83
3.1 Introduction 84
2
3.1.1 Genomic structure of MICA 84
3.1.2 Expression of MICA 85
3.1.3 The MICA receptor 86
3.1.4 Function of MICA 87
3.1.5 Structure of the MICA glycoprotein 88
3.1.6 Polymorhism of the MICA gene 89
3.1.6.1 Single nucleotide polymorphism 89
3.1.6.2 Insertion / deletion 90
3.1.6.3 Microsatellite polymorphism 91
3.1.7 Nomenclature 91
3.1.8 Frequency of the MICA alleles in control populations 92
3.1.9 Disease associations 92
3.1.10 Studies of MICA in Psoriasis and PsA 92
3.1.11 MICA in RA, AS and JIA 93




3.3.3 Reference Samples 94
3.3.4 Preparation of DNA samples 95
3.3.5 Development of a technique for distinguishing the microsatellite alleles of MICA 95
3.3.6 Optimisation of the technique 95
3.3.7 Typing for MICA microsatellite alleles 96
3.3.8 HLA typing 96
3.3.9 Statistics 97
3.4 Results 97
3.4.1 Clinical characteristics of the disease groups 97
3.4.2 Frequencies of the MICA microsatellite alleles in the patient populations 98
3.4.3 Associations of the MICA microsatellite alleles with clinical subgroups of PsA 99
3.4.4 Associations of the MICA microsatellite alleles with clinical manifestations of
PsA 99
3.4.5 Stratification for age of onset of psoriasis 99
3.4.6 Associations of the MICA microsatellite alleles with HLA-Cw6 and HLA-B27 100
3.4.7 Stratification for HLA-Cw6 100
3.4.8 Associations of the MICA microsatellite alleles with the HLA-DRB1 ‘shared 
epitope’ (SE) and HLA-Class II alleles 100
3.5 Discussion 101
CHAPTER 4 POLYMORPHISMS OF EXONS 2.3 AND 4 OF MICA__________128
4.1 Introduction 129
4.1.1 Polymorphisms of MICA 129
4.1.2 PCR-SSP for MICA typing 130
4.2 Aims of the study 131
4.3 Methods 132
4.3.1 Phylogenetic analysis 132
4.3.2 Primer Selection 132
4.3.3 PCR-SSP analysis 133
3
4.3.4 DNA for analysis 134
4.3.5 Statistical Analysis 134
4.4 Results 135
4.4.1 Phylogenetic analysis 135
4.4.2 Associations of the MICA alleles with the disease groups 136
4.4.3 MICA Phenotype frequencies 136
4.4.4 MICA Allele frequencies 137
4.4.5 Associations of the MICA alleles by phylogenetic group 138
4.4.6 Associations of the MICA alleles with clinical characteristics 138
4.4.7 Stratification for HLA-Cw6 139
4.4.8 Associations between the MICA alleles and the HLA Class II alleles 139
4.4.9 MICA Haplotypes from 10th workshop / 4AOH cell lines 139
4.4.10 MICA Haplotypes in Type I Psoriasis 140
4.5 Discussion 142
CHAPTER 5 EXPRESSION STUDIES OF MICA___________________________175
5.1 Introduction 176
5.2 Aims of the study 179
5.3 Methods 180
5.3.1 Polyclonal antibody production 180
5.3.2 Alignment of MICA amino acid sequence with other members of the EMCIF 180
5.3.3 Preparation of antibodies 181
5.3.4 Selection of patient material for immunohistochemistry 181
5.3.5 Synovium sections 181
5.3.6 Skin sections 182






5.4.2.1 Normal Skin 183
5.4.2.2 Skin from patients with Psoriasis 184
5.4.2.3 Control synovium 184
5.4.2.4 Synovium from patients with PsA 185
5.4.2.5 Synovium from patients with RA 185
5.4.2.6 Synovium from patients with non-specific synovitis 185
5.4.2.7 Control sections 185
5.5 Discussion 185
CHAPTER 6 THE ROLE OF THE HLA-DRB1 ‘SHARED EPITOPE’ ALLELES 
IN PSA_______________________________________________________________ 197
6.1 Introduction 198
6.2 Aims of the study 200
6.3 Materials and Methods 200
6.3.1 Study Population 200
6.3.2 Outcome Measures 201
4
6.3.3 HLA-DRB1 typing and HLA-DR4 subtyping 201
6.3.4 HLA-B27 and HLA-Cw6 typing 202
6.3.5 Statistical Analysis 202
6.4 Results 202
6.4.1 Associations of HLA-Cw6 with PsA and psoriasis 202
6.4.2 Associations of HLA-B27 with PsA 203
6.4.3 Associations of HLA-DRB1 alleles with PsA 203
6.4.4 Associations of HLA-DRB1 alleles with PsA subgroups 203
6.4.5 Associations of the SE alleles with demographic and clinical characteristics 204
6.4.6 Associations of the SE alleles with PsA 204
6.4.7 Associations of the SE alleles with PsA subgroups 204
6.4.8 Double dose phenomenon 205
6.4.9 SE and radiological erosions 205
6.5 Discussion 205
CHAPTER 7 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN PSA 
 216
7.1 Introduction 217
7.1.1 Anti-CCP antibodies in conditions other than RA 219
7.1.2 The specificity and sensitivity of anti-CCP antibodies 220
7.1.3 Anti-CCP antibodies are present early in disease 221
7.1.4 Anti-CCP antibodies predict erosive disease 222
7.1.5 Anti-CCP antibodies are associated with the HLA-DRB1 SE 222
7.1.6 Possible immunopathological role for anti-CCP antibodies 223
7.2 Hypothesis 226
7.3 Study design 226
7.4 Methods 226
7.4.1 Patient recruitment 226
7.4.2 Statistical analysis 226
7.4.3 Principle of the Enzyme-linked Immunosorbent assay (ELISA) 227
7.4.4 The anti-CCP ELISA 227
7.4.5 Rheumatoid Factor ELISA 227
7.4.6 HLA-DRB 1 shared epitope 228
7.4.7 HLA-Cw6 and B27 testing 228
7.5 Results 228
7.5.1 Anti-CCP antibodies in PsA, RA and controls 228
7.5.2 Rheumatoid factor and anti-CCP antibodies 228
7.5.3 Characteristics of the anti-CCP positive PsA patients 229
7.5.4 Anti-CCP antibodies and the HLA-DRB 1 shared epitope in PsA 229
7.5.5 Anti-CCP antibodies and the HLA-DRB 1 shared epitope in RA 230
7.5.6 Anti-CCP antibodies and erosive disease in PsA 230
7.5.7 Characteristics of the RF positive and RF negative patients with PsA 230
7.6 Discussion 231
CHAPTER 8 DISCUSSION_____________________________________________ 239
8.1 The challenges of researching the MHC in complex diseases 240
8.2 The challenges of studying PsA 242
5
8.3 The challenges of studying MICA as a candidate gene 244
8.4 The role of MICA in PsA 246
8.5 MICA Haplotype analysis 250
8.6 Studies of the expression of MICA 251
8.7 What are the potential functions for MICA? 253
8.8 MICA and NK cells 254
8.9 HLA associations with PsA 255
8.10 The HLA-DRB 1 shared epitope in PsA -  what does it mean? 256
8.11 Anti-CCP antibodies - are they a useful serological marker in PsA? 257
8.12 Future work 260
8.12.1 Patient material 260
8.12.2 Immunohistochemistry 260






Table 1.1. Published psoriasis susceptibility loci 41
Table 2.1. Primers used for MICA typing 75
Table 2.2. Primers used for HLA B27 and HLA Cw6 typing 76
Table 2.3. Primers used for HLA-DRB 1 typing 76
Table 2.4. Antibodies used for immunofluorescence and
Immunohistochemistry 77
Table 2.5. Laboratories contributing to the 13th IHW on psoriasis 77
Table 2.6. MICA PCR-SSP typing algorithm 78
Table 2.7. Expected product sizes following amplification with
MICA PCR-SSP typing primer pairs 79
Table 2.8. Primer mixes used for the initial HLA-DRB 1 typing 80
Table 2.9. Primer mixes used for the HLA-DRB 1 *01 subtyping 81
Table 2.10. Primer mixes used for the HLA-DRB 1 *04 subtyping 81
Table 3.1. Disease associations with MICA alleles 106-107
Table 3.2. Reference DNA panel for MICA microsatellite typing 108
Table 3.3. Demographic and clinical characteristics of the PsA and
psoriasis populations 109
Table 3.4. Phenotype frequencies of the MICA microsatellite alleles
in the different disease groups 110
Table 3.5. Allele frequencies of the MICA microsatellite alleles in the
different disease groups 111
Table 3.6. Phenotype frequencies of the MICA microsatellite alleles
in the patients with Type I psoriasis from different 
populations 112
Table 3.7. Allele frequencies of the MICA microsatellite alleles in the
patients with Type I psoriasis from different populations 113
Table 3.8. Frequencies of the MICA microsatellite alleles in different

















Frequencies of the MICA microsatellite alleles in erosive 
and non-erosive PsA 115
Associations of the MICA microsatellite alleles with 
HLA Cw6 in the PsA population 116
Associations of the MICA microsatellite alleles with 
HLA B27 in the PsA population 117
Associations of the MICA microsatellite alleles and the 
presence or absence of the HLA-DRB 1 shared epitope 118
Associations of the MICA microsatellite alleles and the 
presence of HLA-DR1 119
Associations of the MICA microsatellite alleles and the 
presence of HLA-DRB 1 *0101 119
Control population genotypes to illustrate observed and 
expected genotypes and their compliance with Hardy 
W einberg equilibrium 120
Reference DNA panel for MICA typing 147
Phenotype frequencies (%) of the MICA alleles in Type I 
Psoriasis, PsA and Controls 148
Phenotype frequencies of MICA in Type I psoriasis from 
the European countries contributing to the 13th IHW 149
MICA allele frequencies in Type I Psoriasis, Psoriatic 
Arthritis and Controls 150
MICA allele frequencies in Type I Psoriasis from the
tliEuropean countries contributing to the 13 IHW 151
The number of alleles (%) within each of the phylogenetic
groups in Type I Psoriasis, PsA and controls 152
MICA haplotypes observed in homozygous cell lines from
the 10th International Workshop cells 153-154
The MICA haplotypes present within the Belgian 13IHW













The MICA haplotypes present within the PsA population
demonstrating the haplotype frequencies and D' values 161 -162
Alignment of the amino acid sequence of the a l and 2
chains of the extended MHC Class I family showing the
position of the peptide used to make the PERB 11.1
204 and 205 antibodies . 189
Demographic and clinical characteristics of the PsA
population 210
Frequency of HLA-DRB 1 alleles in the PsA patient
population compared with controls 211
Clinical and demographic features of PsA patients with
and without the SE 212
Frequency of the SE alleles in the PsA patient population
compared with controls 213
The association of PsA subgroups with the presence of
the SE 214
The association between the presence of the SE and the
presence of radiological erosions 215
Anti-CCP antibodies and RF in the patient and control
populations 235
Characteristics of anti-CCP positive and anti-CCP
negative patients with PsA 236
Features of the anti-CCP positive patients with PsA 237





Figure 1.1 Possible location of the PSORS1 locus 42
Figure 2.1 Algorithm for MICA PCR-SSP typing 82
Figure 3.1 Synonymous and non-synonymous amino acid
substitutions in exons 2,3 and 4 of MICA and their 
positions on the receptor binding platform 121
Figure 3.2 Genescanner ‘t if  image collected by laser scanning the
polyacrylamide gel 122
Figure 3.3 Genescanner graph showing a patient who is heterozygote
for the MICA A4 and A5.1 alleles 123
Figure 3.4 Genescanner graph showing a patient who is heterozygote
for the MICA A4 and A6 alleles 123
Figure 3.5 Genescanner graph showing a patient who is heterozygote
for the MICA A5 and A5.1 alleles 124
Figure 3.6 Genescanner graph showing a patient who is heterozygote
for the MICA A5 and A6 alleles 124
Figure 3.7 Genescanner graph showing a patient who is heterozygote
for the MICA A5.1 and A9 alleles 125
Figure 3.8 Genescanner graph showing a patient who is heterozygote
for the MICA A6 and A9 alleles 125
Figure 3.9 Genescanner graph showing 2 patients who are heterozygote
for MICA A4/A6 and A5/A6 alleles 126
Figure 3.10 Genescanner graph showing 2 patients who are heterozygote
for MICA A4/A5.1 and A4/A6 alleles 126
Figure 3.11 Genescanner graph showing 2 patients who are heterozygote
for MICA A4/A5.1 and A5.1 /A9 alleles 127
Figure 3.12 Genescanner graph showing 2 patients who are both
heterozygote for MICA A5.1 and A6 alleles 127
10
Figure 4.1 Polymorphic positions of the nucleotide sequence of
MICA alleles in numerical order 163
Figure 4.2a Phylogenetic tree of the MICA alleles based on the
nucleotide sequence of exons 2,3 and 4 using the 
programme MEGA 164
Figure 4.2b Polymorphic positions of the nucleotide sequence of
MICA alleles in phylogenetic order 165
Figure 4.3 Phylogenetic tree of the MICA alleles and polymorphic
positions of exons 2,3,4 and 5 166
Figure 4.4 Amino acid substitutions at the polymorphic positions
in the MICA alleles arranged in phylogenetic order 167
Figure 4.5 Agarose gel electrophoresis of two primer pairs within
PCR-SSP Group 1 168
Figure 4.6 Agarose gel electrophoresis of two primer pairs within
PCR-SSP Group 4 169
Figure 4.7 MICA A4 allele haplotypes in Type I psoriasis 170
Figure 4.8 MICA A5 allele haplotypes in Type I psoriasis 171
Figure 4.9 MICA A5.1 allele haplotypes in Type I psoriasis 172
Figure 4.10 MICA A6 allele haplotypes in Type I psoriasis 173
Figure 4.11 MICA A9 allele haplotypes in Type I psoriasis 174
Figure 5.1 Immunofluorescence of normal skin with PERB 11.1 204 190
Figure 5.2 Immunofluorescence of a normal hair follicle with
PERB 11.1 204 190
Figure 5.3 Immunofluorescence of normal skin with PERB 11.1 204 191
Figure 5.4 Immunofluorescence of normal skin with antibodies to
HLA Class I 191
Figure 5.5 Immunohistochemistry of normal skin with PERB 11.1 204 192
Figure 5.6 Immunohistochemistry of normal skin with monoclonal
antibodies to MICA 192
Figure 5.7 Immunohistochemistry of psoriatic skin with PERB 11.1
204 (low power) 193
11
Figure 5.8 Immunohistochemistry of psoriatic skin with PERB 11.1
204 (high power) 193
Figure 5.9 Immunohistochemistry of psoriatic skin with monoclonal
antibodies to MICA 193
Figure 5.10 Immunohistochemistry of normal synovium with
PERB 11.1 204 194
Figure 5.11 Immunohistochemistry of normal synovium with
monoclonal antibodies to MICA 194
Figure 5.12 Immunohistochemistry of RA synovium with
PERB 11.1 204 195
Figure 5.13 Immunohistochemistry of PsA synovium with
PERB 11.1 204 195
Figure 5.14 Immunohistochemistry tissue control 196
Figure 5.15 Immunohistochemistry antibody control 196
12
Summary
Psoriatic arthritis (PsA) is a complex inflammatory arthritis that affects approximately 
15% of patients with psoriasis. The aetiology of PsA is poorly understood but there is 
good evidence from family studies to suggest a strong genetic component. The strongest 
association is with the MHC region on Chromosome 6 where there are a number of 
potential candidate genes. One such gene is the MHC Class I Chain related gene, MICA. 
MICA is a strong candidate gene for both psoriasis and PsA due to its position, function, 
high degree of polymorphism and expression in the target tissues. It is a stress-inducible 
molecule which activates the NKG2D receptor on natural killer (NK) and T cells, cells 
which are known to be important in both psoriasis and PsA.
Patients with PsA and psoriasis were recruited to study the associations of polymorphisms 
of MICA. Alleles of MICA which carry 9 ‘GCT’ repeats in exon 5 (A9) were significantly 
associated with both PsA (pcon^ O.OOOS, OR 2.4) and psoriasis (pcon^ O-OOOS, OR 2.5). 
Further analysis of the extensive polymorphism within exons 2,3 and 4 of MICA revealed 
a strong association between the MICA *002 allele and PsA (pcon^O.OS, OR 2.3) and the 
MICA *017 allele and psoriasis (pCorr<0.0015, OR 5.01). Immunohistochemistry with 
antibodies to MICA demonstrated upregulated expression of MICA in inflamed synovium 
and downregulated expression of MICA in psoriatic skin.
Further studies were performed to investigate whether there was any association between 
PsA and the HLA-DRB 1 ‘shared epitope’ (SE) that is so strongly associated with 
rheumatoid arthritis. This revealed no overall association but the SE was more common in 
patients who developed erosive disease (pcon^O.OS, OR 2.11). In addition, a study was 
performed to examine the prevalence of anti-cyclic citrullinated peptide antibodies in PsA. 
Although anti-CCP antibodies were not significantly increased in PsA, their presence was 
associated with markers of disease severity.
In summary, this thesis examines the immunogenetic factors which contribute to the 
susceptibility to and severity of PsA.
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The aim of this thesis is to study the immunogenetic factors that contribute to the 
development of psoriatic arthritis (PsA). There are three main themes that will be 
explored. Firstly, the genetic and immunological features that aid the diagnosis of 
psoriatic arthritis (PsA) and distinguish it from other inflammatory arthritides such as 
rheumatoid arthritis (RA) and ankylosing spondylitis (AS) will be examined. Secondly, 
the genetic factors primarily associated with psoriasis itself will be distinguished from 
those that contribute to the development of the inflammatory arthritis. Finally, any genetic 
or immunological features that may be associated with the classification and severity of 
PsA will be explored.
1.2 PsA -  background
The association between psoriasis and arthritis was first recognised by Alibert in 1822 and 
was later described as ‘Psoriasis Arthritique’ by Bazin in 1860. However, it was not until 
the discovery of rheumatoid factor (RF) and its absence in the majority of patients with 
PsA that the condition was recognised by the Arthritis and Rheumatism Association in 
1964 (1). The original classification of PsA (2) defined five subgroups comprising 
asymmetrical oligoarthritis, symmetrical polyarthritis, predominant distal interphalangeal 
(DIP) joint disease, predominant spondyloarthopathy and arthritis mutilans. This 
classification has since been challenged and modifications of the criteria have been 
proposed (3-6). Long term follow-up studies suggest that at least two major groups exist - 
those with predominant peripheral joint disease and those with predominant axial disease 
(7). The precise definition and classification of PsA remains controversial and 
internationally agreed diagnostic criteria have yet to be developed and applied.
Psoriasis itself is a common inflammatory hyperproliferative skin disease which affects 
approximately 2% of the Caucasian population (8). It has been classified into two major 
categories : Type I (early onset of disease before 40 years of age) and Type II (late onset 
of disease after 40 years of age). The former has been shown to have the strongest genetic
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predisposition, whereas late onset disease is thought to be predominantly sporadic (9). The 
prevalence of PsA is somewhat harder to ascertain as it depends on the population studied 
and the techniques used for its diagnosis. The prevalence of inflammatory arthritis in 
patients with psoriasis has been shown to vary between 5% and 42% (10). Therefore the 
overall prevalence of PsA may approach that of rheumatoid arthritis (RA) and ankylosing 
spondylitis (AS).
An additional confounding factor in population studies of PsA is the variable temporal 
relationship between the onset of the skin and the joint disease. In the majority of patients 
(approximately 80%), the onset of psoriasis precedes the onset of arthritis. However, in 
some 20% of patients the arthritis appears before there is any evidence of skin disease.
Clues to the correct diagnosis can sometimes be elicited if there is a positive family 
history of psoriasis or in the presence of nail disease. The diagnosis may well be suspected 
on the basis of clinical and radiological features, and indeed, such a condition has been 
coined psoriatic arthritis ‘sine psoriasis’. Interestingly, approximately 35% of patients 
exhibit clear simultaneous exacerbations of their skin and joint disease (4), whereas others 
show no such correlation. It is possible that closer analysis of such patients may reveal 
some genetic or immunological factors that are common to both the skin and the joint 
disease and others that are unique. There may also be a disparity between the severity of 
the skin disease and the severity of the arthritis. Some patients have severe psoriasis but 
never develop arthritis whilst others have a small patch of psoriasis and develop a 
disabling and deforming arthritis. However, in general terms, it is more common to 
develop arthritis if the psoriasis is severe (11).
The acceptance of PsA as a distinct disorder, rather than the fortuitous association of two 
common disorders (psoriasis and arthritis) is supported by epidemiological studies. The 
observed prevalence of PsA is much higher than the combined prevalence of psoriasis and 
inflammatory arthritis (12). The most likely explanation for this is that PsA exists as a 
distinct entity with unique clinical characteristics. An alternative explanation could be that 
psoriasis acts as a risk factor for a non-specific inflammatory arthritis or that psoriasis and 
arthritis share a common genetic or environmental trigger. Since psoriasis is a common
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condition, there will be patients with psoriasis who develop RA or AS. Separating those 
patients with true PsA from those who have psoriasis and a co-existing inflammatory 
arthritis is clearly important for diagnosis, prognosis and appropriate treatment of patients. 
It is also vital for those involved in the study of the genetic contribution to PsA to be able 
to distinguish it from other inflammatory arthritides. The lack of consensus on diagnosis 
and classification has been a key contributory factor to the relative lack of research into 
the aetiology of PsA.
Taxonomically, PsA belongs to the spondyloarthropathies. This family of conditions share 
several characteristics such as predominant axial and asymmetrical peripheral joint 
involvement, association with HLA-B27, negative RF and enthesopathy (13). Recent 
studies using magnetic resonance imaging have led to the proposal that the synovitis 
associated with PsA is secondary to entheseal inflammation (14). This could be a common 
thread with the other spondyloarthropathies and appears to be a distinguishing feature 
from RA where the synovitis is a primary event. However, the enthesis is a very avascular 
structure. It is possible therefore that the inflammation actually starts in the adjacent bone. 
Clearly, there are additional and more complex factors involved in the aetiology of PsA 
that influence the diversity of joint involvement, erosion, ankylosis and destruction.
There are certain features that help distinguish PsA from the other spondyloarthropathies 
and RA. Clinical features include involvement of the DIP joints, nail disease, asymmetry, 
the distribution of affected joints in a ‘ray’ rather than a ‘row’, enthesitis, dactylitis and 
axial disease. There are also radiological features that can aid diagnosis such as erosion 
with new bone formation, asymmetrical sacroiliitis and ‘chunky’ syndesmophytes. 
Clearly, some of the clinical and radiological features are more diagnostically helpful than 
others. A prospective study of patients in the Norfolk arthritis register suggested that 
patients who had psoriasis and early inflammatory arthritis had a similar degree of 
symmetry and metacarpophalangeal (MCP) joint involvement to those patients without 
psoriasis (15). They found a slight increase in DIP joint involvement, significant reduction 
in RF and fewer radiological erosions in the group of patients who had co-existing 
psoriasis.
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A further study suggested that the one feature that distinguished PsA from other forms of 
polyarthritis was DIP joint involvement, although this was not frequent enough to be a 
sensitive diagnostic marker (16). Population studies suggest a different demographic 
profile for patients with PsA, RA and AS. Firstly, there is an equal sex incidence in PsA in 
contrast to RA which is significantly more common in females and AS which is more 
common in men. The peak incidence of PsA is in the 5th and 6th decades of life as opposed 
to RA which increases in frequency with age and AS which rarely presents after the 5th 
decade.
With regards to pathogenesis, several studies of synovial fluid cytokine profiles suggest 
that any differences between PsA and RA are largely quantitative rather than qualitative 
(17; 18). For example, levels of tumour necrosis factor alpha (TNFa) are highest in the 
synovial fluid of late RA, followed by early RA, then late PsA and finally early PsA 
which has the lowest levels. This might reflect differences in the intensity of the 
inflammatory response rather than any distinct pathogenetic mechanisms. However, others 
have demonstrated some differences in cytokine and growth factor profiles on synovial 
biopsies of patients with PsA and RA (19). For example, interleukin 10 (IL-10) is reduced 
in the synovial fluid of patients with late PsA compared with RA and osteoarthritis (OA) 
where the levels of IL-10 are increased (20).
There is also some evidence that psoriatic arthritis synovium exhibits distinct vascular 
patterns with more blood vessels and an increased tortuosity compared with RA (21). The 
lining layer of the joint is not as hyperplastic in PsA as it is in RA. Studies of angiogenesis 
factors have shown that levels of vascular endothelial growth factor (VEGF) and the 
angiogenesis factors 1 and 2 are increased in the synovial membrane and skin of patients 
with PsA and psoriasis (22). The differential expression of these angiogenesis factors may 
explain some of the differences in vascular pattern observed in PsA.
In PsA, there tend to be fewer macrophages compared with RA but equal numbers of 
lymphocytes staining for CD3, CD4 and CD 8. However, patients with RA have twice as 
many CD4 positive T cells in the peripheral blood as patients with PsA. There is also 
evidence that the CD4:CD8 ratio is reversed in PsA compared with RA (23) (24). The
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ratio of CD4:CD8 is 0.7 : 1 in PsA but 1.1 : 1 in RA. Most of the CD8 positive T cells in 
PsA carry DR4 and CD45RO suggesting that they are activated and mature. Thus CD8 
positive T cells may be the main effector T cell in PsA leading to the release of cytokines, 
upregulation of adhesion molecules, recruitment of further inflammatory cells and 
perpetuation of the inflammatory response. The role for natural killer (NK) cells in PsA as 
well as the immunological differences between PsA and psoriasis will be discussed later in 
the chapter.
Genetic studies of PsA are confounded by diagnostic and classification difficulties both 
within the disease itself and in relation to the other inflammatory arthritides. 
Misclassification of clinical phenotypes, incomplete penetrance, variable expression and 
genetic heterogeneity are likely to complicate the detection of a gene(s) for PsA. 
Interestingly, there appears to be differential expression of PsA according to the sex of the 
disease-transmitting parent, with excessive paternal transmission (25). Another key issue 
is whether any genetic susceptibility to PsA is beyond that which predisposes to psoriasis 
itself. Relatively few genetic studies of PsA contain an adequate control group of patients 
who have psoriasis but no arthritis. The presence of occult arthritis in patients with 
psoriasis is well described and failure to account for this will weaken any apparent genetic 
association. Conversely, almost without exception, genetic studies of psoriasis ignore the 
possibility of co-existent arthritis. Failure to recognise the different phenotypes within 
psoriasis will certainly limit the interpretation of such genetic studies.
1.3 Psoriasis - background
Psoriasis is a chronic inflammatory hyperproliferative skin disease that affects 
approximately 2% of the Caucasian population. It is rarely fatal but leads to significant 
physical impairment and psychological distress. It is a complex disease in terms of its 
aetiology and phenotypic spectrum. The most common phenotype is plaque psoriasis but 
there is a spectrum of presentations, including pustular psoriasis and erythroderma. A 
proportion of patients will also develop psoriasis of the nails with nail pitting, ridging and 
onycholysis. Involvement of the nails is often associated with an accompanying arthritis, 
particularly in the DIP joints. Susceptibility to psoriasis, like PsA, is likely to involve
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environmental triggers and a particular genetic and immunological background. Some of 
these will be common to both psoriasis and PsA, whilst others will be unique to each 
condition.
1.4 Genetics of psoriasis
A significant genetic contribution to psoriasis is supported by familial clustering of 
disease and increased concordance rates in monozygotic twins. There are numerous 
reports of disease association with the HLA-Cw6 antigen, particularly with early onset 
(Type I) psoriasis. However, the percentage of patients with psoriasis who are HLA-Cw6 
positive is relatively low, depending on the population studied. The prevalence is 
approximately 45% in Caucasians but only 10% in the Japanese population (26) (27) (28). 
In addition, psoriasis only appears to run in families approximately one third of the time. 
Psoriasis does not follow simple patterns of dominant or recessive inheritance implying 
that several genes at several different loci are required for the disease to develop. It is 
likely that these genes will affect susceptibility to psoriasis, severity of the disease and the 
variety of its many clinical manifestations. Some of these genes will be unique to psoriasis 
whilst others will be common to other inflammatory skin diseases perhaps via more 
generalised regulation of the immune response.
Twin studies offer some of the most compelling evidence for a strong genetic component 
to psoriasis. Concordance rates are three times greater in monozygotic than dizygotic 
twins, although these levels differ according to the population studied (29-31). These 
studies can be used to calculate the heritability of the condition (the proportion of 
variability of a trait that is due to genetic factors). Estimates of the heritability of psoriasis 
range from 60-90%, placing it amongst the highest of the multifactorial genetic disorders
(32). Family studies offer further support for the genetic contribution to psoriasis. The risk 
ratio (prevalence of disease in a given relative divided by the prevalence of disease in the 
general population) for first degree relatives of a patient with Type I psoriasis is 
approximately 10 (8). This would certainly make psoriasis amenable to genetic linkage 
studies.
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Several candidate loci for psoriasis have been identified using genetic linkage. The major 
susceptibility locus appears to be within the MHC on Chromosome 6 and has been termed 
‘PSORS1’. An increasing number of other loci outside the MHC have been suggested as 
additional contributors to the development of disease {Table 1.1.). Some of these 
susceptibility loci may not be disease specific. For example, there is some overlap with the 
susceptibility regions defined for atopic dermatitis and psoriasis (PSORS2, PSORS4, 
PSORS5 and chromosome 20p) suggesting a common pathway for the development of 
inflammatory skin disorders. Most work has concentrated on the association with the 
MHC in an attempt to further refine the PSORS1 region and identify the major psoriasis 
gene.
1.4.1 The PSORS1 locus
The association between psoriasis and the MHC has been recognised for over 30 years
(33). This association is stronger with Type I psoriasis than Type II psoriasis (8). Case 
control studies have shown the strongest associations are with haplotypes containing 
HLA-Cw6 (ancestral haplotypes AH13.1, AH57.1 and AH37.1) (32). In northern Europe 
and the United States, approximately two thirds of patients with psoriasis carry HLA-Cw6
(34). This is much lower in other populations in particular Oriental populations where 
HLA-Cw7 plays a more prominent role.
A number of independent groups have presented robust data linking psoriasis to the MHC 
region with the use of whole genome scans (a technique using a collection of polymorphic 
markers distributed evenly throughout the genome to test for genetic linkage with a 
particular trait) {Table 1.1). Linkage was detected with HLA-C with a lod score of nearly 
10 (35). A lod score is a measure of genetic linkage that refers to the logarithm of the odds 
ratio. The odds ratio is defined as the likelihood of encountering the observed outcome if 
the marker and disease are linked, divided by the likelihood of the same outcome if the 
marker and disease are unlinked. Linkage between HLA-C and psoriasis does not mean 
that HLA-Cw6 is PSORS1. There is no clear direct pathological role for HLA-Cw6 in 
psoriasis. The MHC region is nearly 3.5 million base pairs long and contains over 200 
genes including several strong functional candidate genes in close proximity to HLA-C. In
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addition, not all HLA-Cw6 bearing haplotypes confer equal risk for psoriasis suggesting 
that HLA-Cw6 itself is not the psoriasis gene (35).
Further definition of the PSORS1 locus was achieved following the analysis of extended 
or ancestral haplotypes. Founder population haplotypes will recombine through successive 
generations (36). Analysis of the minimal conserved haplotype that segregates with 
disease can help determine the segment of the MHC region that is likely to carry the ‘risk 
allele’. Two major studies (35; 37) have demonstrated that the strongest link with psoriasis 
is with the 57.1 ancestral haplotype (Cw6-B57-DR7-DQ3). This is consistent with 
serological studies that have demonstrated associations with individual components of this 
haplotype (32).
The PSORS1 region has been further refined using linkage disequilibrium (LD) fine 
mapping (38). Three independent studies (39-41) used distinct statistical approaches 
leading to differing conclusions as to the location and extent of the PSORS1 region 
(Figure 1.1). It should be noted that these studies involved different ethnic populations 
from northern Europe, USA and Japan. This may account for some of the differences in 
the localisation of PSORS1. Psoriasis does seem to be associated with different haplotypes 
in the Japanese, where those containing HLA-Cw7 predominate. It has been postulated, 
however, that a more lenient interpretation of the data may result in a 150kb region for 
PSORS1 that is common to all ethnic groups (42).
1.4.2 Candidate gene analysis in psoriasis
A number of candidate genes that lie within or close to the PSORS1 region have been 
investigated. HLA-Cw*0602 is an obvious candidate that has been consistently shown to 
be the most significant marker for psoriasis (39; 43; 44). However, the variable disease 
risks conferred by the differing haplotypes bearing HLA-Cw6 together with the lack of a 
clear functional role and its apparent location outside the PSORS1 region make it a less 
attractive candidate gene. Other candidates that have been proposed include 
comeodesmosin (CDSN) (43-46), HCR (47-49), MICA (50-52), OTF3 (53) and TCF19 
(54). Several of these candidates have , shown significant associations with psoriasis, but
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the presence of these alleles along the same disease associated haplotype hampers the 
ability to dissect out which gene is primarily responsible. Clearly, it is possible that 
several genes along a disease-associated haplotype contribute to the development of 
psoriasis and need not, therefore, be mutually exclusive. Some of the candidate genes have 
a more plausible functional role in psoriasis than others. This, together with expression 
and functional studies of the gene products in the skin, may help delineate which genes are 
the most important for future study.
1.5 Immunology of psoriasis
Psoriasis is associated with keratinocyte hyperproliferation and a dermal and epidermal 
infiltration of activated T lymphocytes (9). At the cellular level, psoriasis is characterised 
by epidermal proliferation and abnormal differentiation, dilatation and elongation of 
capillaries and a mixed inflammatory cell infiltrate.
In addition to T cells, NK cells are also present in psoriatic plaques although their exact 
role in the pathogenesis of the condition remains unclear. It would appear that certain 
phenotypes of NK and NK-T cells are present in psoriasis more often than others. One 
study has demonstrated increased numbers of CD 16, CD57, CD94 and CD 158 NK cell 
markers as well as CD 161 (found predominantly on NK-T cells) in psoriatic plaques 
compared with adjacent normal skin (55). Reduced numbers of circulating NK cells 
(CD 16+, CD56+, CD94+, CD 158+) have been reported in the peripheral blood of patients 
with psoriasis compared with controls (56). Reduced numbers of NK-T cells (CD3+, 
CD56+) have also been described in association with psoriasis (57). The number of these 
cells does rise following specific anti-psoriatic therapies, but it never reaches a level seen 
in the control population, suggesting some intrinsic deficiency in the patients who develop 
psoriasis. This suggests a possible role for NK cells in the immunopathology of psoriasis.
One of the key cytokines in psoriasis appears to be IL-18. It plays an important role in the 
TH1 response primarily via its ability to induce interferon-gamma production in T cells 
and NK cells. IL-18 is produced by keratinocytes as well as monocytes and macrophages, 
therefore local production in the skin may enhance the cutaneous immune response.
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Immunohistochemical analysis has demonstrated enhanced expression of IL-18 in lesional 
psoriatic skin (58). In addition, levels of IL-18 in the plasma of patients with psoriasis 
correlates with the severity of their psoriasis as judged by the psoriasis area severity index 
(PASI) (59).
1.6 Genetics of PsA
Unfortunately, there is no data available from twin studies in PsA. However, family 
studies do show that first degree relatives have an increased risk of developing the disease. 
The original family studies of Moll and Wright suggested a much higher risk for siblings 
(h) developing PsA than psoriasis itself (2). The familial recurrence risk for PsA appears 
to be about ten times greater than for psoriasis alone or RA (60). This would certainly 
suggest that the genetic contribution to PsA is even greater than that to psoriasis alone.
1,6.1 HLA studies in PsA
Case control studies have demonstrated associations between PsA and a variety of HLA 
antigens. The strongest association has repeatedly been shown to be with HLA-Cw6 (61), 
although this association would appear to be stronger with psoriasis itself than with PsA. 
The reported associations with HLA-B13, B57 and DR7 are likely to be secondary to their 
presence on recognised ancestral haplotypes, AH 13.1 and AH 57.1, which both contain 
HLA-Cw6 (36).
Some of the HLA antigens have been linked with certain clinical manifestations of PsA. 
For example, HLA-B38 and B39 have been associated with a peripheral arthritis (62). The 
association with HLA-B27 remains controversial, with differing conclusions as to the 
strength of the link with psoriatic spondyloarthritis and sacroiliitis (63). HLA-B27 has 
also been reported in association with DIP joint disease, suggesting that the link represents 
more than simply the co-existence of AS and psoriasis (61). HLA-DR4 has been 
associated with a peripheral symmetrical polyarthritis resembling RA (28), although this 
has not been replicated by others. It is worth noting that in the studies where psoriasis
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controls were used as well as population controls, many of these HLA associations were 
much weaker with PsA than with psoriasis alone (63; 64).
One study has attempted to map the disease susceptibility locus in PsA (65). However, the 
sample size used for the study was small (n=95) and the results must therefore be 
interpreted with caution. It was suggested that the susceptibility region for Spanish 
patients with psoriasis was telomeric to HLA-C, in a region containing the microsatellite 
marker Cl_4_4, OTF3 and HCR. The region for PsA was delimited by HLA-C and the 
Cl_4_4 marker, thus providing an overlapping interval of lOOkb between HLA-C and 
OTF3 which might contain the PsA gene. Clearly more powerful studies are needed in 
order to better refine the susceptibility region for PsA.
1.6.2 Candidate gene analysis in PsA
A small number of studies have examined potential contributions to PsA from non-HLA 
genes within the MHC region, with particular emphasis on the region neighbouring HLA- 
B and HLA-C. The MHC Class I Chain related antigen A (MICA) is one such candidate 
which has been studied in two relatively small populations with PsA (66-68). The role for 
MICA in PsA will be explored in Chapters 3-5, where the associations of this fascinating 
and highly polymorphic gene within our PsA population will be presented.
Another gene which has generated a significant level of interest is the tumour necrosis 
factor (TNF) gene which lies just centromeric to MICA (20; 69-71). Associations have 
been reported between the ‘-3 08’ polymorphism and PsA, although these studies do not 
include an adequate control group with psoriasis and no arthritis. It remains unclear 
whether this association is primarily with psoriasis, or whether a separate risk is associated 
with PsA. It is equally difficult to establish whether the association is secondary to a 
stronger link with another gene along a disease-associated haplotype. This problem 
continues to confound most genetic case-control association studies within the MHC 
region due to the highly conserved nature of the genetic sequence along ancestral 
haplotypes. Several other neighbouring candidates have been examined, but none as yet 
have shown any convincing association over and above the known associations with the
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HLA antigens themselves. The majority of the studies have only examined the 
neighbouring genes in psoriasis (where no reproducible major candidate genes have been 
located). Therefore more studies will be needed to examine the MHC region in PsA.
There has been some interest in genes which lie outside the MHC region for their potential 
role in PsA. A recent study suggested an association between the CARD 15 gene on 
chromosome 16q and PsA in a Canadian population (72). This is interesting as the 
CARD 15 gene has been shown to be strongly associated with Crohns disease (73) which 
shares some features in common with the seronegative arthritides. In addition, 16q has 
been reported as one of the potential susceptibility regions for psoriasis (74). However, 
more studies are needed to confirm this association between CARD 15 and PsA as some 
studies have failed to replicate the results (75).
Another region of interest is the IL-1 gene cluster on chromosome 2q, particularly as 
expression of IL-1 is upregulated in the serum and synovium of patients with PsA (76) 
(77). Associations between polymorphisms of the IL-1 gene cluster have been made with 
RA, psoriasis, ankylosing spondylitis and ulcerative colitis (78). A recent publication has 
confirmed an association with the IL-1 alpha 889C polymorphism and PsA (78).
1.7 Environmental factors in PsA
1,7.1 Infection
The theory that infectious agents have a role in the aetiology of both psoriasis and PsA 
remains a contentious one. It is possible that certain infections may be a common 
aetological factor for both psoriasis and PsA. Alternatively, infectious agents may act to 
increase the susceptibility of patients with psoriasis to develop arthritis. There is certainly 
good evidence to support a role for streptococcal infection in guttate psoriasis. There is 
also some evidence to support a role for streptococcal infection in PsA. Antibodies to 
Group A streptococcal endotoxins have been demonstrated in the serum of 50% of 
patients with PsA, a level which is approximately double that seen in either RA or 
psoriasis (79). There may also be a role for viral infection in PsA. Circulating levels of 2-
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5 A, an adenylic acid polymer thought to be a marker of viral replication, are increased in 
PsA compared with RA and controls (80). Patients with PsA also have an increased 
frequency of Hepatitis C infection, which is double that seen in uncomplicated psoriasis 
(81).
The evidence for HIV infection is more compelling; a recent study from Zambia found 
94% of consecutive patients with PsA were HIV positive compared with 30% of the 
general population (82). This contrasts with RA which is not increased in HIV infected 
individuals. HIV infection may be directly involved in the triggering of the disease or it 
may herald the co-existence of other infectious triggers. Equally, it may alter the T cell 
balance in favour of developing PsA. It is also interesting that certain HLA haplotypes are 
known to alter the expression of HIV: the 57.1 ancestral haplotype (which has been linked 
with PsA) is associated with long term non-progression to AIDS (83; 84).
The association between the infection and the arthritis may therefore not be a direct 
trigger, but simply a reflection of a common HLA susceptibility. It is possible that certain 
haplotypes are associated with disease through differing immunological responses to 
infection. No one organism would appear to be responsible for triggering PsA. It is likely 
that a variety of infectious organisms can trigger the onset of PsA, depending on the 
environment the individual is exposed to and their particular genetic background.
2.7.2 Trauma
There have been several reports of trauma inducing PsA, leading to speculation that there 
may be a ‘deep Koebner’ phenomenon occurring within the joints which mirrors the 
superficial response known to occur in the skin with psoriasis. Trauma certainly seems to 
be a relatively common feature prior to the development of PsA compared with RA; 8-9% 
of patients with PsA report a clear acute traumatic event compared with only 1-2% of 
patients who develop RA (85; 86). It is intriguing that some of the clinical features of PsA, 
such as DIP joint involvement and plantar fasciitis, may be a response to chronic trauma. 
However, the diverse nature of the types of trauma thought to predate PsA, probably 
suggests more of a role for psychological stress than direct physical contact. This may
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well be a feature in common with psoriasis which is frequently exacerbated by 
psychological stress.
1.8 Immunology of PsA
There are some similarities between PsA and psoriasis in terms of their immunological 
basis. In histological sections, both psoriatic skin and synovium have dilated blood vessels 
and a perivascular inflammatory infiltrate consisting largely of mononuclear cells, 
predominantly CD8 and CD4 positive T cell clonal expansions (23) (24). Both diseases 
are commonly regarded as T cell mediated conditions -  the lymphocyte infiltrate is an 
early event and both conditions respond to treatment with anti-T cell therapies such as 
ciclosporin (87) and alefacept (88). Equally, the occurrence of both psoriasis and PsA after 
bone marrow transplantation from a donor who has psoriasis suggests at least some 
common immunological mechanism. However, there are important differences between 
the skin and the joint that suggest unique mechanisms are involved. Firstly, T cells derived 
from psoriatic skin injected into severe combined immunodeficient (SCID) mice can 
induce psoriasis in normal human grafted skin. However, the same T cells do not induce 
an arthritis in the SCID mice. Secondly, the cytokine profile differs between the two 
conditions: the production of THl-type cytokines, such as IL-2 and interferon-y, is 
increased in psoriatic skin but not in the synovium. Thirdly, T cell receptor oligoclonal 
patterns from paired skin and synovial samples are not the same, suggesting different roles 
for the T cells in the two compartments. Finally, T cells positive for the skin-homing 
receptor cutaneous lymphocyte antigen (CLA) accumulate in the skin but not in paired 
synovium (89).
Some of the T cells that are detected in the synovium and serum of patients with 
inflammatory arthritis possess receptors that are also found on NK cells. A cytometric 
analysis of T cell receptor subsets in RA found that the expanded population of T cells 
were CD4+CD28- and possessed CD 161, one of the receptors usually found on NK cells 
(90). A further study has demonstrated the presence of NKG2D receptors on this 
expanded CD4+CD28- T cell population in RA (91). In addition to the presence of NK 
cell receptors on T cells, NK cells themselves are expanded within inflamed joints,
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particularly those bearing CD56 (92). A further study has confirmed an increased number 
of CD56 positive NK cells in RA synovium (93). In this study, the absolute number of 
NK cells was not increased but the phenotype of cells differed between RA and healthy 
synovium, with an increase in CD56 and CD94 and a reduction of CD 158. The functional 
significance of this phenotype has yet to be confirmed. The role of NK cells in PsA has 
been less explored. There is some evidence that NK cells and NKT cells are increased in 
the synovial fluid of patients with PsA (94). Levels of the activatory NK cell receptor, 
CD69, are upregulated on NK and NKT cells in synovial fluid from patients with PsA. In 
addition, the levels of CD57, a receptor associated with apoptosis, are reduced. This 
suggests that those NK cells that are present in the PsA synovium are not only activated 
but also protected from apoptosis and therefore able to persist within the joint.
1.9 Immunogenetic studies of PsA
1.9.1 Patient selection
Psoriatic arthritis is a heterogeneous condition where patients not only exhibit a wide 
variety of different phenotypes but also have the capacity to move between subsets (95). 
Therefore accurate clinical assessment and documentation is imperative in any study 
which attempts to examine the genetic and immunological background of such patients. 
The patients with PsA who participated in the research outlined in this thesis attended a 
specialist clinic at the RNHRD in Bath, where clinical, laboratory and radiological data 
were collected prospectively on an annual basis over many years. Some patients have now 
been followed up for over 15 years. The carefully documented clinical details should 
ensure a high level of quality for subsequent genetic or immunological studies.
Many genetic studies of PsA do not contain an adequate control group of patients with 
psoriasis but no arthritis. Thus it is impossible to demonstrate which associations are truly 
with PsA and which are accounted for by the psoriasis alone. Equally, almost all studies of 
psoriasis do not control for the presence of a complicating inflammatory arthritis. In the 
search for specific genetic or immunological features of PsA, it is therefore necessary to 
examine a group of patients with a similar severity and duration of psoriasis but have not
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developed an arthritis. We have therefore recruited patients from a Dermatology clinic and 
a General Practice and screened them for the presence of arthritis with a questionnaire and 
full clinical examination. Due to the high prevalence of asymptomatic sacroiliitis in 
patients with psoriasis (96), all patients also underwent sacroiliac joint radiographs and 
any patients with sacroiliitis were excluded from the control group. The availability of 
such a control group not only allows accurate distinction from patients with PsA, but also 
provides a unique group in which to study the genetic basis of psoriasis.
1.9.2 The MICA gene
A major part of this thesis has been devoted to the study of the MHC Class I Chain related 
gene, MICA. This fascinating gene is a strong candidate gene for PsA by virtue of its 
position within the MHC, its high level of polymorphism and its putative function. It is 
expressed on a wide variety of epithelial cells and activates T and NK cells via the 
NKG2D receptor. Expression of NKG2D can be induced by TNFa and IL-15, two 
cytokines found in abundance in the inflamed synovium and serum in both RA and PsA. 
The synoviocytes in RA express MICA, which, via an interaction with the NKG2D 
receptors, were capable of stimulating the T cell cytokine and proliferative responses. 
Peripheral blood serum samples from RA patients were found to contain substantial 
amounts of synoviocyte-derived soluble MICA. This soluble MICA was unable to down- 
modulate the NKG2D receptors due to the opposing activity of TNFa and IL-15.
Therefore, a dysregulation of the MICA / NKG2D interaction may be a factor in auto­
reactive T cell stimulation and may play a role in the self-perpetuating pathology of 
inflammatory arthritis. Equivalent experiments in PsA have yet to be done but would be 
likely to exhibit very similar mechanisms. The role of polymorphisms within the 
transmembrane and extracellular segments of MICA in PsA is explored in Chapters 3 and 
4, respectively. An investigation into the expression of MICA in the skin in psoriasis and 
the synovium in PsA has been undertaken in Chapter 5.
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1.9.3 HLA associations o f PsA
The sixth chapter has been dedicated to the study of associations between the HLA 
antigens themselves and PsA. Particular emphasis has been given to the role of HLA-Cw6 
and HLA-B27 as well as the HLA Class II HLA-DRB1 antigens. The results were 
analysed for any clinical correlations, in particular any associations with disease 
phenotype and subset. An assessment was also made as to whether there were any 
associations with markers of disease severity such as the presence of erosive disease on 
radiographs. In addition, the role of a subset of HLA-DRB1 alleles bearing the ‘shared 
epitope’ (SE) was explored. This group of alleles, predominantly HLA-DRB1*0101, 
*0401 and *0404 have been strongly associated with RA (97). A study was therefore 
undertaken to investigate whether the ‘shared epitope’ alleles are associated with any 
particular subset of PsA, perhaps those resembling RA or with a more severe disease 
presentation.
1.9.4 Anti-CCP antibodies
Antibodies to cyclic citrullinated peptides (anti-CCP) have been shown to be highly 
specific for RA (98). The test is now being used in laboratories to help establish a 
diagnosis of RA in preference to RF due to its high specificity and sensitivity. The 
presence of anti-CCP antibodies in RA is associated with more severe erosive disease. In 
addition, they are a useful diagnostic test in the early arthritis setting as they can be 
present up to several years in advance of the onset of clinical symptoms.
The link between anti-CCP antibodies and the SE is intriguing and may provide some 
more insight into the precise nature of the autoantigens involved in the antibody response. 
It has been demonstrated that the SE alleles such as HLA-DR*0401 present peptides 
containing citrulline but not arginine (99). Therefore citrullination of proteins, a process 
which often results from hypoxia or other tissue damage, appears to be a crucial step in the 
generation of these antibodies and the initiation of the inflammatory response.
The prevalence and prognostic significance of anti-CCP antibodies in PsA has never been 
adequately investigated. The final chapter has therefore been dedicated to the assessment
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of the role of anti-CCP antibodies in PsA. Particular emphasis was placed on the 
associated clinical features, such as disease subset or markers of disease severity. In 
addition, the association between the presence of anti-CCP antibodies and the presence of 
the SE was examined.
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1.10 Aims
The aims of this thesis are:
• To obtain a well characterised population of patients with
-PsA
- Type I Psoriasis screened for the presence of arthritis
• To explore the role of the highly polymorphic gene MICA in PsA and Psoriasis
the role of the microsatellite polymorphism in the transmembrane region 
the role of the extracellular region polymorphism
- the expression patterns of MICA in the synovium and skin
• To examine the role of the HLA Class I and II antigens in PsA with regards to
- Disease subset and classification 
Disease severity and progression
• To investigate the prevalence and associations of the ‘shared epitope’ in PsA
• To examine the prevalence of anti-CCP antibodies in PsA
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Table LI. Published Psoriasis susceptibility loci
Locus Name Chromosomal location Sources
PSORS1 6p21.3 Trembath et al (100) 
Nair et al (39; 74)
Oka et al (40)
B alendran et al (41) 
Veal et al (101) 
Enlund et al (102) 
Samuelsson et al (103) 
Capon et al (104) 
Jenisch et al (35) 
Burden et al (34)
PSORS2 17q25 Nair et al (74) 
Samuelsson et al (103) 
Tomfohrde et al (105) 
Enlund et al (102)
PSORS3 4q Matthews et al (106)
PSORS4 lq21 Bhalerao and Bowcock (107) Capon et al (108)
PSORS5 3q Samuelsson et al (103) 
Enlund et al (109)
PSORS6 19pl3-ql3 Lee et al (110) 
Veal etal (101)
PSORS7 Ip35-p34 Veal et al (101)
unnamed 2p Veal etal (101)
Bhalereo and Bowcock (107)
unnamed 2q Trembath et al (100)
unnamed 4ql3 Bhalerao and Bowcock (107) 
Samuelsson et al (103)
unnamed 7 Veal et al (101)
1 unnamed 8q Trembath et al (100)
1 unnamed 14q Bhalerao et al (107) 
Veal et al (101)
unnamed 15 Samuelsson et al (103)
unnamed 16q Nair et al (74)
unnamed 20p Nair et al (74)
Trembath et al (100) |
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Figure 1.1 Possible location of the PSORS1 locus. Adapted from Capon et al, J Invest Derm 2002, 118:745-751




MICB MICA HLA-B HLA-C OTF3





Balendran etal, 1999 
UK, N Europe
| Published minimal intervals
Possible extensions o f  these intervals 
proposed by Capon et al
Oka et al, 1999 
Japan________











Name of reagent Supplier
Agarose Seakem, Scot Scientific, USA
Alconox Sigma, USA
Ammonium Persulfate Amresco, USA
Boric acid Sigma, USA
Bromophenol blue Sigma, USA
Copper Sulphate Sigma, USA
EDTA Sigma, USA
Ethidium Bromide Sigma, USA
Hydrogen Peroxide Sigma, USA
Sodium Chloride Sigma, USA
Sodium Citrate Sigma, USA
Sodium Hydroxide Sigma, USA
Sucrose Boehringer Mannheim, USA
Tris base Sigma, USA
Trizma Base Sigma, USA
2.1.2 Enzymes
Taq DNA Polymerase 250units (5.5U/pl) Fisher Biotec, Australia
2.1.3 Primers
All primers were supplied by Geneworks, Australia or ABgene, UK. Each primer was 
supplied as a dry powder containing a given amount in nmol. This was diluted with double 
distilled water (ddH20) to give a stock concentration of 250pmol/pl. A working dilution 
of 25pmol/pl was made by diluting the stock 1:10 with ddH^O. The primers used for the 
MICA typing are listed in Table 2.1. The primers used for HLA-B27 and HLA-Cw6 




The antibodies used for the immunofluorescence and immimohistochemistry studies are 
listed in Table 2.4.
2.1.5 Buffers and Solutions
1% Agarose solution with ethidium bromide
4g Agarose (SeaKem, Scot Scientific)
400mls 0.5 x TBE
20pl Ethidium bromide stock solution (1 Omg/ml)
Add the agarose to the 0.5 x TBE in a sterile 500ml glass bottle. Microwave on high 
without a lid for 2-3 minutes until all the agarose is dissolved and large bubbles form 
when the gel is gently agitated. When cooled slightly, add the ethidium bromide and 
agitate until dispersed. Use immediately or, if allowed to cool and set, reheat in the 
microwave as above.
2.5% Agarose solution with ethidium bromide
lOg Agarose
400mls 0.5 x TBE
20pl Ethidium bromide stock solution (1 Omg/ml)
The gel is prepared as detailed for the 1% agarose gel.
1% Alconox solution (Tor cleaning Gene Scanner 2000 glass plates)
5g Alconox
500mls ddH20
10% Ammonium Persulfate solution (APS)
50 mg Ammonium Persulfate (pro-pure proteomics grade)
500pl ddH20
Store the APS in a desiccater in aliquots to avoid excess exposure to moisture.
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Antibody diluent solution
Supplied ready for use
Bind Silane solution
Supplied ready for use
Chloroform





10 x DNA Polymerase Reaction Buffer Fisher Biotec, Australia
Supplied ready for use
Dideoxvnucleotide triphosphates (dNTPs) Fisher Biotec, Australia
Supplied as a highly purified nuclease free solution of each dNTP (dATP, dCTP, dGTP, 
dTTP). Each dNTP was supplied at a concentration of lOOmM, pH 7.5 and diluted with 
ddH20 to a working concentration of lOmM.
100% Ethanol solution Fisher Biotec, Australia
Supplied ready for use
Haematoxylin solution Fisher Biotec, Australia
Supplied ready for use




Lois and Keith, USA
Sigma, USA
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6 x Loading buffer for agarose gels
40 % Sucrose Boehringer Mannheim,USA
0.25% Bromophenol blue Sigma
Use neat to load samples into the agarose gel wells at a ratio of 2 pi loading buffer: 5 pi 
PCR product.
4 x Loading buffer for Gene Scanner
6.5mls Ficoll Type 400 (300mg/ml)
3.5mls Blue Dextran (lOOmg/ml)
3.5mls Dextran Sulphate (2Omg/ml)
4mls 20 x TBE
2.5mls ddH20
Filter the stock using 5pm pore sized filters, followed 
at -20°C.
Loading Buffer for Gene Scanner
300pi 4x Loading Buffer
125 pi 6x TBE
150pl 59 bp internal marker
25pl 555bp internal marker
Mix 1 pi loading buffer: lpl PCR sample prior to loading samples into the wells.
Long Ranger solution (polyacrylamide gel) AT Biochem, USA
Supplied and used as a 50% concentrate solution. Store at 4°C protected from light.
Magnesium Chloride Solution 25mM Fisher Biotec, Australia
Supplied ready for use
Mid lOObp marker (for agarose gels) Fisher Biotec, Australia
Molecular weight marker with 30 bands every lOObp (100-3000bp) and brighter bands at 
lOOObp and 3000bp. Supplied as 150pl of 200pg/ml solution. Dilute as follows:




by 0.45pm filters. Aliquot and store
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375pl 6 x loading buffer
225pl ddH20
Use 3 pi as a size marker for PCR products on agarose gel electrophoresis. Store at 
20°C.
Molecular Weight M arker (for Gene Scanner 2000) Bresatec, Australia
pUC-19 DNA supplied ready digested with the restriction enzyme Hpall (band sizes 26,
34, 68, 117, 120, 147, 190, 242, 331, 404, 489, 501 base pairs). The internal 59 and 555
base pair markers are made in house at CMII, Perth, Australia
75pl pUC-19
150 pi 0.6 x TBE
150pl 4 x LB
50pl 555bp marker
150pl 59bp marker






Supplied ready for use
Polyacrylamide gel (for Gene Scanner 2000)
For 8% long gel (total volume 40mls)
6.4ml 50% Long Ranger
2.4ml lOx TBE
31.2ml ddH20
200pl Ammonium Persulfate Solution (APS)
20pl TEMED
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Gently mix the Long Ranger, TBE and ddH20  in a 50ml syringe. Degas the syringe by 
creating a vacuum in the syringe and tapping the syringe on the workbench several times. 
Release the gas from the syringe. Quickly add the APS and TEMED, mixing gently, 









Supplied ready for use
3M Sodium Acetate
Supplied ready for use
5M Sodium Chloride
14.62g NaCl
up to 50mls ddH20
Gradually add NaCl to ddH20 , mixing thoroughly until all NaCl is dissolved.
Store at room temperature.





216g TrizmaBase Sigma, USA
llOg Boric Acid Sigma, USA
80 ml 0.5M Disodium EDTA pH8 Sigma, USA
Adjust pH to 8.3. Add sterile ddH20 to lOOOmls. Aliquot, autoclave and store at room
temperature in the dark. Dilute appropriately to provide concentration of TBE required
with ddH20 .
10 x TBE
500mls 20 x TBE
500mls ddH20
0.6 x TBE
60mls 10 x TBE
940mls ddH20
0.6 x TBE with Ethidium Bromide
lOOOmls 0.6 x TBE
3 pi Ethidium bromide (1 Omg/ml stock solution)
0.5 x TBE







Make up to 20 litres with ddH20 . Adjust pH to 7.6.
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TEMED solution (N,N .N ’ ,N ’ -Tetramethylethylenediamine) Amresco, Ohio
Supplied ready for use. Store at 4°C.





Adjust pH to 8. Dilute 1:10 with ddH20  prior to use.
Xylene solution (for rinsing slides)
Supplied ready to use
2.1.6 Equipment
Spectrophotometer Beckman DU 640, Australia
Palm-Cycler Version 2.0 Thermocycler Fisher Biotec, Australia
PTC-200 DNA Engine MJ Research, UK
Gene Scanner GS 2000 Corbett Research, Australia
Agarose electrophoresis tank with ‘Powerpac 300’ Biorad, Australia 
Wellwash 4 Mark 2 plate washer Labsystems, Sweden
Multiskan Ascent plate reader Labsystems, Sweden
2.1.7 Commercial kits
LSAB+ peroxidase kit DAKO
Anti-CCP ELISA kit Axis-Shield, UK
RF ELISA kit Sigma, USA
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2.2 Patient recruitment and clinical data
2.2.1 Ethics approval
Approval was sought from the Local Research Ethics Council (LREC) in Bath prior to the 
initiation of this study; Full approval was given for the collection of the clinical and 
radiological data detailed herein. Approval was also granted for the collection of blood 
samples for the extraction and storage of serum and DNA for use in the immunogenetic 
analysis described in this thesis. Approval was provided for the DNA samples to be 
transported to Perth in Australia for the continuation of this work.
2.2.2 Recruitment of subjects
2.2.2.1 Controls
DNA samples from random blood donors were provided by the Tissue Typing centre, 
Southmead Hospital, Bristol. Although screened for the presence of many conditions, 
psoriasis was not actively screened for and therefore the presence of background psoriasis 
in the controls cannot be excluded. The controls were matched for sex (70 male: 78 
female) but the age of the donors was not known.
2.2.2.2 Patients with Psoriatic Arthritis (PsA)
Patients with PsA were recruited from a specialist clinic at the RNHRD in Bath. Patients 
from this clinic have their clinical and radiological details recorded prospectively by a 
rheumatologist or allied health professional at least once a year. These details are then 
stored on an Access (Microsoft) database together with background demographic 
information and details of previous genetic and epidemiological studies. Some patients 
have been followed for over 15 years.
Patients were invited to participate in this research programme whilst attending the PsA 
clinic for routine follow-up. All patients were given an information sheet (Appendix 1) to 
read prior to the consultation. If they agreed to participate they were asked to sign an
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informed consent (Appendix 2). The original consultation was either extended or they 
were examined separately after the routine clinic appointment. Clinical and demographic 
information was recorded on a defined proforma (Appendix 3) and background 
information was documented if the patient was new to the clinic (Appendix 4 and 5). The 
data was then inputted into the PsA Access database. The clinical information that was 
collected included a psoriasis area severity score (PASI), nail score, modified Ritchie 
tender and swollen joint count (111), Health Assessment Questionnaire (HAQ) (112) and 
a visual analogue scale (VAS) for pain (Appendix 6).
2.2,23 Patients with Psoriasis
Ethical approval was given to recruit subjects with psoriasis who did not have a 
complicating inflammatory arthritis. These subjects were recruited from a specialist 
Dermatology clinic at the Royal United Hospital (RUH), Bath and from the Number 18 
Surgery General Practice in Oldfield Park, Bath. The differing methods of recruitment 
were intended to capture a broad spectrum of severity of psoriasis. This would enable the 
patients with PsA who had varying severities of psoriasis to be well matched with the 
psoriasis-only population for subsequent immunogenetic studies.
Patients with psoriasis attending the department of dermatology of the RUH, Bath were 
targeted by attendance of speciality psoriasis clinics by a member of the research team. 
Patients were offered an information sheet inviting them to take part in the study 
(Appendix 7). If they agreed to participate they were interviewed and examined in the 
dermatology department. Patients with psoriasis in General Practice were targeted by 
searching the practice database for all patients with a known diagnosis of psoriasis. A 
letter of invitation (Appendix 8) was then sent to these patients together with the 
information sheet and a stamped addressed envelope. Any patients who replied were 
contacted and invited to attend the RNHRD, Bath for a consultation.
Once a patient decided to participate they were asked to sign an informed consent form 
(Appendix 9). They were then asked to complete a short screening questionnaire 
(Appendix 10) intended to gather some demographic information and to screen for the
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presence of an inflammatory arthritis. The questionnaire was designed by a group of 
rheumatologists working at the RNHRD in Bath in consultation with Prof D Symmonds 
from the ARC Epidemiology Institute in Manchester. The patients were then examined by 
a member of the research team (rheumatologist or allied health professional). The three 
elements of the examination included a tender, swollen and damaged joint score, a PASI 
score and a nail involvement and severity score (Appendix 3). After informed consent a 
blood sample was taken for serum and DNA extraction. If consent was given for 
radiographs to be taken and there were no contraindications (eg pregnancy, age<16), all 
subjects attended for radiographs of the sacroiliac joints regardless of the findings of the 
examination and questionnaire. If the assessing health professional felt there was clinical 
evidence to suggest an underlying arthritis, further radiographs (eg. hands and feet) were 
requested with the patient’s permission.
th13 International Histocompatibility Workshop
The Centre for Molecular Immunology and Instrumentation (CMII) in Perth was chosen to 
coordinate the psoriasis component of the 13 th International Histocompatibility Workshop 
(13IHW) held in Seattle, USA in May 2002. This workshop meets every four years and 
acts as a forum for international researchers to meet and discuss the current thinking on 
the immunobiology of the MHC. A large and active component of the workshop is that 
interested in MHC and disease. Participating laboratories collaborate to investigate areas 
of interest in different ethnic populations.
The psoriasis workshop involved collaborations between clinicians and laboratories in the 
UK, Belgium, Germany, Italy and Australia. Samples of DNA from patients with psoriasis 
were sent to CMII, Perth for investigation of polymorphisms of MICA. The details of the 
participating laboratories and the number of samples received is given in Table 2.5.
2.2.2.4 Reference samples
A well characterised reference panel of DNA extracted from cells which formed part of 
the 4th Asia-Oceania Histocompatibility Workshop (4AOH) and the 10th International 
Histocompatibility Workshop (10IHW) was available for analysis. These cell panels had
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been sequenced along HLA Class I and II as well as several genes in the Class III region 
including MICA. Cells containing examples of the different alleles of MICA could 
therefore be selected for use as reference alleles for the development and optimisation of 
MICA typing techniques. Two examples of each MICA transmembrane TM allele were 
used for reference whilst developing and performing the TM typing. The cell panel did not 
contain examples of all of the described alleles of MICA based on the extracellular 
sequence. Therefore, during the development of this technique, some alleles were tested 
without the benefit of a positive control.
2.2.3 The Psoriasis Area Severity Index
The PASI is a measure of the extent and severity of psoriasis (Appendix 3) (11). It is 
commonly used for research purposes as well as monitoring the response of the skin to 
treatments. It examines the degree of erythema, infiltration and desquamation of the skin 
in 4 main areas (head, arms, trunk and legs). The PASI is then calculated as the total 
extent multiplied by the total severity of the skin disease (maximum score = 72).
2.2.4 Psoriasis Nail Score
Involvement of the nails by psoriasis is relatively common. A score which records the 
presence or absence of nail disease in each of the fingernails has been developed 
(Appendix 3). The feet are also commonly involved but not included in the score as fungal 
infections of the toenails can be virtually indistinguishable. The presence of three key 
features is recorded: pitting (small pits on the surface of the nail), onycholysis (lifting of 
the thickened nail from the nail bed) and hyperkeratosis (thickened, often yellow nails). 
The presence of severe nail deformity is recorded separately. The presence of all four of 
these features in ten fingernails gives a maximum nail score of 40.
2.2.5 Modified Ritchie tender and swollen joint counts
The widely used Ritchie joint scoring system (111) was modified for use in PsA by 
inclusion of the distal interphalangeal joints. A total of 71 tender joints and 62 swollen
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joints were recorded prospectively every year on all patients attending the PsA clinic 
(Appendix 3). Where serial measurements were available, a median PASI score was 
calculated and used for the purposes of the genetic analysis. A measure of the destruction 
caused by the arthritis was also obtained by recording which of the joints showed signs of 
damage (eg. fixed flexion deformities, valgus deformities). If examination of the spine 
suggested the presence of a spondyloarthritis, the patients were referred to the 
physiotherapy department for formal metrology. Following joint examination, the patient 
was assigned to a subgroup of PsA as originally defined by Moll and Wright (2), ie. DIP 
disease only, oligoarthritis (<4 involved joints), polyarthritis ( > 4 involved joints), 
spondyloarthritis (predominant spinal involvement with sacroiliitis +/- syndesmophyte 
formation), monoarthritis or arthritis mutilans. These details were all recorded on the 
database. For the purposes of the analysis, the most recently allocated clinical subgroup 
from the latest clinical assessment was used.
2.2.6 Health Assessment Questionnaire
The HAQ is a functional index designed to measure any difficulties with activities of daily 
living experienced by a patient (112). The questionnaire was completed by the patients on 
an annual basis and the information recorded on the database. A visual analogue scale 
(VAS) asking the patient to score the amount of pain (on a scale of 0-10) related to their 
arthritis that they have suffered in the last week was also recorded (Appendix 6).
2.2.7 Radiology
Plain anteroposterior radiographs of the hands, feet and sacroiliac joints were taken on all 
patients at baseline. Radiographs of the hands and feet were updated every two years. The 
radiographs were reported by a radiologist. Some of the radiographs from patients who 
had participated in previous research studies had been scored using a modified Sharp score 
(113). The majority of the patients were simply recorded on the database as “erosive” or 
“non-erosive” depending on the results of the most recent radiographs. The presence of 
sacroiliitis or other radiological features of spondyloarthritis were also recorded.
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2.2.8 Laboratory tests
Routine blood tests were taken following the clinic appointment as judged necessary by 
the clinician. At baseline all patients were screened with a rheumatoid factor (RF). 
Inflammatory markers (C Reactive Protein and plasma viscosity), full blood count, renal 
and liver function tests were checked at least at every annual appointment, if not more 
frequently. Following informed consent, blood was taken for serum and DNA extraction.
2.3 Serum and DNA collection
2.3.1 Collection of whole blood
Following informed consent, 20mls of peripheral blood was collected from the patient into 
a 10ml plain tube and a 10ml EDTA tube. It was then taken at room temperature to the 
laboratory for extraction of the serum and DNA.
2.3.2 Extraction of serum
The serum was separated from whole blood following centrifugation at 1200 r.p.m. for 10 
minutes. The serum was then removed with a pipette into a clean tube and stored at -20°C 
until required.
2.3.3 Extraction of DNA
1. Centrifuge the 10ml tubes of whole blood at 1200 r.p.m. for 10 minutes
2. Carefully pipette the “buffy coat” (containing the white blood cells) into a clean tube
3. Add 8ml red cell lysis buffer to the buffy coat, mix gently and leave for 20 minutes
4. Centrifuge at 1200 r.p.m. for 10 minutes
5. Pour off the supernatant (red cell lysate) and resuspend the pellet in 3ml nuclei lysis 
buffer, lOOpl proteinase K and lOOpl 20% SDS
6. Incubate in a water bath at 55°C for 3 hours
7. Add 1ml of 5M NaCl and shake the tube vigorously for 20 seconds
8. Centrifuge at 1200 r.p.m. for 10 minutes
9. Collect the supernatant into a universal vial, taking care not to disturb the pellet which 
contains the precipitated proteins
10. Add 8ml of 100% ethanol and mix by gently inverting the tube several times
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11. Remove the precipitated DNA by winding onto the end of a sealed Pasteur pipette, 
squeezing the excess alcohol out onto the side of the tube
12. Transfer the DNA to a 0.5ml Eppendorf tube and dissolve the DNA in lOOpl ddt^O
13. Quantify the amount of DNA using a spectrophotometer and store at -20°C
2.3.4 Labelling and storage o f the DNA samples
All DNA samples were labelled with a unique identifier and anonymised for storage and 
transport in accordance with the requirements of the Ethics committee. The patient details 
relating to the DNA samples were recorded on a password protected Microsoft Access 
database. An aliquot of each sample was transported to Australia for genetic analysis 
using a recognised freight company. All samples were passed through the Australian 
Quarantine and Inspection Service (AQIS) on Permit number 200118650. The samples 
were then quantified and a working dilution of 20ng/pl was made. All samples were then 
stored at -20°C.
2.3.5 Quantification o f DNA by spectrophotometry
Nucleotides in solution absorb light in the ultraviolet (UV) region of the spectrum, with a 
maximum absorption at a wavelength of 260nm. Proteins also absorb UV light but 
maximally at 280nm wavelength. Therefore, DNA samples can be quantified and the 
purity of the preparation can be estimated by measuring the absorption of UV light at 260 
and 280nm in a spectrophotometer.
The stock solution of DNA was thoroughly mixed on a vortex to ensure the DNA was 
resuspended. The sample to be tested was then diluted 1:50 by diluting 2 pi of the DNA 
sample in 98pl ddt^O and mixing thoroughly. The Beckman Spectrophotometer was 
switched on at least 5 minutes before use to allow the UV lamp to warm up. The machine 
was set to read the samples at a 1:50 dilution. The machine was blanked by placing lOOpl 
of the ddPbO that was used to dilute the DNA samples into the cuvette. One hundred 
microlitres of the 1:50 diluted DNA samples was then placed in turn into the cuvette and a 
reading taken. The cuvette was washed out between samples with ddl^O. The readings
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were obtained for the absorbency of UV light at 260nm and 280nm wavelengths. The 
software attached to the spectrophotometer then calculated the concentration of DNA in 
ng/pl and the concentration of protein in ng/pl. The equation utilised to calculate the 
concentration is :
DNA concentration (ng/pl) = Absorbance at 260nm x 50 x dilution factor (50)
Protein concentration (ng/pl) = Absorbance at 280nm x 50 x dilution factor (50)
The ratio of absorbancy at 260nm/280nm gave an indication of the purity of the sample. A 
ratio of 1.8 indicated pure samples. Any samples with a ratio below 1.7 were purified 
according to the method given below.
2.3.6 Purification o f DNA
1. Add an equal volume of phenol to the DNA suspension
2. Shake in a closed tube to form an emulsion of the denatured protein
3. Centrifuge at 1300 r.p.m. for 15 seconds
4. Transfer the ‘upper’ phase into a fresh Eppendorf
5. Add an equal volume of 1:1 mixture of phenol and chloroform and mix, centrifuge and 
separate as before, retaining the ‘upper’ phase
6. Add a 1/10 volume of 3M sodium acetate, followed by 2 volumes of 100% ethanol
7. Mix thoroughly and centrifuge as before
8. Take off as much fluid as possible taking care not to disturb the DNA pellet
9. Wash the pellet twice more with ethanol and leave to airdry
10. Resuspend in lOOpl dcfflbO and re-quantify by spectrophotometry
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2.4 Genetic analysis
2.4.1 MICA exon 5 microsatellite typing
2.4.1.1 PCR Conditions
All PCR reactions were performed in a total volume of 20pl. A master mix of all reagents 
except the DNA and the Taq DNA polymerase was made by multiplying the volumes 
below by the number of reactions to be performed. Each 20ng/pl DNA dilution was mixed 
thoroughly and 5 pi added directly to one of the wells of the PCR strip. Each PCR run 
contained the test DNA, a number of positive DNA reference samples and a control well 
(ddH20 instead of DNA) to check for contamination. The PCR reactions were set up on 
ice in sterile conditions in a laminar flow hood. The Taq DNA polymerase was added to 
the master mix at the last moment and mixed thoroughly. Fifteen pi of the master mix was 
then added to the DNA in each well and gently mixed with the pipette. The wells were 
sealed with a tight-fitting lid and placed into the heating plate of the thermocycler. The 
reactions were carried out in a Palm-cycler Version 2.0 (Fisher Biotec, WA). Once the 
cycles were completed the samples were stored at 4°C until needed.
The following concentrations of reagents were found to yield optimal results in terms of 
the intensity, clarity and specificity of the PCR product by experimentation with differing 
concentrations of the individual reagents.
Reagent Volume added Concentration
10 x PCR Buffer 2 pi 1 x PCR Buffer
lOmMdNTPmix lpl 500pM
25mM MgCh 1.2pl 1.5mM
Taq DNA polymerase 0.2pl 1 Unit
Forward Primer (25pmol/pl) lpl 1.25pM
Reverse Primer (25pmol/pl) lpl 1.25pM
DNA (20ng/pl) 5 pi lOOng
Double distilled water 8.6pl
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Cycling conditions
The annealing temperature was adjusted until the intensity and specificity of the product 
bands was maximised. The following conditions were found to be optimal:
PERTMF + PERTMR
Cycle Step Temp (°C) Time Number of cycles
1 1 96 60 sec 1
2 1 96 25 sec
2 70 45 sec >* 5
3 72 30 sec
3 1 96 25 sec
2 65 45 sec 21
3 72 30 sec
4 1 96 25 sec
2 55 60 sec |>- 4
3 72 120 sec —*
5 1 72 10 mins 1
PERTM100F + PERTM100R
Cycle Step Temp (°C) Time Number of cycles
1 1 95 1 min •N
2 66 1 min ► 30
3 75 1 min
2.4.1.2 Preparation o f the gel
The polyacrylamide gel was prepared in a 50ml syringe as described in Chapter 2.1.5. The 
lower glass plate was placed horizontally in the plate holder. A strip of 0.1 pm spacer tape 
was placed on the long edges of the lower glass plate to allow the formation of a 0.1pm 
thick gel between the glass plates. The upper, inner edge of the top glass plate was wiped 
with bind silane solution to aid in the formation of the wells. The top plate was placed on 
top of the lower plate, with the front of the top plate elevated so that the gel can be
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squeezed gently from the syringe between the plates. The top plate was then gently 
lowered onto the bottom plate, forming the gel, ensuring no air bubbles appeared in the 
gel. A 48 well comb was placed between the upper edges of the plates to form the wells. 
The plate holder was then screwed down to ensure equal pressure between the plates to 
ensure the gel set uniformly. The gel was allowed to set for 1 hour at room temperature 
before removal of the 48 well comb. The outer surfaces of the glass plates were checked to 
ensure no gel had spilled onto the outside. Any excess gel was wiped off with 100% 
ethanol and lint free paper. The plates were now ready to be placed vertically into the 
Gene Scanner 2000.
Placing the gel into the Gene Scanner 2000
The lower chamber was placed in situ and the electrical connections were established. The 
plates were placed vertically into the lower chamber with the lower glass plate at the back, 
flush with the vertical surface of the Gene Scanner. The lower chamber was then filled to 
the designated line with 0.6x TBE + 3pl/litre Ethidium Bromide buffer. The upper 
chamber was then attached over the plates onto the Gene Scanner and the electrical 
connections were established. The upper chamber is then filled with 0.6x TBE {no 
Ethidium Bromide). The wells were washed out with 0.6x TBE using a fine gauge needle 
and syringe to ensure no air bubbles remain in the wells. The door is then closed over the 
chambers containing the gel and the power is switched on. The buffers were then pre-run 
through the gel by selecting “pre-run” at 1000V and 25°C for 30 minutes. The wells were 
then washed out as before.
Loading the gel
The samples were then loaded into the wells by mixing lpl of PCR product with lpl of 
Gene Scanner Loading Buffer on a piece of parafilm. A maximum of five samples were 
loaded at a time to ensure the samples did not evaporate, lpl of this mixture was then 
loaded into each well following a designated proforma, lpl of molecular weight marker 
for the Gene Scanner was loaded at the beginning, end and between every five samples.
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Running the gel
The samples were then “pulsed” into the gel by selecting “pulse” at 1000V for 60 seconds. 
The excess sample in the wells was washed out as before. The gel was then run at 1000V 
for 4 hours until the product and marker had run through the gel. The marker and products 
were scanned by a laser as they ran through the gel, to produce an image which was stored 
on the computer as a ‘.flf file.
2.4,13 Analysis o f the gel
The resultant ‘.flf file was converted by the Genescanner 2000 software programme into 
a ‘.tif file for analysis. The lanes of the gel were centralised through the product bands 
correcting for any irregularity in the gel. The resultant file was then saved as a ‘.txf file 
and opened using Microsoft Excel. A line graph was then plotted for each sample, with the 
intensity of the band(s) on the ‘y’ axis against time on the ‘x’ axis. Each graph was 
corrected for ‘smile’ in the gel due to slight variations in current by aligning the internal 
markers. The sample graphs were then compared with the graphs obtained for the known 
MICA alleles from reference DNA samples. Each sample graph was aligned with each 
reference graph using the Genescanner 2000 software. The MICA TM alleles for each 
patient sample could therefore be assigned.
2.4.2 Typing exons 2,3 and 4 of MICA
2.4.2.1 Background
The rationale for the PCR-SSP technique employed for the typing of the alleles of MICA 
defined by the single nucleotide polymorphisms (SNPs) in exons 2-4 is detailed in 
Chapter 4.
2.4.2.2 Phylogenetic analysis
The nucleotide sequence of the currently described alleles of MICA was downloaded from 
the IMGT/HLA database (http://www.ebi.ac.uk/imgt/hla/) in FASTA format (114). This 
was then imported into the Molecular Evolutionary Genetics Analysis software 
programme, MEGA (115). This programme uses the nucleotide sequence of the alleles of
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a gene to generate a ‘family tree’ by comparing similarities in sequence. An analysis can 
also be performed on the amino acid sequence to compare similarities between alleles on a 
protein level. Since the analysis was performed in order to generate primers for 
subsequent analysis, the nucleotide sequence was used.
The full nucleotide sequence of exons 5 and 6 of MICA has not yet been published for 
approximately 50% of the MICA alleles. The absence of full data for these alleles could 
influence the phylogenetic analysis. The analysis was therefore performed solely on the 
nucleotide sequence of exons 2,3 and 4 with exclusion of the incomplete data. The 
resultant phylogenetic tree was then utilised to select group-specific primers for the PCR- 
SSP technique.
2.4.2.3 Selection o f Primers
The details of the primers used for the typing of exons 2,3 and 4 of MICA are given in 
Table 2.1. The majority of the primers were those used in an earlier PCR-SSP technique to 
define the alleles of MICA when there were only 16 alleles described in the literature 
(116). There are currently 54 alleles of MICA whose sequences have been (at least 
partially) sequenced. Therefore, there are now many more alleles of MICA that are 
recognised by these original primers.
The nucleotide sequences of the 54 alleles of MICA were downloaded from the 
IMGT/HLA database as before. The sequences were then imported into a Microsoft Excel 
spreadsheet and aligned. All non-polymorphic nucleotide positions were deleted. The 
polymorphic positions of all of the currently described 54 alleles were then labelled 
according to the nucleotide position starting from the beginning of exon 1. The alleles 
were then arranged in phylogenetic order according to the nucleotide sequence without 
exons 5-6 (as detailed above).
A column for each forward and each reverse primer was made and each allele that was 
recognised by that particular primer was marked with a “+”. A separate table listing all 
potential primer pair combinations was formulated. Any combinations that resulted in a 
PCR product less than lOObp or more than 1500bp were discarded as these would be
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difficult to detect on simultaneous agarose gel electrophoresis. Products that would be 
close to the size of the internal control (480bp) were also discarded. All potential primer 
combinations were then examined for those that divided the alleles into equal-sized, 
mutually exclusive groups. Five primer pairs were selected which could separate the 54 
alleles into 5 groups that were all mutually exclusive. There was only one rare allele 
(MICA *044) which was recognised by two of the primer pair groups (Groups 2 and 3). 
The segregation of the alleles of MICA largely followed the phylogenetic analysis barring 
a few exceptions {Figure 4.3)
The 2nd stage of the PCR-SSP procedure required the definition of alleles known to be 
present at a frequency of > 1% (117; 118). Although some of the original primers could 
be used, some novel primers were required to recognise the more common newly 
described alleles. The novel primers were designed to be compatible with the existing 
primers in terms of length, GC content and melting temperatures (Tm). They were 
designed to recognise the required polymorphic position and checked against all known 
human sequences to ensure there was no cross-reactivity using the programme ‘BLAST’ 
(ncbi.nlm.nih.gov/BLAST/).
2.4.2.4 PCR conditions
The PCR reactions were set up in exactly the same way as described for the MICA TM 
typing. Successful amplification of each reaction was confirmed with the presence of a 
pair of internal control primers specific for a conserved region of the Human Growth 
Hormone (HGH) gene. The PCR was found to be optimal with the following reaction mix:
Reagent





Reverse Specific Primer (25pmol/pl)
Forward HGH Control Primer (2.5pmol/pl)
Volume Concentration








Reverse HGH Control Primer (2.5pmol/pl) lpl 
DNA (20ng/pl) 5 pi




The original PCR-SSP method described for MICA (116) used the conditions detailed 
below. These conditions worked well for most primer pairs in this updated PCR-SSP 
method but some PCR reactions were sub-optimal. Adjustments to the annealing 
temperatures of these primer pairs yielded better results (see below).
Cycle Step Temp(°C) Time Number of cycles
1 1 95 5 min 1
2 1 95 20 sec 1
2 65* 50 sec |y 30
3 72 30 sec -J1
*The following primer pairs have a different annealing temperature: 
F10+R17 (62°C), F14+R2 (66°C), F4+R6 (67°C) and F7+R7 (69°C)
Each sample was tested with five initial (1st stage) primer pairs. The alleles were then 
further defined using the 2nd stage primer pairs appropriate to each group following the 
typing algorithm given in Table 2.6. and Figure 2.1.
2.4.2.5 Agarose Gel Electrophoresis
The PCR products were then identified by agarose gel electrophoresis. The majority of the 
PCR products were identified using 1% agarose gels but 2.5% agarose gels are used if the 
product sizes were less than 250 bp.
2.4.2.6 Preparation o f the gel
The agarose gel was prepared following the instructions given in Section 2.1.5. The plastic 
gel mould was placed on a level surface and the comb(s) for the number of wells required 
was inserted into the mould. The gel was microwaved for 2-3 minutes until fully dissolved 
and large bubbles formed when the hot gel was gently agitated. The gel was then poured
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into the mould until the gel was approximately 7mm thick and left to set for 30 minutes. 
The comb(s) was then removed and the gel is placed into the electrophoresis tank.
2.4.2.7 Loading the gel
The gel was covered with 0.5x TBE. 5pi of Mid-100 marker was pipetted into the first 
well and between every 8 samples. 2pi of loading buffer and 5pi of PCR product were 
mixed on a piece of parafilm and the total volume (7pl) was then loaded into each well 
until all the samples had been loaded.
2.4.2.8 Running the gel
The positive and negative terminals were then connected to the power pack. The controls 
were set at 200V and 400mA. The gel was allowed to run for 20 minutes.
2.4.2.9 Interpretation o f the gel
The gel was then removed from the tank and the bands visualised on an ultraviolet light 
box and photographed. The size of the product band was compared with the 100-3000bp 
molecular weight marker. Successful PCR amplification was verified with a 480bp band 
resulting from the internal control primers (HGHF + HGHR). The appearance of a specific 
band of the expected size confirmed the presence of an allele recognised by the primer 
pair used in the reaction. The expected product sizes are given in Table 2.7. The absence 
of a specific band but presence of a control band confirmed that the sample tested did not 
possess an allele recognised by that primer pair. The absence of a control and specific 
band was regarded as a failed PCR reaction and was repeated.
2.4.3 HLA-DRB1 ‘shared epitope9 typing
2.4.3.1 Printers
The primers used for the HLA-DRB1 typing and HLA-DRB1*01 and HLA-DRB1*04 
subtyping are given in Table 2.3. Initial HLA-DRB1 typing was performed using 10 
forward primers and 16 reverse primers to form 20 primer pairs (Table 2.8) (119). Each 
reaction also included a primer pair specific for a conserved sequence in the 3rd intron of 
HLA-DRB1 (C3+C5) to act as an internal amplification control. Specific amplification of
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the individual HLA-DRB 1*01 and HLA-DRB1*04 alleles was performed with an 
additional 4 and 8 primer pairs, respectively (120; 121). The primer mixes used for the 
HLA-DRB1*01 and HLA-DRB1 *04 subtyping are listed in Tables 2.9 and 2.10, 
respectively.
2,43,2 PCR conditions
The primer mixes were prepared to give a final concentration of 0.25mM of each specific 
primer and 0.05mM of each control primer within each reaction. Five pi of the primer mix 
was added to 5pi of reaction mix in each well of the PCR plate. The reaction mix was 
prepared depending on the number of primers to be used, eg. for 20 primer pairs (initial 
HLA-DRB 1 screening), 105 pi of reaction mix was prepared:
22pl reaction buffer (750mM Tris HC1, pH8.8),200mM (NH4)2SO4,0.1% Tween 20)
22pi dNTP (dATP, dGTP, dTTP, dCTP) (125pM)
12pl Magnesium Chloride (25pM)
4 lpl sucrose/cresol red (60% sucrose, ImM cresol red, (Sigma))
8 pi DNA (200ng/pl)
1.1 pi Taq polymerase (added just prior to use)
(All PCR reagents were supplied by ABgene, UK)
The PCR amplifications were carried out in a M J Research PTC-200 DNA Engine using 
the following cycling parameters:
Cycling parameters
1. 96°C for 2 minutes
2. 94°C for 25 seconds 
65°C for 50 seconds 
75°C for 30 seconds
3. 96°C for 10 seconds 
61°C for 50 seconds 
72°C for 30 seconds




The PCR products were visualised following electrophoresis on a 2% agarose gel as 
before and the HLA-DRB 1 alleles were allocated by reference to the table of primer pair 
specificities (Table 2.8).
2.4.4 HLA Class I typing
All samples (PsA, Type I Psoriasis and controls) were sent to the 13th International 
Histocompatibilty Workshop coordinating laboratory (J. Hansen, Seattle, USA) for full 
sequence-based HLA typing at the HLA-A, B, C, DR, DQ and DP loci. This work is still 
awaiting completion. The PsA samples were therefore typed for HLA-B27 and HLA-Cw6 
using PCR-SSP until the full HLA Class I typing was available. The primers (Table 2.2), 
reaction mixes and cycling parameters used were based on the published technique by 
Bunce et al (122).
2.4.5 Analysis of Genetic data
2.4.5.1 Basic statistics
The allele frequencies were determined by direct counting using the filter facility on 
Microsoft Excel. The MICA alleles were examined for the presence of Hardy-Weinberg 
equilibrium by comparing the observed with the expected genotype frequencies. These 
were then compared using the Chi-squared test with the appropriate degrees of freedom. 
Allele frequencies were expressed as a fraction (0-1) by dividing the total number present 
of any given allele by the total number of alleles within the population (n x 2). The results 
were also expressed as phenotype frequencies (the number of individuals within the 
population who express at least one copy of the allele).
Differences between patient groups and controls were determined using the Chi-squared 
test with Fisher’s Exact test if the sum of the numbers within a 2 x 2 table were less than
20. All statistical tests were performed using Microsoft Excel and SPSS for Windows 
(Microsoft). Continuous variables that were not normally distributed (eg. PASI, swollen 
and tender joint counts) were compared using the Mann Whitney U test. It should be noted 
that ethnically matched controls were not available for the European patients that were 
participants in the 13IHW. Comparison with the UK controls is not statistically valid,
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however, the values will be reported to illustrate trends. Further work with ethnically 
matched controls would need to be undertaken.
The p values were considered to be significant if less than 0.05. The p  values were 
adjusted using the Bonferroni correction for the number of alleles observed. For example, 
the p  values comparing patient and control groups for the MICA TM alleles would be 
multiplied by a factor of 5 for the 5 recognised alleles. Thus, an initial p  value of 0.01 
would be needed for the final result to obtain significance. When a significant result was 
observed, the odds ratio was calculated together with 95% confidence intervals. The 
relatively small sample sizes of the populations studies will lead to a lack of power within 
the study. The results should therefore be interpreted with due caution.
2.4.5.2 Haplotype analysis
Some of the data from the patient samples was available for haplotype analysis. The DNA 
samples from the patients with PsA had been typed at the HLA Class II loci, HLA-DRB 1 
and HLA-DQB1. The HLA Class I typing in the PsA group was not sufficient for 
haplotype analysis as samples had only been examined for the presence or absence of 
HLA-B27 and HLA-Cw6. The Type I psoriasis patients from the 13IHW had full HLA 
typing at the HLA Class I and II loci and were therefore available for haplotype analysis.
The MICA data was examined using the population genetics data analysis software 
package ‘Arlequin’ (123), available for download at www.lgb.unige.ch/arlequin/. Arlequin 
is an exploratory population genetics software programme able to handle large samples of 
molecular data (RFLPs, DNA sequences, microsatellites), while retaining the capacity of 
analyzing conventional genetic data (standard multi-locus data or mere allele frequency 
data). It has die ability to compare genetic similarities between sequences and calculate the 
most likely haplotype sequences and frequencies. The likelihood of the predicted 
haplotypes is provided by reference to a Chi-squared value. The patient and control data 
was imported from an Excel database and converted into the correct format using the 
progamme PantelidisP5mod (personal communication). Haplotype combinations and 
frequencies were determined by the Arlequin programme. The linkage disequilibrium 
between individual polymorphic loci was calculated to obtain D values (a measure of
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deviation from random association between alleles at different loci) (117). The D' values 
were then calculated (the D value standardised by the maximum value it can take given 
the allele frequencies). A D' value of 0 suggests independent association of two alleles, 
whereas a D' value of 1 suggests strong linkage disequilibrium between loci.
2.5 Expression work
2.5.1 Antibodies
The antibodies used for immunofluorescence and immunohistochemistry are detailed in 
Table 2.4. All antibodies were used at a working dilution of 1:50 except huMICA M673 
which was used at a dilution of 1:10.
2.5.2 Immunofluorescence
1. Remove frozen sections of skin from the freezer and allow to thaw
2. Dilute primary antibody with antibody diluent (DAKO) using differing dilutions 
between 1:10 and 1:100
3. Place several drops of diluted primary antibody onto each section and leave for 15mins
4. Wash with PBS (pH 7.6) for 10 mins
5. Dilute appropriate secondary antibody (eg swine anti-rabbit or rabbit anti-mouse) 1:20 
with antibody diluent (DAKO)
6. Add a few drops of diluted secondary antibody and leave for 15 minutes
7. Wash 3 times with PBS
8. Mount the sections with mounting solution and a cover slip
9. Examine slides for presence of fluoresence with dark background microscopy
10. Photograph slides using microscope camera to produce projection slides




1. Label formalin fixed, paraffin-embedded skin sections on glass slides for the antibody 
to be tested
2. Make dilutions of the primary antibodies with antibody diluent (DAKO) (between 
1:20 and 1:100) if optimal dilution is not yet known
3. Place slides in a vertical rack
4. Dewax and rehydrate the slides by placing the rack sequentially in 4 chambers of
xylene and 2 chambers of alcohol, leaving the rack in each chamber for 5 minutes
5. Whilst the slide rack is in the 3rd chamber of xylene, fill a buffer chamber with 500mls 
of TRIS/ EDTA pH 8 and place a lid on top of the chamber. Place 300mls of ddH20 in 
the bottom of a pressure cooker. Place the buffer chamber inside the pressure cooker 
and microwave (without pressure cooker lid) on high for 15 minutes
6. Rinse the slide rack under running water
7. Place the slide rack in the hot buffer solution, put a lid over the buffer chamber and
microwave on high in the water-filled pressure cooker (without lid) for a further 10
minutes. This is the antigen retrieval step.
8. Rinse in cold water for 30 minutes until the slides are cool
9. Place the slide rack in 3% hydrogen peroxide for 5 minutes to block endogenous 
peroxide production
10. Rinse the slide rack with running water
11. Place the slides onto a horizontal rack over a container with some ddHiO placed in the 
bottom to lessen evaporation. Add 2 drops of diluted primary antibody solution to each 
slide. Cover the container and leave for 30 minutes
12. Place the slides back in the vertical rack and rinse with TBS by placing the rack into a 
TBS-filled chamber and agitating the slides gently for 1 minute. Place the slides back 
on the horizontal rack.
13. Add 2 drops of secondary antibody solution (biotinylated anti-mouse, rabbit and goat 
antibodies from LSAB+ peroxidase kit, DAKO). Leave for 30 minutes
14. Rinse with TBS in the vertical rack as before and then replace on the horizontal rack.
15. Add 2 drops of streptavidin conjugated with peroxidase from the LSAB+kit (DAKO). 
Leave for 30 minutes
16. Rinse with TBS in the vertical rack as before and replace on the horizontal rack.
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17. Add 2 drops of the substrate solution, Diaminobenzidine. Leave for 5 minutes for the 
brown colour to develop
18. Immediately place the slides in the vertical rack and rinse with TBS as before
19. Place the slide rack in copper sulphate solution for 2 minutes, haemotoxylin solution 
for 8 seconds then rinse thoroughly under running water
20. Place the slide rack in 2 chambers of alcohol and then 4 chambers of xylene, for 
approximately 1 minute each, gently agitating the slide rack to rinse the slides.
21. Place the slides into a mounting machine for the mounting solution and cover slips to 
be added
22. Examine slides on a light microscope
23. Photograph the slides using a digital camera attachment and download the images onto 
a CD-ROM
2.6 Anti-CCP antibodies
2.6.1 Collection o f serum
Blood samples were collected from patients following informed consent into plain tubes. 
Serum was extracted following centrifugation to remove the cellular pellet. The samples 
were given a unique identifier and stored at -20°C until use.
2.6.2 Anti-CCP ELISA
The presence of anti-CCP antibodies was tested using a commercial ELISA plate (Axis- 
Shield, UK). The second generation kit (CCP2) was used to provide higher sensitivity and 
specificity. All samples were diluted according to the manufacturer’s instructions and 
tested in duplicate together with calibrating positive and negative controls. Several 
samples were tested on consecutive plates to ensure good inter-assay reliability. All plates 
were washed thoroughly between the stages of the ELISA with a Wellwash 4 Mark 2 plate 
washer (Labsystems, Sweden). On completion of the ELISA, the plates were read using a 
Multiskan Ascent plate reader (Labsystems, Sweden). The optical density for each sample 
was converted by the integral software into IU/ml. A cut-off value of >6IU/ml was chosen 
to represent a positive result.
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2.6.3 Rheumatoid Factor ELISA
A commercial ELISA plate (SIGMA, St Louis, USA) was used to test the serum samples 
for the presence of IgM RF. All samples were diluted according to the manufacturer’s 
instructions and tested in duplicate together with calibrating positive and negative 
controls. The plates were read with the Multiskan Ascent plate reader (Labsystems, 
Sweden) and the optical density of each sample was converted into the corresponding 
IU/ml by the attached software. A positive value was regarded as >6IU/ml.
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Table 2.1. Primers used for MICA typing
1 Primer name Sequence (S’-S*) Target
PERTMF TCACCTGCTACATGGAACACAGCG MICA Exon 5
PERTMR CTTTTCTCACCTGGACCCTCTGCA MICA Exon 5
PERTM100F ACATTCCATGTTTCTGCTGTTG MICA Exon 5
PERTM100R TCACCTGGACCCTCTGCAG MICA Exon 5
Primer name Sequence (5*-3f) Target Nucleotide
Position
FI TAACCTCACGGTGCTGTCCT MICA Exon 2 109T
F2 CCTCACGGTGCTGTCCG MICA Exon 2 109G
F3 GGAACTACGGCGATATCTAG MICA Exon 3 586G
F4 TCAGCCCTTCCTGCGCTA MICA Exon 2 176 A
F5 AGGAACTACGGCGATATCTAA MICA Exon 3 586A
F7 TGTGCAGTCAGGGTTTCTCG MICA Exon 2 139CG
F8 ACGGCGATATCTAGAATCCG MICA Exon 3 592G
F10 CAGAGCCCCACAGTCTTCC MICA Exon 2 86C
F ll TTTCTTGAAGGAAGATGCCG MICA Exon 3 520G
F14 CCCAGCATTTCTACTACGATA MICA Exon 3 409A
F18 CTGTGCAGTCAGGGTTTCTCA MICA Exon 2 139CA
F20 GGCTTGCATTCCCTCCG MICA Exon 3 341G
F25 GCTCTTCCTCTCCCAAAACG MICA Exon 3 433G
R1 TGGGGCATTGTCCATTCCTT MICA Exon 3 442T
R2 CTCAGGACTACGCCGGATTT MICA Exon 3 586T
R4 GGCCAGCGTCCGTACCTC MICA Exon 3 611C
R5 AACCTCTGCTCCTCTCCTC MICA Exon 4 821C
R6 CCTGTTCTCCTCAGGACTAT MICA Exon 3 595T
R7 CTCTGGAGGACTGGGGCAT MICA Exon 3 454T
R8 CCTGACGCCAGGTCAGTA MICA Exon 4 707A
R12 CTGCATGCATAGCGTGATAGA MICA Exon 3 536A
R13 TCTGGAGGACTGGGGCAC MICA Exon 3 454C
R16 GTGTCGTGGCTCAAAGATAG MICA Exon 4 730G
R17 GGCCAGCGTCCGTACCTG MICA Exon 3 611G
R22 GCTCACCAGAGGGCACAGC MICA Exon 4 880C
R29 TGAACCTCTGCTCCTCTCCTT MICA Exon 4 821T
HGHF CAGTGCCTTCCCAACCATTCCCTTA HGH Gene
HGHR ATCCACTCACGGATTTCTGTTGTGT HGH Gene |
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Table 2,2, Primers used for HLA B27 and HLA Cw6 typing
Name Primer sequence Target allele
280 (sense) GCTACGTGGACGACACGCT HLA-B*2701-9
281 (antisense) CTCGGTCAGTCTGTGCCTT HLA-B*2701-9
367(sense) TACTACAACCAGAGCGAGG HLA-Cw0602
127(antisense) GGTCGCAGCCATACATCCA HLA-Cw0602
Table 2,3, Primers used for HLA-DRB1 typing
Name Forward Primer Sequence Name Reverse Primer Sequence
5*01 TT GT GGC AGCTT AAGTTTGAA 3*01 CCGCGCCTGCTCCAGGAT
5'02 TCCTGTGGCAGCCTAAGAG 3'02 AGGTGTCCACCGCGGCG
5'03 TACTTCCATAACCAGGAGGAG 3'03 TGCAGTAGTTGTCCACCC
5'04 GTTCTTGGAGCAGGTTAAACA 3*06 CTGGCTGTTCCAGTACTC
5'05 GTTTCTTGGAGTACTCTACGT 3'08 CACTGTGAAGCTCTCCAC
5'06 GACGGAGCGGGTGCGGTA 3'10 CCCGCTCGTCTTCCAGGA
5'07 CCTGTGGCAGGGTAAGTATA 3'11 TCTGCAATAGGTGTCCAC
5'08 AGTACTCTACGGGTGAGTGTT 3'12 TCCACCGCGGCCCGCC
5'09 GTTTCTTGAAGCAGGATAAGT 3'15 CCGCCTCTGCTCCAGGAG
5T0 CGGTTGCTGGAAAGACGCG 3'17 CCCGCCTGTCTTCCAGGA
3*18 GCTGTTCCAGTACTCGGC
Name Control Primers 3'19 CTGTTCCAGTGCTCCGCA
C5 TGCCAAGTGGAGCACCCAA 3*041 GTCCACCGCGGCCCGCT













Table 2,4, Antibodies used for immunofluorescence and immunohistochemistry
1 Name Type Target Source
PERB 11.1 204 Rabbit Polyclonal MICA (+MICB) CMII, Perth
PERB 11.1 205 Rabbit Polyclonal MICA (+MICB) CMII, Perth
huMICA-M673 Mouse Monoclonal MICA Immunex, USA











Table 2,5, Laboratories contributing samples to the 13th IHW on psoriasis
Country Lead Researcher Psoriasis samples Psoriatic Arthritis samples
UK DrNJ McHugh 90 . 158
Belgium Dr Dupont 102 -
Germany Dr T Hohler 37 23
Italy Dr G Novelli 50 -
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Table 2.6. MICA PCR-SSP typing algorithm
1 Group 1st stage
Primer
Pair



















3 F2+R13 *013, *022, *044










*012, *021, *032 
*005, *035, *037, *039, *042 
*007, *026, *029, *037, *038, 
*039, *040, *043, *045 
(+ all Group 5 alleles)










Table 2.7. Expected product sizes following amplification with MICA PCR-SSP 
typing primer pairs
Group 1st stage Amplicon Annealing 2nd stage Amplicon Annealing
primer pair size (bp) Temp °C primer pair size (bp) Temp °C
1 FI +R8 1525 65 F8 + R8 739 65
F10 + R17 841 62
F3 + R16 770 65
2 F3 + R29 861 65 F25 + R17 215 65
F4 + R6 730 67
F25 + R4 215 65
F2 + R13 653 65
3 F2 + R13 653 65
4 FI +R2 780 65 F18 + R1 617 65
F1+R12 741 65
F5 + R5 861 65
F7 + R7 628 69
5 F2 + R2 777 65 F14 + R2 218 66
F20 + R7 148 65
F ll +R22 979 65
Internal HGH F + R 485 62-69
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Table 2.8. Primer mixes used for initial HLA-DRB1 typing
| Primer Mix 5' primer 3' primer Amplified DRB1 alleles
1 5*01 3'15 *0101, *0102
2 5'01 3'10 *0103
3
5'02 3'01 *1501-1502
4 5’02 3'02 *1601-1602
5 5'03 3'03 *0301-0302
6
5'06 3'048 *0301
7 5'03 3'047 *0302,*1302,*1305, *1402-1403
8 5'04 3'047 *0401-0411
9 5'07 3'079 *0701-0702
10 5'08 3'045 *0801-0805
11 5'09 3'079 *0901
12 5'10 3'047 *1001
13 5'05 3'06 *1101-1104
14 ‘ 5'08 3'08 *1201-1202
15 5'03 3'10 *1301-1302
16 5'05 3'045 *1303-1304
17 5'03 3'17 *1305
18 5'05 3'11 *1401, *1404-1405
19 5'03 3'12 *1305, *1402-1403
20 5'04 3'19 *1410
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Table 2.9. Primer mixes used for HLA-DR*01 subtyping
Primer mix 5' primer 3' primer Amplified DRB 1*01 alleles
1 5*01 3'A *0101, *0103
2 5*01 3'B *0102
3 5'01 3'C *0101, *0102
4 5'01 3'D *0103 |
Table 2.10. Primer mixes used for HLA-DR*04 subtyping
Primer 5' primer 3* primer Amplified DRB1 *04 alleles
1 5'04 3'041 *0401, *0402, *0409
2 5'04 3'042 *0402
3 5'04 3'043 *0403, *0406, *0407, *0411
4 5'04 3'044 *0401, *0402, *0404, *0405, *0408, *0409, *0410
5 5'04 3'045 *0405, *0409, *0410, *0411
6 5'04 3'046 *0406
7 5'04 3'047 *0401, *0405, *0407, *0408, *0409
8 5'04 3'048 *0402, *0403, *0404, *0406, *0410, *0411
81
Figure 2,1, Algorithm for MICA typing
Stage 1 Stage 2 TM allele if known
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TM A6  ►
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NB all group 5 alleles and *014/*036 also F7R7+
neg for above ► TM A4 ►















CHAPTER 3 MICROSATELLITE 




3.1.1 Genomic structure of MICA
The MHC Class I Chain related Gene A (MICA) is one of the most polymorphic non- 
HLA genes in the human genome. It lies 46kb centromeric to HLA-B within the heart of 
the MHC complex. The MICA gene was discovered in 1994 by two independent 
laboratories (124; 125). Since then, the closely related MICB gene has been identified 
83kb centromeric to MICA. Subsequently, five related pseudogenes, MICC, MICD, 
MICE, MICF and MICG have been discovered (126). So far, none of the pseudogenes 
appear to be functional, although it is possible that MICE may serve some function in 
certain haplotypes.
Both MICA and MICB are unusually large genes: MICA is 11.7kb and MICB is 12.9kb 
(127; 128). This compares with the average length of the MHC Class I genes which is 
3.5kb. The overall genomic structure of MICA and MICB mirrors that of the MHC Class I 
genes with distinct functional domains (3 extracellular, a transmembrane and a 
cytoplasmic domain) each encoded by separate exons. The extracellular domains of MICA 
and MICB (al, a2 and a3) show an average 21%, 19% and 34% homology, respectively, 
to the MHC Class I genes. There is a striking difference in the size of the first intron of the 
MIC genes compared with the MHC Class I genes: 6.8kb in MICA, 7.4kb in MICB and 
less than 200bp in the Class I genes. In addition, MICA and MICB possess unique exons 
that encode the cytoplasmic tail and 3' untranslated segment. The major discernible 
difference between MICA and MICB lies in the presence of a microsatellite repeat in the 
transmembrane segment encoded by exon 5 of MICA which is absent in MICB. The 
significance of these genomic features remains uncertain.
There are a number of genes which share some homology with both the MIC genes and 
the Class I MHC genes. These genes collectively form a family known as the ‘Extended 
MHC Class I Family” or EMCIF. The genes within this family serve a wide variety of 
functions including iron haemostasis, the transfer of maternal immunity and interaction 
with bacterial and viral ligands. The genes are dispersed throughout the genome, with only 
HFE having a place within the MHC complex. The additional members of the EMCIF
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include CD1, MR1, Zinc a2 glycoprotein, neonatal Fc receptor, HFE and the CMV 
binding proteins, the ULBPs (129).
There is clear evolutionary conservation of the MIC genes across mammalian species. The 
apparent exception to this is rodents where degenerate PCR has failed to find any remotely 
homologous sequences. The region of the mouse H2 complex where the MIC genes would 
be expected to be located has been truncated from 173 to 40kb. Intriguingly, deletion of 
the same region of the human MHC has resulted in a haplotype found in some southeast 
Asians. This haplotype, the MIC ‘null’ haplotype (AH48.1) carries complete deletion of 
the MIC genes (130). This haplotype is extremely uncommon outside southeast Asia with 
the exception of some Amerindians. In southeast Asia, the AH48.1 is relatively common 
with a frequency of 3.2% and an expected homozygous carriage of 0.1%. So far, 8 
individuals homozygous for the MIC null haplotype have been reported in the literature. 
Ostensibly, these individuals have no clinical symptoms and a limited exploration of their 
NK and T cell repertoires has proved unremarkable. This would suggest that either the 
MIC genes are not essential for life, which seems unlikely in view of the high level of 
polymorphism, or that they are replaced in these individuals by functional homologues.
3.1.2 Expression o f MICA
In contrast to classical MHC genes, MIC genes are not ubiquitously expressed. Initially, 
expression of MICA was reported to be limited to the intestinal epithelium (131). 
However, it has since been confirmed that MICA is present in epithelial cells from a large 
variety of tissues, including the skin, liver and kidney. Notable exceptions to expression 
include the central nervous system and the spleen. MIC transcripts are not detectable in 
cells of lympho-haematopoietic lineage.
Transcription of the MIC genes is not enhanced by interferons and the gene sequence does 
not contain interferon response elements. However, it does contain sequences with 
significant homology to promoters of the heat shock protein gene (131). These sequences 
contain duplications of the heat shock response element (HRE) pentanucleotide motif 
common to a number of stress-induced genes such as the HSP70 gene. Transcription of
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MIC mRNA can be enhanced and cell surface expression increased by stressing epithelial 
cells at a variety of temperatures (131; 132). The physiological relevance of these in vitro 
experiments remains unclear. Equally, the effects of some of the stressful challenges 
experienced by epithelial cells in vivo such as hypoxia or infection have not yet been 
directly investigated.
MICA and MICB glycoproteins can be detected in a variety of transfected cells of diverse 
lineages (131). The presence of MICA mRNA would appear to be sufficient for 
expression. However, monoclonal and polyclonal antibodies to MICA do show tissue and 
site specific staining. There are several possible explanations for this. Differential 
expression may be related to the polymorphism within the gene. Another explanation may 
be the high level of glycosylation within the MIC genes. MICA has 8 N-linked 
glycosylation sites compared with only one in classical Class I proteins. Thus tissue or site 
specific glycosylation may cause differences in cell surface expression.
The native MICA molecule has been shown to localise to the basolateral surface of the 
intestinal epithelium. This intracellular targeting of the glycoprotein appears to be 
dependent on the cytoplasmic tail. This has been demonstrated by analysis of both a tail­
less construct and a construct containing the MICA A5.1 allele that has no cytoplasmic 
tail. The latter results in faulty location of the MICA molecule onto the apical surface of 
the cell, which may well lead to a loss of interaction with its receptor (133).
3,1.3 The MICA receptor
The receptor for MICA and MICB was originally thought to be the V51 receptor on y/5 T 
cells (134). However, there were several reasons to suggest that this was not the true 
receptor. Firstly, MIC expression patterns do not match V51 expression patterns. 
Secondly, direct physical contact between MICA and the V51 receptor has never been 
proven. Thirdly, direct V51 interaction has been shown more recently with another 
contender, CDlc. Finally, direct involvement of MICA with another receptor found 
ubiquitously on NK and T cells has now been demonstrated.
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MICA has been shown to interact directly with the NKG2D receptor found on NK and T 
cells (135). NKG2D belongs to the lectin family of NK cell receptors encoded by a cluster 
of genes on chromosome 12 (12pl2-13). NKG2D is the most genetically divergent of this 
family. NKG2D receptors are expressed on most ap and y8 CD 8+ T cells and NK cells in 
association with a signal-transducing unit called DAP 10 (136). In NK cells, MICA can 
lead to direct stimulation via the NKG2D receptor. In contrast, the mechanism of 
activation in T cells, is indirect and co-stimulatory by amplifying signals mediated through 
the T cell receptor.
Interestingly, unlike MICA, there is a murine orthologue of NKG2D. This would suggest 
that MIC molecules are not the sole occupier of these receptors. Indeed, soluble NKG2D 
binds to HLA Class I molecules with considerable avidity (137). In addition, more 
recently, a distinct set of ligands for NKG2D has been identified during a search for 
molecules which interact with the cytomegalovirus UL16 glycoproteins (129). These 
ULBPs are absent from most adult tissues but appear to be selectively expressed by 
tumour cells. They may well be a major signal for NK cell-mediated killing of tumour 
cells.
3.1.4 Function o f MICA
It is possible that the function of MICA in health differs from its function in disease. 
Although MICA is widely expressed in a variety of tissues there is some evidence for 
tissue and site specific expression. In addition, expression may be upregulated by cell 
‘stress’. When MICA is expressed on the cell surface of epithelial cells it binds to the 
NKG2D receptor on NK and T cells leading to cell activation. Activatory signals within 
NK and T cells then lead to the generation of specific cytokines that can further activate 
the immune response. MICA may therefore play a role in the response of the host to any 
stress, perhaps such as cell damage, hypoxia or infection. It may act as an important co­
stimulator of T cells in addition to Class I HLA molecules. The activation of NK cells 
leads to targeted cell destruction through the release of lytic particles. However, the 
NKG2D receptor is not the only receptor controlling the activation of NK cells. Any one
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NK cell has many receptors, including a number of the ‘immunoglobulin-like’ inhibitory 
receptors or KIRs. Thus, the profile of receptors on an individual’s NK cells (determined 
by the Leucocyte Receptor Complex on chromosome 19q) may also influence the ability 
to respond to signals of activation by MICA.
The strength of the immune response may well be related to the affinity of binding of 
MICA to NKG2D. Some polymorphisms have been shown to directly affect the binding 
affinity of MICA to its receptor by up to 50 fold, although the functional consequences of 
this are not known (138). This may be one of the driving forces for the extensive degree of 
polymorphism within the MICA gene.
It has been demonstrated that the MIC molecules certainly play a role in the recognition of 
self. They appear to be involved in the rejection of HLA-matched kidney transplants, 
where specific antibodies to MIC have been isolated (139). In addition, MIC seems to be a 
component of the evasion of NK cell immunity by tumour cells. Several epithelial 
tumours have been shown to over-express MIC molecules. Recently, it has been 
demonstrated that the NK cells of patients with adenocarcinoma of the colon lack 
expression of NKG2D receptors which have been internalised and down-modulated by 
high levels of soluble MIC in the serum (140). Thus tumours can evade the host immune 
response by deactivating NKG2D receptors by the overproduction of MIC. It is possible 
that a similar dysregulation of the MIC / NKG2D system may play a part in an 
individual’s response to viral or other infections and triggers. Equally, continued 
stimulation of the NK and T cell response may promote autoreactivity and perpetuation of 
an immune response leading to the development of an inflammatory arthritis.
3.1.5 Structure o f the MICA glycoprotein
The crystal structure of a soluble MICA glycoprotein (allele *001) has been analysed 
(141). It is a 383 amino acid polypeptide with a molecular weight of 43kDa. The 3 
dimensional structure closely resembles that of MHC Class I with the membrane-proximal
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a3 domain and the al and a2 domains forming a distal eight stranded, antiparallel, p 
pleated sheet topped by two largely parallel a helices. Unlike MHC Class I, MICA is not 
associated with P2-microglobulin (p2m). The reason for this is unclear, although the large 
number of glycosylation sites and the lack of well-documented P2m contact points are 
possible explanations. It may also be related to the remarkable flexibility of the MICA 
molecule due to a long linker peptide between the a3 domain and the ala2 platform. In 
contrast to Class I molecules, there is no intimate contact between these two sections of 
the protein, indeed they are separated by a deflection of 113.5 degrees.
The putative binding cleft of the MICA molecule is significantly smaller than that seen in 
MHC Class I molecules. The distance between the two a  helices is much narrower (7-10 
A) than Class I molecules (>18 A). Indeed, it is even narrower than related molecules 
(CD1 and FcRn) that have been shown not to bind to a peptide. Multiple attempts to detect 
a peptide that associates with MICA have failed. In addition, there is no unaccounted for 
electron density within the crystal structure (141). Thus far, it would appear that MICA 
does not require any additional cargo to interact with its receptor. This feature is 
apparently out of keeping with the high degree of polymorphism detected within the 
MICA gene.
3,1.6 Polymorphism of the MICA gene
The MICA gene displays a very high level of polymorphism. To date, 54 alleles have been 
described (http://www.anthonvnolan.org.uk). There are three main mechanisms of 
polymorphism: single nucleotide polymorphism (SNP), insertion/deletion and triplet 
repeat microsatellite polymorphism.
3.1.6.1 Single nucleotide polymorphism
There are a total of 40 SNPs in the MICA gene which are located predominantly in exons 
2,3 and 4 which encode the extracellular domains. There is a very high level of non- 
synonymous substitution (75%), particularly in exon 3 where 15 out of 16 SNPs result in a
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change of amino acid {Figure 3.1). Another interesting feature of the SNPs within MICA 
is the strictly biallelic nucleotide substitution, that is, there is only ever one alternative 
nucleotide at each position. This contrasts with MHC molecules where any nucleotide can 
be substituted at any position.
The nature of the selective forces maintaining this polymorphism is not known. In 
classical MHC molecules, much of this selective pressure is thought to derive from ever- 
changing infectious agents generating an increasingly diverse range of peptides. The fact 
that the majority of polymorphism in Glass I MHC molecules is located near the peptide 
binding cleft supports this theory. However, virtually none of the polymorphic positions 
found in Class I MHC molecules are mirrored in the MICA molecule. In MICA, many of 
the polymorphic sites are in positions where they can influence the NKG2D receptor 
binding site {Figure 3.1). Thus, the driving force for the polymorphism appears to be 
related to changes in the avidity of receptor binding. The reason for this has not yet been 
discovered.
MICB seems to be less polymorphic than MICA although this may reflect the fact that it 
has been less thoroughly studied. There are 15 SNPs, 12 of which are non-synonymous, 
which define the 16 currently recognised alleles (MICB001 -  MICB016) (142). One of 
these alleles, MICB010, has a stop codon in exon 3. This allele is always associated with a 
lOOkb deletion rendering it a MICB and MICA null allele. Between the MICB and MICA 
genes is a 1000 fold ‘TA’ repeat which may represent a hot spot for recombination, 
although some alleles do appear to be maintained along ancestral haplotypes.
3.1.6.2 Insertion /  deletion
There are several examples of the insertion or deletion of a single nucleotide within the 
MICA gene. This seemingly trivial event can trigger a frame shift, truncation of the 
polypeptide and potentially dramatic effects on protein function. An insertion of a guanine 
within the triplet microsatellite repeat in exon 5 results in the most commonly occuring 
allele, A5.1. The resultant protein lacks a cytoplasmic tail which affects the localisation of 
the protein on the cell surface (133). Deletion of a guanine at the end of the 4th exon
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thoccurs in the MICA *015 and *017 alleles. This changes the reading frame for the 5 
exon resulting in a totally different TM segment with a long, hydrophobic polyleucine 
region and a shortened cytoplasmic tail. The functional consequences of this deletion are 
not yet known.
3.1.6.3 Microsatellite polymorphism
The microsatellite ‘GCT’ repeat in exon 5 is another interesting contributor to the genetic 
diversity of MICA (143). It is one of the features of the polymorphism of MICA not 
shared by MICB. The microsatellite encodes 4, 5, 6, 9 or 10 alanines producing the alleles 
A4, A5, A6, A9 and A10, respectively (143; 144). It is curious why there appears to be no 
A7 or A8 allele. One of these alleles (A5) has an additional insertion of a guanine 
producing the A5.1 allele.
3,1.7 Nomenclature
The nomenclature of MICA can be confusing. There are two main groups of alleles that 
are commonly referred to in clinical studies. Firstly, the alleles can be divided into just 6 
groups by virtue of the microsatellite repeat in exon 5. Thus, this nomenclature comprises 
the A4, A5, A5.1, A6, A9 and A10 alleles. However, these alleles can differ in exons 2,3 
and 4 due to single nucleotide polymorphisms. Therefore there are in fact several alleles 
that are ‘A4’, ie. that have 4 GCT repeats in exon 5. These include MICA *001, *007, 
*012 and *018. The more correct and official nomenclature therefore labels these alleles 
MICA *001- *049 (114). Some of the alleles are very closely related and only differ by 
one SNP that does not result in an amino acid change. These alleles are labelled as 
subdivisions of a single allele, for example, *00201, *00202, *00701, *00702, *00801, 
*00802, *00803, *00901, *00902, *01201, *01202. Historically, there is no *003 allele as 
the allele that was originally thought to be *003 was not correctly sequenced.
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3.1.8 Frequency o f the MICA alleles in control populations
There have been several studies of the frequency of the alleles of MICA in a variety of 
ethnic populations (118; 145). There are some differences in allele frequencies, 
particularly between Caucasian and non-Caucasian populations. The best characterised 
populations come from the USA, UK and Japan. By far the most common allele in all 
studied populations is MICA*008. This allele has a TM region containing 5 GCT repeats 
and a guanine insertion and is thus one of the A5.1 alleles. The next most common alleles 
are MICA*002, *004, *009 and *010. A recent study of inflammatory bowel disease in 
the UK examined a large number of controls and patients for the presence of all 54 alleles 
(117). Only 13 of the 54 alleles were present at a frequency of greater than 1%, suggesting 
the more recent evolutionary generation of new alleles from a series of more conserved 
ancestor alleles.
3.1.9 Disease associations
Due to the proximity of MICA to the HLA Class I genes, a growing number of studies 
have examined associations between polymorphisms of MICA and disease. Although 
most studies have involved the diseases classically associated with Class I HLA genes 
(Behcets, Psoriasis, AS, Inflammatory Bowel Disease) many other diseases have been 
investigated. The majority of studies have concentrated on the microsatellite repeat in 
exon 5. Fewer studies have attempted to address the more complex polymorphism within 
the 2nd, 3rd and 4th exons. The disease associations that have been reported are outlined in 
Table 3.1.
3.1.10 Studies of MICA in Psoriasis and PsA
Associations of the polymorphism within the transmembrane region of MICA have been 
studied in Type I psoriasis. One study in Australian patients found an association between 
Type I psoriasis and the MICA allele which has 9 GCT repeats (A9) and a guanine 
deletion at the beginning of intron 4 (50). The allele with the same number of GCT repeats 
(also A9), but no deletion, was not associated. Other studies in Chinese and Korean 
patients have shown an association between the truncated form of the protein, A5.1, and
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Type I psoriasis (51; 52). None of these studies looked for the presence of arthritis 
complicating the psoriasis.
Three studies have found an association between PsA and the MICA A9 allele but 
relatively small numbers of patients have been studied considering the complexity of the 
condition. The first study examined 45 patients with psoriasis and 65 patients with PsA 
from Spain (67). The patients with psoriasis were not specifically screened for the 
presence of arthritis or silent radiographic sacroiliitis. The frequency of the A9 allele was 
significantly higher in the PsA group, but the frequency in psoriasis was no different from 
controls. These findings were later confirmed in a slightly larger group of 81 patients with 
PsA (68). The third study to find a positive association between the A9 allele and PsA was 
in a Jewish population of 52 patients but there was no psoriasis control group (66).
3.1.11 MICA in RA, AS and JIA
MICA has also been investigated in a number of other rheumatological conditions 
including RA, AS and JIA (146). The A6 allele has been shown to be protective for RA 
(147). The frequency of the A4 allele is increased in AS (148-151), although it would 
appear that this is due to its close association with HLA-B27. The A4 allele has also been 
associated with Juvenile Idiopathic Arthritis (152).
3.2 Aims of the study
The aim of this study was to investigate whether there was any association between the 
microsatellite polymorphism of MICA and PsA. Patients with well documented PsA, 
patients with Type I psoriasis screened for the presence of arthritis and controls were 




Three major groups of patients were included in this study:
(i) The first group consisted of patients with well-documented PsA who were recruited 
from a specialist Rheumatology outpatient clinic at the RNHRD in Bath (n=158), as 
described in Chapter 2.2.2.
(ii) The second group of patients had psoriasis. They were recruited from a specialist 
dermatology clinic and GP practice in Bath, UK, as described in Chapter 2.2.2. A total of 
90 patients were recruited, of whom 49 were found to have Type I psoriasis 
uncomplicated by arthritis, 15 had Type II psoriasis and 26 had Type I/II psoriasis 
together with clinical or radiological evidence for an inflammatory arthritis. For the 
purposes of the analysis, only the 49 patients with uncomplicated Type I psoriasis were 
included. The remaining patients were analysed separately.
(iii) The third group of patients were recruited from the 13th International 
Histocompatibility Workshop on psoriasis. Samples from patients with Type I psoriasis 
were contributed from laboratories in Belgium (n=72), Germany (n=33) and Italy (n=26). 
None of the patients were screened for the presence of a complicating arthritis.
3.3.2 Controls
The control samples (n=148) were recruited from random blood donors in the UK as 
described in Section 2.2.2. All controls underwent appropriate screening but the presence 
of mild background psoriasis can not be excluded. It should be noted that no ethnically 
matched controls were available for the 13IHW patients.
3.3.3 Reference Samples
Samples from the 4AOH and 10th IHW panels with well documented MICA alleles were 
used for reference (Table 3.2).
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3.3.4 Preparation of DNA samples
DNA was extracted from blood samples following the procedure outlined in Section 2.3.3. 
The concentration of DNA in each sample was then measured on a spectrophotometer and 
any samples with a high protein content were purified accordingly (Section 2.3.6). 
Working dilutions of 20ng/pl were made by diluting the DNA with dcfflhO. The stock 
solutions and diluted DNA samples were then frozen until needed.
3.3.5 Development of a technique for distinguishing the microsatellite alleles o f MICA 
There have been a number of techniques published for the separation of the MICA 
microsatellite alleles. The basis for all these techniques is the separation of the alleles by 
size. Most of the alleles differ by 3 base pairs, but one (A5.1) only differs by 1 base pair. 
Therefore a high resolution separation technique is needed. It was decided to utilise a 
Gene Scanner 2000 (Corbett Research) which separates PCR products on the basis of their 
size and can be adapted for high resolution. There are several advantages of this machine 
over some of the other techniques used to separate different sized products. Firstly, it is 
able to detect double stranded PCR products thus avoiding the need for a denaturing gel. 
Secondly, the products can be detected by ethidium bromide using a laser, therefore no 
extra labelling of the sample is required. Thirdly, the resolution of the technique has been 
shown to be high, with the ability to discriminate products that differ in size by just 1 base 
pair.
3.3.6 Optimisation o f the technique
Initially, previously published primers were selected to amplify a region of exon 5 
containing the GCT repeat microsatellite (50). These primers, called PERTMF and 
PERTMR (Table 2.1) yielded products varying in size according to their allele: 
297bp(A4), 300bp(A5), 301bp(A5.1), 303bp(A6) and 312bp(A9). In order to achieve 
maximum resolution of the products, the concentration of polyacrylamide in the gel was 
increased gradually from 4% to 10%. At the higher concentrations, there was some loss of
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clarity of the gel with blurring of the products and increased “smile” in the gel due to 
uneven distribution of current. The optimal concentration was found to be 8%. However, 
resolution of the products was not high enough, even with the use of a longer gel (30cm). 
Thus a smaller product size was sought to maximise the ability to detect small differences 
in size.
The primer pair, PERTM100F and PERTM100R (67) yields product sizes of just over 
lOObp. The sizes of the products for the different alleles are: 118bp(A4), 121bp(A5), 
122bp(A5.1), 124bp(A6) and 133bp(A9).
3.3.7 Typing for MICA microsatellite alleles
Details of the reaction mix and PCR conditions used for the MICA microsatellite typing 
are given in Chapter 2.4.1.1. The PCR samples were then analysed using the Gene 
Scanner 2000 using the method described in Section 2.4.1. The resultant image of the gel 
produced by the laser scanning the PCR products is stored as a tif image. An example of a 
gel is given in Figure 3.2. Molecular weight marker is loaded at regular intervals between 
groups of eight samples. The MICA alleles are assigned for each PCR product after 
conversion of the tif image into a text file which is then imported into an excel 
spreadsheet. Each product is then plotted as a line graph with intensity of the product on 
the ‘y’ axis and time on the ‘x’ axis. Examples of the resultant graphs for varying 
combinations of alleles are given in Figures 3.3-3.12. The results were then inputted into 
an excel database containing all demographic and clinical information on the patients.
3.3.8 HLA typing
All PsA, Type I psoriasis (UK) and control samples were typed for HLA-Cw6 and HLA- 
B27 using sequence-specific primers (122) (Chapter 2.4.4). Some of the 13IHW samples 
(Belgian, n=72) were provided with full Class I and Class II HLA typing. The PsA 
samples were also typed for the HLA-DRB1 SE as described in Chapter 2.4.3.
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3.3.9 Statistics
The frequencies of the MICA alleles were determined by direct counting. Results were 
expressed as phenotype frequencies (the number of patients with at least one allele) and 
allele frequencies (the total number of alleles present). Differences between patient 
groups and controls were determined using the Chi-squared test with Fisher’s Exact test 
where necessary. No ethnically matched controls were available for the 13IHW patients. 
The results were therefore compared with the UK controls but the results should therefore 
be interpreted with caution. For continuous variables, such as tender and swollen joint 
counts and PASI, the Mann Whitney U test was applied. The p  values were considered to 
be significant if <0.05. Thep  values were corrected using the Bonferroni correction for the 
number of alleles observed. Odds ratios with 95% confidence intervals were also 
calculated.
3.4 Results
3.4.1 Clinical characteristics o f the disease groups
The demographic and clinical information on the patients with PsA and Type I psoriasis 
from the UK are given in Table 3.3. There was very limited clinical information available 
for the patients from Belgium, Italy and Germany who took part in the 13th IHW. Due to 
the methods of recruitment, there were some inherent differences between the patients 
with PsA and the patients with psoriasis. The patients with uncomplicated Type I psoriasis 
were significantly younger and had a significantly younger age of onset of psoriasis. Some 
of these differences were overcome by stratifying the patients with PsA for the age of 
onset of their psoriasis. Although some patients with psoriasis were recruited from general 
practice, the majority of patients were recruited from a specialist dermatology clinic. This, 
not surprisingly, resulted in a higher median PASI score for the psoriasis only group. It is 
interesting to note that the incidence and severity of nail disease was very similar in the 
two groups.
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3.4.2 Frequencies o f the MICA microsatellite alleles in the patient populations
The frequencies of the MICA microsatellite alleles in the patient populations have been 
expressed as both phenotype frequencies and allele frequencies. The phenotype 
frequencies in PsA, Type I psoriasis (UK), Type I psoriasis (13IHW) and controls are 
given in Table 3.4. The MICA A9 allele was significantly increased in the PsA 
(Pcorr<0.0005, OR 2.4 (1.48-3.88) and 13IHW ^ < 0 .0 0 0 5 , OR 2.5 (1.52-4.15)) 
populations. A similar increase was not observed in the UK Type I psoriasis population. 
MICA A4 was increased in the PsA population, but this did not reach significance. The 
majority of the increase in MICA A9 was accounted for by a decrease in MICA A5.1, but 
this did not reach significance. There were no significant differences in the other MICA 
phenotype frequencies.
If the MICA microsatellite alleles were expressed as allele frequencies, once again MICA 
A9 was significantly increased in the PsA (pCOir=0.0025, OR 2.31) and 13IHW psoriasis 
(Pcorr=0.0005, OR 2.31) populations (Table 3.5). The allele frequencies of MICA A5.1 
now become significantly reduced in the PsA (pcorr=0.008, OR 0.59) and 13IHW 
(pcorr<0.0005, OR 0.55) populations compared with controls.
The phenotype frequencies of the MICA microsatellite alleles in the different populations 
of Type I psoriasis are illustrated in Table 3.6. The A9 allele was significantly increased in 
the Belgian (pcon^O.005, OR 2.8 (1.55-5.04)) and German populations (pCoir=0.05, OR 
2.63 (1.21-5.71)), but not in the UK or Italian populations. If all of the Type I psoriasis 
populations were grouped together, A9 was significantly increased (pcoir=0.005, OR 2.8 
(1.55-5.04)). If the results were expressed as allele frequencies, only the Belgian and total 
psoriasis groups reached significance (Table 3.7). Once again the reduction in MICA A5.1 
became significant if the total number of alleles was considered. The significance of these 
results cannot be guaranteed due to the lack of an ethnically matched control group for the 
European patients.
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3.4.3 Associations of the MICA microsatellite alleles with clinical subgroups of PsA 
The phenotype frequencies of the MICA microsatellite alleles in the subgroups of PsA are 
expressed in Table 3.8. The main clinical subgroups were polyarthritis, oligoarthritis and 
spondyloarthritis. Patients with spondyloarthritis could also have peripheral joint 
involvement. Patients in the UK psoriasis group who were screened and found to have 
occult arthritis were also included in this analysis. The MICA A9 allele was increased in 
all groups, although, perhaps due to sample size, this only reached significance in the 
polyarthritis and oligoarthritis groups. The frequency of MICA A5.1 was significantly 
reduced in the polyarthritis group. The frequency of MICA A4 was increased in all groups 
but this failed to reach significance.
3.4.4 Associations o f the MICA microsatellite alleles with clinical manifestations o f PsA 
There were no significant associations between the MICA microsatellite alleles and any of 
the clinical parameters of disease severity measured, including tender and swollen joint 
counts, PASI, nail score, DMARD use or HAQ. There was no association between the age 
of onset of psoriasis or the age of onset of PsA and any of the MICA alleles. There was 
also no association between any of the MICA alleles and positive family history of either 
psoriasis or PsA. The MICA alleles were present at equal frequencies between those PsA 
patients that had erosive disease and those that had not developed erosions (Table 3.9). In 
particular, MICA A9 was present in 47% of erosive patients and 47% of non-erosive 
patients.
3.4.5 Stratification for age o f onset ofpsoriasis
If the patients with PsA were stratified according to the age of onset of their psoriasis (<40 
and >40 years of age), the A9 allele was still significantly increased in both groups. 
Marginally more of the patients with PsA with early onset psoriasis were positive for the 
MICA A9 allele compared with those with a later onset of their skin disease (49% vs 40%, 
NS).
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3.4.6 Associations of the MICA microsatellite alleles with HLA-Cw6 and HLA-B27
The frequency of HLA-Cw6 was significantly higher in the PsA than the control 
population (65/151 (43%) HLA-Cw6 positive PsA patients compared with only 26/131 
(20%) controls, p<0.0001, OR 3.05 (1.79-5.22)). HLA-Cw6 was also highly significantly 
associated with Type I psoriasis (33/46 (72%) Type I psoriasis (UK) compared with 
26/131 (20%) controls (p<0.0001, OR 10.25 (4.74-22.19)). The MICA A9 allele is 
significantly associated with HLA-Cw6 (pcorr<0.0005, OR 3.36 (1.71-6.59)) (Table 3.10.).
The MICA A4 allele was significantly associated with HLA-B27 (88% of A4 alleles were 
associated with HLA-B27 (pCOrr<0.0005, OR 47 (13-173)) {Table 3.11). MICA A9 alleles 
were observed more frequently in HLA-B27 negative patients, although this significance 
disappeared on correction for multiple testing. There were no other associations between 
the MICA alleles and HLA-B27.
3.4.7 Stratification for HLA-Cw6
The patients with PsA were analysed separately according to their HLA-Cw6 status. If all 
HLA-Cw6 patients and controls were removed, 34% of the remaining patients were 
positive for MICA A9 compared with 19% of controls (puncorr=0.015, pcorr=0.075, OR 2.24  
(1.16-4.32). Conversely, if the MICA A9 positive patients were removed from the 
analysis, HLA Cw6 was present in 30% of the patients with PsA compared with 11% of 
controls (puncorr=0.002, pCOIT=0.01, OR 3.25 (1.48-7.16)).
3.4.8 Associations o f the MICA microsatellite alleles with the HLA-DRB1 *shared 
epitope* (SE) and HLA-Class II alleles
Overall, there was no association between any of the MICA alleles and the HLA-DRB1 
SE alleles (HLA-DRB1*0101, *0102, *0401, *0404, *0405, *0408, *1001) {Table 3.12). 
MICA A9 was more likely to be associated with SE negative alleles, but this significance 
was no longer present after correction for multiple testing. Comparison of the MICA 
alleles was also made with HLA-DR1, HLA-DR4 and HLA-DR7. There was a significant 
association between the MICA A4 allele and HLA-DR1 (puncorr = 0.006, pcorr = 0.03, OR
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2.8 (1.33-5.88)) (Table 3.13). On further analysis, this association was primarily due to 
HLA-DRB1* 0101 (pmcori =0.003, p ^  =0.015, OR 3.25 (1.47-7.19)) (Table 3.14). There 
were no further associations between any of the MICA alleles and HLA-DR4 or HLA- 
DR7.
3.5 Discussion
Patients who develop PsA have a significantly higher proportion of MICA alleles that 
contain 9 GCT repeats in exon 5 than controls. In fact nearly 50% of patients with PsA 
possess at least one MICA A9 allele compared with only 26% of controls. This finding is 
highly significant whether one considers the number of patients with a particular allele 
(phenotype frequency) or the absolute number of alleles (allele frequency). The increase in 
MICA A9 seems to be largely at the expense of the MICA 5.1 allele. This reaches 
significance if the absolute numbers of alleles is taken into account. The MICA A5.1 
allele is the commonest allele in most populations and could therefore be assumed to be 
associated with ‘health’. The MICA A9 allele has been previously described in association 
with both psoriasis and PsA (50; 66)(67) albeit in much smaller populations than 
described here. There have been no reports of the association of MICA A9 with any other 
diseases except Insulin Dependent Diabetes Mellitus in a Taiwanese population (153). It 
would appear therefore that there is something unique about this allele that contributes to 
the development of PsA. A key question, however, is whether the association is 
predominantly with PsA or whether MICA A9 is more important in the development of 
psoriasis.
In order to address this question, a control group of patients with Type I psoriasis was 
recruited who were screened for the presence of arthritis. Interestingly, MICA A9 was not 
increased in frequency in this population. However, MICA A9 was increased in the 
population of patients with Type I psoriasis who were involved in the 13IHW, particularly 
the Belgian and German patients. There could be several explanations for this. Firstly, the 
13IHW psoriasis populations were not specifically screened for the presence of arthritis. 
Therefore the increase in the frequency of MICA A9 in this group could be explained by a 
high prevalence of either overt or occult arthritis. This explanation assumes that the 
primary association with A9 is with psoriatic arthritis rather than psoriasis. Secondly, the
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UK psoriasis population is relatively small (n=49), therefore the figures may fail to reach 
significance because of the sample size. Thirdly, MICA A9 may be important in the 
development of psoriasis in some European populations but not in others. This final 
argument would be supported by differences in the MICA allele frequencies between the 
psoriasis populations. In particular, the Italian psoriasis population would appear to be 
different to the others with a lower frequency of MICA A9 and a higher frequency of 
MICA A4. The 13IHW results must be interpreted with caution due to the lack of an 
ethnically matched control group.
Another potential problem when comparing the allele frequencies between the PsA and 
psoriasis groups was the difference in the onset and severity of the psoriasis. The patients 
with PsA had a significantly later age of onset of their psoriasis compared with the 
patients with Type I psoriasis recruited in the dermatology and GP clinics in the UK. 
Therefore, some of the patients who were classified as psoriasis without arthritis could 
potentially still develop arthritis in the future. Indeed the patients in the psoriasis group 
were significantly younger than the patients with PsA. However, the overall duration of 
psoriasis between the two groups was similar (25 and 28 years). It is known that most 
patients with PsA develop the arthritis after the psoriasis, but it would be unusual for 
many patients to develop arthritis after having psoriasis for at least 25 years. The patients 
with PsA were stratified according to the age of onset of their psoriasis and MICA A9 was 
found to be equally significant in patients with PsA with both early and late onset 
psoriasis.
The patients with Type I psoriasis also had a higher PAS I score suggesting that their 
psoriasis was in general more severe than the patients with PsA. This is not entirely 
surprising in view of the recruitment strategy used. The majority of patients were recruited 
from a hospital Dermatology clinic and therefore would have more severe skin disease 
than those recruited from general practice or indeed the community. These differences 
must be taken into account when directly comparing the results between PsA and 
psoriasis. Ideally the groups should be better matched for age, age of onset of psoriasis 
and severity of psoriasis. However, it is still helpful to have a psoriasis only control group 
and despite these clinical and demographic differences it will certainly help distinguish
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those genes that are important for the skin disease from those that are important in 
arthritis.
The distribution of the MICA alleles between the different clinical subgroups of PsA was 
fairly even. MICA A9 was globally increased in all groups, including those with occult 
arthritis recruited in the dermatology clinic. The increase in MICA A9 only reached 
significance in the polyarthritis and oligoarthritis groups, probably due to sample size. The 
increase in MICA A4 just failed to reach significance once the statistics were corrected for 
multiple testing.
None of the MICA alleles, including A9, were associated with any of the clinical or 
radiological parameters of disease severity such as tender and swollen joint counts, PASI, 
DMARD use or the development of erosions. This was also the case in the psoriasis 
population, where there were no associations between the MICA alleles and the PASI. 
This would suggest that MICA A9 is a susceptibility and not a severity gene. This would 
be supported by the lack of association between MICA A9 and the HLA-DRB1 SE. It will 
be demonstrated later that the SE is associated with the development of erosive disease in 
PsA and may therefore be a ‘severity’ gene. MICA A9 is negatively associated with the 
SE alleles (although not significantly so), suggesting that they are independent of one 
another, perhaps one acting to increase susceptibiblity to PsA and the other modifying its 
presentation.
There were some associations between the MICA alleles and HLA-B27 and HLA-Cw6. 
MICA A4 was strongly associated with HLA-B27 suggesting strong linkage 
disequilibrium between the two alleles. This is corroborated by the findings of several 
studies that have demonstrated an association between MICA A4 and ankylosing 
spondylitis (148; 150; 151). MICA A4 is also associated with HLA-DR1, particularly the 
HLA-DRB 1 *0101 allele, due to its presence on the same ancestral haplotype. MICA A9 
was found to be strongly associated with HLA-Cw6. Clearly HLA-Cw6 is known to be 
associated with psoriasis and to a lesser degree PsA and the relationhip between HLA- 
Cw6 and MICA A9 requires further examination.
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A major problem encountered during the interpretation of significant associations between 
alleles within the MHC region and disease is whether the association is indeed primarily 
with the gene of interest or whether the association is secondary to a stronger association 
with a neighbouring gene. In the case of MICA, it is possible that the association with 
MICA A9 and PsA is all due to the presence of MICA A9 on haplotypes containing HLA- 
Cw6. To explore this possibility, the patients with PsA were stratified and analysed 
according to their HLA-Cw6 status. Removal of all HLA-Cw6 positive patients and 
controls resulted in a loss of significance for MICA A9 after correction for multiple 
testing ((puncorr=0.015, pCoir=0.075, OR 2.24 (1.16-4.32)). Thus it would appear that a 
major reason for the association of MICA A9 with PsA is due to its linkage with HLA- 
Cw6. However, a component of the MICA association is independent of HLA-Cw6. This 
component just failed to reach significance perhaps due to the smaller numbers in the 
groups once HLA-Cw6 patients had been eliminated. There are several MICA alleles that 
have 9 GCT repeats in exon 5 (A9 alleles). Some of these are known to be present on 
HLA-Cw6 bearing haplotypes (such as MICA *017), whereas others (such as MICA 
*002) are more independent of HLA-Cw6. Further analysis of the MICA alleles that are 
associated with PsA would clarify the situation.
The technique utilised for the identification of the microsatellite alleles of MICA was easy 
to use and relatively quick to interpret. There were some inherent problems with the 
technique. One problem encountered was uneven current running through the gel. This 
resulted in ‘smile’ across the gel where the products in the centre of the gel progressed 
more rapidly than the products on the edges of the gel. Care needed to be taken when 
pouring and setting the gel to ensure an even gel was produced. Molecular weight marker 
was loaded at regular intervals to provide accurate reference points for the interpretation 
of the products. The use of internal markers within the loading buffer for each sample also 
gave a static reference point. The vast majority of allele combinations were easy to 
distinguish. However, homozygous samples and samples that were heterozygous for A5 
and A5.1 required some caution in their interpretation since the level of discrimination 
was down to one base pair. It is possible that some errors occurred. Further exploration of 
the MICA alleles could be used to confirm the allele designation based on the 
microsatellite repeat.
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It is unclear why a repeat of the GCT microsatellite in exon 5 of the MICA gene should be 
associated with disease. The MICA A9 polymorphism results in 9 alanines in the 
transmembrane region. This would result in a slightly longer TM segment but the 
functional consequences of this are not known. It is possible that the polymorphism may 
affect the transportation to or stability of the molecule at the cell surface. It may have 
some effect on the interaction with the NKG2D receptor but this would seem unlikely 
since there is no direct contact between the TM region of the protein and the receptor. It 
would seem more likely that a polymorphism within the a l or a2 domains where the 
platform for receptor binding is formed would be responsible for an association with
tVidisease. There are several alleles of MICA that have 9 GCT repeats in the 5 exon. A 
more detailed exploration of the polymorphisms within the 2nd, 3rd and 4th exons of the 
MICA gene would clarify which of the A9 alleles are associated with PsA and which, if 
any, are associated with psoriasis.
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Table 3.1. Disease associations with the MICA alleles






Psoriatic arthritis A9 *002 Caucasian (Spain) (67)
A9 Caucasian (Israel) (66)
Psoriasis PERB11.1 *06 (A9) - Caucasian (Australia) (50)
A5.1 - Oriental (Korea) (52)
A5.1 _ Oriental (China) (51)
Ankyiosing A4 - Caucasian (Europe) (148)
Spondylitis
A4 - Caucasian (Europe) (150)
- *007 and 
*010
Oriental (Japan) (149)





Caucasian, African and Asian (154)
Rheumatoid
Arthritis
A6 (protective) - Caucasian (Europe) (147)
Juvenile Idiopathic A4 - Caucasian (Latvia) (152)
Arthritis
Inflammatory - NS Caucasian (UK) (117)
Bowel Disease
A6 - Oriental (Japan) (155)
NS
(HLA-B52)
- Oriental (Japan) (156)
- *007 Caucasian (UK) (157)
IBD + peripheral - *00801 Caucasian (UK) (157)
arthropathy











Oriental (Japan) and 














A4 +A5.1 - Oriental (Japan) (163)
A6 (protective) - Oriental (Japan) (163)
A5 - Caucasian (Italy) (164)
















Leprosy A5 (protective) - Oriental (China) (168)
Cervical neoplasia NS - Caucasian (Sweden) (169)
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Table 3.2. Reference DNA panel for MICA microsatellite typing
MICA TM 
allele






A4 *001 EVA SP 100051Y 9135 18.2
A4 *00701 BM92 10020IF 9092 51
A5 *010 BSM 100073N 9032 62.1
A5 *016 J0528239 100019U 9041 35.1
A5.1 *00801 REE,GD 100044V 9132 8.1
A5.1 *00801 PLH 100064P 9047 47.1
A6 *004 RSH 100007B 9021 42.1
A6 *006 KAS116 100154N 9003 51
A9 *00201 YAR 100009X 9026 38.1
A9 *017 DBB 100084G 9052 57.1
108
Table 3.3. Demographic and clinical characteristics of the PsA and psoriasis 
populations
I Characteristic Psoriatic arthritis 
(n=158 )
Type I psoriasis (UK) 
(n=49)
Sex M:F 79F: 79M 22F: 27M
Median age (yrs) (range) 60 (33-92) 41 (17-80)1
Median age of onset of psoriasis (yrs) 
(range)
31 (3-70) 19 (3-39)2
Median duration of psoriasis (yrs) (range) 28 (7-79) 25 (2-67)
Median age of onset of arthritis (yrs) 
(range)
37 (10-71) -
Median duration of arthritis (yrs) (range) 19 (7-67) -
Nail involvement 71% 59%
Median Nail score 1.5 (0-13.5) 2.9 (0-23)
Median PASI (range) 1 (0-27) 2.9 (0.2-16.5)3
1 p<0.0001 comparing median age of PsA and Type I Ps patients
p<0.0001 comparing median age of onset of psoriasis of PsA and Type I Ps patients
3 p<0.0001 comparing median PASI of PsA and Type I Ps patients
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Type I Psoriasis 
(UK) (n=49)




A4 46 (29%) 7 (14%) 37 (28%) 26 (18%)
A5 17(11%) 5 (10%) 22 (17%) 28 (19%)
A5.1 97 (61%) 37 (76%) 80 (61%) 110(74%)
A6 48 (30%) 16 (33%) 39 (30%) 50 (34%)
A9 73 (46%)' 16 (33%) 62 (47%)2 39 (26%)
1 Puncorr <0.0001, pc^O.0005, OR 2.4 (1.48-3.88)
2 Puncorr <0.0001, pCOiT<0.0005, OR 2.51 (1.52-4.15) (compared with UK controls) 
NB. No ethnically matched control group was available for the 13IHW patients
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Type I Psoriasis 
(UK) (n=98)





A4 0.158 0.071 0.145 0.091
A5 0.054 0.051 0.084 0.101
A5.1 0.3711 0.510 0.3512 0.497
A6 0.158 0.184 0.160 0.179
A9 0.2593 0.184 0.2604 0.132
Total 1 1 . 1 1
1 Puncorr = 0.0016, p corT = 0.008, O R  0.59
2 Puncorr < 0.0001, pcorr < 0.0005, O R  0.55 (compared with UK controls)
3 Puncorr = 0.0005, p ^  = 0.0025, O R  2.31
4 puncorr = 0.0001, Pcorr = 0.0005, O R  2.31 (compared with UK controls)
NB. No ethnically matched control group was available for the 13IHW patients
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Table 3.6. Phenotype frequencies of the MICA microsatellite alleles in the patients

























A4 7 (14%) 19 (26%) 9 (27%) 9 (35%) 44 (24%) 26(18%)
A5 5 (10%) 17 (24%) 2 (6%) 3 (12%) 27 (15%) 28 (19%)
A5.1 37 (76%) 43 (60%) 21 (64%) 16 (62%) 117(65%) 110(74%)
A6 16 (33%) 19 (26%) 11 (33%) 9 (35%) 55 (31%) 50 (34%)
A9 16 (33%) 36 (SO^o)1 16 (48 %)2 10 (38%) 78 (43%)3 39 (26%)
VuncoiT = 0.001, Pcorr = 0.005, OR 2.80 (1.55-5.04) compared with UK controls 
2puncorr = 0.01, pcorr = 0.05, OR 2.63 (1.21-5.71) compared with UK controls 
3puncorr= 0.001, pcotr = 0.005, OR 2.80 (1.55-5.04) compared with UK controls 
NB. No ethnically matched control group was available
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Table 3.7. Allele frequencies of the MICA microsatellite alleles in the patients with
Type I psoriasis from different populations
MICA Type I Type I Type I Type I Type I Controls 











A4 0.071 0.132 0.136 0.192 0.125 0.091
A5 0.051 0.118 0,030 0.058 0.075 0.101
A5.1 0.510 0.3401 0.379 0.346 0.3942 0.497
A6 0.184 0.132 0.197 0.192 0.167 0.179
A9 0.184 0.2783 0.258 0.212 0.2394 0.132
Total 1 1 1 1 1 1
1pUncoiT= 0.002, pCOir= 0.01, OR 0.523 compared with UK controls
2Puncorr= 0.0002, p COrr= 0.001, OR 0.660 compared with UK controls
3Puncorr=  0 .0 0 9 ,  p Con-=  0 .0 4 5 ,  O R  2 .5 3  compared with UK controls
4Puncorr= 0.0005, p Corr= 0.0025, OR 2.07 compared with UK controls
NB. No ethnically matched control group was available for the 13IHW patients
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A4 26 (30%) 16 (24%) 11 (29%) 9 (35%) 26(18%)
A5 10 (12%) 5 (8%) 5 (13%) 5 (19%) 28 (19%)
A5.1 50 (58%)' 44 (67%) 25 (66%) 16 (62%) 111
(75%)
A6 25 (29%) 21 (32%) 11 (29%) 5 (19%) 50 (34%)
A9 40 (47%)2 32 (48%)3 17 (45%) 12 (46%) 39 (26%)
1 Puncoir= 0.01,Pcoit = 0.05, O R  0.48 (0.27-0.84) compared with controls
2 Puncorr = 0.002, pCOir = 0.01, O R  2.43 (1.39-4.25) compared with controls
3 Puncorr= 0.001, p COrr= 0.005, O R  2.63 (1.44-4.82) compared with controls
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Table 3,9. Frequencies of the MICA microsatellite alleles in erosive and non-erosive
PsA





A4 26 (27%) 17 (29%) NS
A5 13 (13%) 4 (7%) NS
A5 1
55 (57%) 39 (67%) NS
A6 32 (33%) 16 (28%) NS
A9 46 (47%) 27 (47%) NS
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Puncorr Pcorr OR (95% Cl)
A4 15 (23%) 28 (33%) N S N S -
A5 3 (5%) 14(16%) N S N S
A5.1 40 (62%) 52 (60%) N S N S -
A6 20 (31%) 27 (31%) N S N S -
A9 4 1  ( 6 3 % ) 29 (34%) p < 0 .0 0 0 1 p < 0 .0 0 0 5 3 .3 6  ( 1 .7 1 - 6 .5 9 )
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Puncorr Pcorr OR (95% Cl)
A4 24 (88%) 18 (14%) p<0.0001 p<0.0005 OR 47 (13-173)
A5 2 (7%) 15 (12%) NS NS -
A5.1 13 (48%) 81 (65%) NS NS -
A6 6 (22%) 12 (9%) NS NS -
A9 7 (25%) 63 (50%) p=0.02 NS -
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Table 3.12. Associations of the MICA microsatellite alleles and the presence or
absence of the HLA-DRB1 shared epitope





A4 25 (35%) 20 (24%) NS
A5 9 (13%) 8 (9%) NS
A5.1 44 (63%) 48 (58%) NS
A6 20 (29%) 27 (33%) NS
A9 27 (37%) 45 (54%) 0.05 0.25
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Puncorr Pcorr OR (95%CI) 1
A4 20 (45%) 25 (23%) 0.006 0.03 2.8 (1.33-5.88)
A5 7 (16%) 10 (9%) NS - -
A5.1 20 (45%) 72 (66%) 0.02 0.1 0.43 (0.21-0.87)
A6 11 (25%) 36 (33%) NS - -
A9 22 (50%) 50 (46%) NS - -








Puncorr Pcorr OR (95%CI)
A4 17 (50%) 28 (24%) 0.003 0.015 3.25 (1.49-7.19)
A5 4 (12%) 13(11%) NS - -
A5.1 17 (50%) 75 (63%) NS - -
A6 9 (26%) 38 (32%) NS - -
A9
. ..
16 (47%) 56 (47%) NS -
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Table 3,15, Control population genotypes to illustrate observed and expected 
genotypes and their compliance with Hardy Weinberg equilibrium
I Genotype OBSERVED number of 
controls with this genotype
EXPECTED number of 
controls with this genotype
A4 A4 1 1.2
A4 A5 4 2.7
A4 A5.1 12 13.4
A4 A6 7 4.8
A4 A9 2 3.6
A5 A5 2 1.5
A5 A5.1 11 14.9
A5 A6 7 5.4
A5 A9 4 4
A5.1 A5.1 37 36.5
A5.1 A6 25 26.3
A5.1 A9 25 19.4
A6 A6 3 4.7
A6 A9 8 7
A9 A9 0 2.6
Total 148 148
CHI-SQUARE = 5.86 
14 degrees of freedom 
p value= 0.969788
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Figure 3.1. Synonymous and non-synonym ous amino acid substitutions in Exons 2,3 and 4 of 
M ICA and their positions on the receptor binding platform
Exon 2 (a l) Exon 3 (a2)
Position Position
6 CGT CCT Arg Pro 91 CAG CGG
14 TGG GGG Trp Gly 105 AGG AAG
23 CTC CTT Leu Leu 112 TAC TAT
24 ACT GCT Thr Ala 114 GGG CGG
26 GTA GGA Val Gly 122 CTG GTG
36 TGT TAT Cys Tyr 124 ACT TCT
56 AAT AAC Asn Asn 125 AAG GAG












191 AGC AGT Ser Ser
Arg Lys 193 GCC GCA Ala Ala
Tyr Tyr 198 ATT ATC He lie
Gly Arg 205 TCT TCC Ser Ser
Leu Val 206 GGC AGC Gly Ser
Thr Ser 210 TGG CGG Trp Arg
Lys Glu 213 ACA ATA Thr He
Met Val 215 AGC ACC Ser Thr
Val lie 221 GTA CTA Val Leu
Met Val 247 ACC ACT Thr Thr
His Leu 251 CAA GAA Gin Glu
His Arg 251 CAA CGA Gin Arg
Lys Glu 255 CAG CAA Gin Gin
Gly Ser 256 AGG AGT Arg Ser
Val lie 268 AGC GGC Ser Gly










































Figure.3.2. Genescanner *tif image collected by laser scanning the polyacrylamide gel
MW marker MW marker MW marker MW marker
i ± i  L
II
1 2  3 4 5 6 7 8 910111213141516 17181920 21222324
! i llnpi i
• i
59 base pair internal marker
Lane MICA allele
Lane 1 A4 homo
Lane 2 A5 + A6
Lane 3 A5.1 homo
Lane 4 A6 homo
Lane 5 A9 homo
Lane 6 A5 + A5.1
Lane 7 A5.1 + A9
Lane 8 A6 homo
Lane 9 A6 + A 9
Lane 10 A4 +A5.1
Lane 11 A5.1 + A9
Lane 12 A4 +A5.1
Lane 13 A6 + A 9
Lane 14 A5 + A5.1
Lane 15 A5.1 homo
Lane 16 A5 + A 9
Lane 17 A5 +A5.1
Lane 18 A5.1 homo
Lane 19 A5.1 homo
Lane 20 A9 homo
Lane 21 A5.1 + A9
Lane 22 A5 + A5.1
Lane 23 A4 +A 5
Lane 24 A4 +A 5
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1 34 67 100 133 166 199 232 265 298 331 364 397 430 463 496 529 562 595 628 661 694 727 760 793 826 859
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CHAPTER 4 POLYMORPHISMS OF 
EXONS 2,3 AND 4 OF MICA
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4.1 Introduction
The major contribution to the high level of polymorphism within the MICA gene is from 
single nucleotide polymorphisms within exons 2,3 and 4 which encode the extracellular 
portion of the molecule. It is this part of the molecule which directly interacts with the 
NKG2D receptor on NK and T cells to influence the immune response. It is not known 
why such a high degree of polymorphism exists since, unlike classical MHC molecules, 
MICA does not appear to bind to a ligand. An ever increasing diversity of ligands that 
need to be presented to T cells is the clear driving force behind the extensive 
polymorphism within the MHC. The situation with MICA is less certain. It is known that 
certain polymorphisms within the region of MICA that binds to its receptor can influence 
the affinity of binding by up to 50 fold (138). It would not be unreasonable to assume that 
the affinity of binding may influence the ability of MICA to activate NK or T cells. Thus 
polymorphisms within the extracellular part of the molecule are potentially of great 
interest in disease association studies.
4.1.1 Polymorphisms o f MICA
In the previous chapter it has been demonstrated that alleles of MICA that contain 9 GCT 
repeats in exon 5 are strongly associated with PsA and possibly psoriasis. However, there 
are several alleles of MICA that possess 9 GCT repeats in exon 5 which differ due to 
polymorphisms within exons 2, 3 and 4. The aim of this study is to devise a technique for 
the identification of the polymorphism within these extracellular exons and use this to 
identify any associations with PsA and psoriasis.
There are a total of 40 SNPs within exons 2,3 and 4 of MICA. The majority of these are 
non-synonymous, resulting in a change of amino acid. These SNPs, together with the 
microsatellite polymorphism in exon 5, define the 54 currently recognised MICA alleles. 
Recently, a number of new SNPs have been identified by nucleotide sequencing of 
subjects participating in genetic studies. However, the application of sequencing to a large 
number of samples in a case-control study is both time consuming and expensive. The
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development of a technique using sequence-specific primers (PCR-SSP) would therefore 
be potentially advantageous.
4.1.2 PCR-SSP for MICA typing
Two publications have independently described methods for typing the 54 currently 
recognised alleles of MICA using PCR-SSP (117; 170). Both methods require all samples 
within the test population to be screened with a large number of primers before the 
appropriate MICA allele can be assigned. One of these studies is an update on a 
previously published method for typing the 16 alleles of MICA that were recognised at the 
time (116). The study utilised the 10th International Histocompatibility Workshop cell 
panel (171) to verify accurate amplification with the newly designed primer pairs. 
However, it should be noted that positive examples of 22 of the 54 alleles were not 
available for analysis. Furthermore, the technique was not applied to a sample control or 
disease population. A large number of the primer pairs used in the technique therefore 
remain theoretical rather than proven identifiers of certain alleles. The described method 
uses a total of 71 sequence specific primers and 2 internal control primers to make 68 
primer pair combinations that are used to test each sample. This allows the independent 
identification of all 54 MICA alleles. Primers were also used to identify the MICA/B 
deletion on the B*4801 haplotype and the presence of methionine at position 129 which is 
known to enhance binding affinity with the NKG2D receptor. Some heterozygote 
combinations would not be able to be distinguished with this technique, including 
MICA*002/*020, MICA*007/*026 and MICA*009/*049.
The second publication on high resolution MICA typing uses PCR-SSP to examine a 
population with inflammatory bowel disease (IBD) (117). The method was designed to 
investigate a possible association with the extracellular polymorphism of MICA and IBD 
as an association with the TM A4 allele of MICA had previously been demonstrated 
(157). The technique was applied to a large Caucasian population (577 patients with IBD 
and 354 controls). A total of 64 specific primers forming 56 primer pair combinations 
were used. These included one primer pair specific for the lOOkb deletion on the B*4801 
haplotype. Only 23 of the 54 alleles were actually detected in the patient and control
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populations and, of these, only 13 occurred at a frequency of more than 1%. This 
represents one of the largest studies of MICA allele frequency in Caucasian populations 
ever published. It suggests that the majority of the more recently described alleles, many 
of which have only been reported in Japanese populations, are either not present or present 
at a very low frequency in Caucasians. Large population studies have yet to confirm the 
frequency of the MICA alleles in other populations.
The two methods described above provide invaluable reference material and are clearly 
necessary if an unusual allele is discovered. However, when studying complex genetic 
conditions such as IBD it is unlikely that any of the alleles occurring at a frequency less 
than 1% will be relevant. The majority of the more common alleles are those which can be 
detected by the simpler original PCR-SSP technique by Stephens et al (116), with the 
notable exceptions of MICA*017, *018 and *019. The presence of only a minority of the 
54 possible MICA alleles in the Caucasian population vindicates the use of a simpler, less 
laborious system. Clearly, the presence of some of the rarer alleles could not be 
specifically excluded with a simplified scheme. However, the yield from routinely 
checking every sample in case control studies with such a large number of primer pairs is 
likely to be very low. It is also very time consuming, expensive and potentially wasteful of 
limited DNA resources. Since over 50% of the Caucasian population are known to possess 
at least one copy of MICA*008, it would make sense to approach the typing of MICA in a 
logical, step-wise fashion rather than routinely testing all samples for all possible alleles 
irrespective of how rare they may be.
4.2 Aims of the study
The aim of the current study was to produce a simple, more logical technique for typing 
MICA that could be applied to a large number of patient samples. A group-based, step­
wise PCR-SSP method was developed. The groups were based on a phylogenetic analysis 
of the available nucleotide sequence of the MICA alleles. This segregated the alleles into 
evolutionarily similar groups enhancing the significance of alleles present on disease- 
associated haplotypes. Alleles within each group could then be further defined utilising a 
second stage PCR. Rarer alleles within each group would not be specifically excluded
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with these primer combinations. However, a third stage PCR using the published primers 
that specifically recognise these rarer alleles could be applied if desired (117; 170).
4.3 Methods
The method utilised for the PCR-SSP technique is given in Chapter 2.4.2. A summary of 
the rationale for the method is presented here.
4.3.1 Phylogenetic analysis
The nucleotide sequence of the currently recognised alleles of MICA published in the 
IMGT/HLA database (http://www.ebi.ac.uk/imgt/hla/) was imported into the phylogenetic 
analysis programme MEGA (Molecular Evolutionary Genetic Analysis) (115). The 
analysis was performed on the sequence of exons 2,3 and 4 of MICA. The sequence of 
exon 5 (TM region) was omitted in the analysis as approximately half of the MICA alleles 
have not been sequenced along this exon. The defining polymorphic positions of the 
MICA alleles in exons 2,3,4 and 5 are illustrated in numerical order in Figure 4.1. This 
order reflects the current nomenclature of MICA but does not reflect the structural 
similarity of the alleles. The alleles are presented in phylogenetic order in Figure 4.2. 
following analysis of the alleles with the programme MEGA. The alleles of MICA then 
become arranged in an order which better reflects their structural and evolutionary 
similarity. The resultant amino acid sequence of the alleles once they are arranged in 
phylogenetic order is demonstrated in Figure 4.4.
4.3.2 Primer Selection
The phylogenetic order of the alleles defined by the MEGA analysis was then used to 
form the basis for the PCR-SSP typing system. The MICA alleles defined by the primers 
originally designed by Stephens et al were updated to take account of the new alleles that 
have now been described in the literature. The new primer specificities were then 
tabulated onto an excel spreadsheet (116). All possible primer combinations were then 
calculated, choosing those primer combinations that resulted in a PCR product between 
100 and 1500 bp where possible to simplify future gel electrophoresis. Five primer pairs
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that defined mutually exclusive phylogenetic groups of MICA alleles were chosen to form 
the initial PCR-SSP groups. Only one allele, MICA*044, was present in more than one 
group. Within each PCR-SSP group there were a few deviations from the order defined by 
the phylogenetic analysis but the majority were in agreement. The PCR-SSP groups 
(Groups 1-5) are shown in combination with the phylogenetic analysis of the MICA 
alleles in Figure 4.3.
4,3.3 PCR-SSP analysis
Stage One
All patient samples were screened in a first stage PCR with all 5 of the group-specific 
primer pairs. Full details of the primers used are given in Table 2.1. A sample could then 
be classified as containing two alleles from two different groups (eg. PCR products from 
Group 1 and Group 5) or two alleles from the same group (eg. PCR product only from 
Group 5). In the latter case, this could represent homozygosity for the same allele within 
Group 5 (eg. MICA *002 / *002) or heterozygosity for different alleles within Group 5 
(eg. MICA *002/*017).
Stage Two
A second stage PCR was then designed to define the most common alleles within each 
primary group. The primer pairs used in this second stage were limited to those 
recognising alleles present at an expected frequency of >1%. Some of the rarer alleles 
within each group were therefore not specifically targeted (eg. MICA*041, MICA*042 
etc). In the majority of cases, permutations of existing published primers could be used 
(116). Additional primers were designed to recognise the more frequent newly described 
alleles (MICA *017, *018, *019, *023, *027). These primers were designed to have 
similar annealing temperatures to the existing primers so that they could all be used in 
combination. Full details of the primers used are given in Table 2.1.
The presence of a particular allele was identified by the appearance of a PCR product band 
of the correct size (Table 2.7) using agarose gel electrophoresis as described in Chapter
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2.4.2. All reactions were verified with the use of internal control primers that recognise a 
conserved sequence within the human growth hormone (HGH) gene. An algorithm for the 
MICA PCR-SSP typing scheme is given in Figure 2.1.
4.3.4 DNA for analysis
Genomic DNA was available from the 10th International Histocompatibility Workshop 
(IHW) cell reference panel. This DNA was used to verify the MICA primer specificities.
rtiExamples of the representatives of the MICA alleles from the 10 IHW are given in Table 
4.1.
The PCR-SSP technique was applied to the same patient samples used for the analysis of 
the exon 5 microsatellite polymorphism: Type I Psoriasis (n=180), Psoriatic Arthritis 
(PsA) (n=158) and matched controls (n=148). All the Type I Psoriasis samples were from 
European Caucasians from the UK (n=49), Belgium (n=72), Germany (n=33) and Italy 
(n=26). The patients with Type I psoriasis from the UK were screened for the presence of 
occult arthritis as detailed before. The other 13IHW samples were not specifically 
screened for the presence of arthritis. The samples from patients with PsA and controls 
were both from the UK.
4.3.5 Statistical Analysis
Full details of the statistical methods used for analysis are given in Chapter 2.4.5. Allele 
frequencies (the fraction of chromosomes containing each allele) were determined for 
each disease group and the control group. Phenotype frequencies (the number of patients 
in possession of at least one allele) were also determined for each group. Associations 
between the alleles and the disease groups were determined with the Chi squared test with 
Fishers Exact test for small sample numbers. A Bonferroni correction factor was applied 
for multiple comparisons according to the number of MICA alleles identified (correction 
factor = 15). Any significant results were also expressed as Odds Ratios with 95% 
confidence intervals. Any continuous clinical data, such as PASI or tender and swollen 
joint counts were compared with the MICA alleles using the Mann Whitney U test. A p
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value of <0.05 was considered to be statistically significant. Once again, it should be 
noted that there were no ethnically matched controls for the 13 IHW patients from Europe 
and the results were compared with UK controls. These results should therefore be 
interpreted with caution.
The HLA associations with the MICA alleles were determined by analysis with the 
Arlequin programme (Chapter 2.4.5.2). This facilitated the construction of likely 
combinations of alleles into extended haplotypes. The frequency of the haplotypes within 
the patient population was also determined. Haplotype analysis could be performed on the 
13IHW samples with Type I psoriasis that had full HLA typing. A further analysis of the 
HLA Class II associations with the MICA alleles could be performed on the patients with 
PsA who were all typed at the HLA-DRB1 and HLA-DQB1 loci. Unfortunately, full HLA 
Class I typing was not available for all patient and control groups. In these cases more 
simplified analysis was performed based on the presence or absence of HLA-Cw6 and 
HLA-B27. A stratification for the significance of MICA in the absence of HLA-Cw6 gave 
an indication of the degree of any independent association of the MICA alleles.
4.4 Results
4,4,1 Phylogenetic analysis
The results of the phylogenetic analysis of the MICA alleles are shown in Figures 4.2 and 
4.3. There is considerable rearrangement of the order of the MICA alleles from the 
numerical order used in the current nomenclature (Figure 4.1). Interestingly, the alleles 
appear to fall into 2 groups, based largely on the presence of a sequence in exon 4. The 
significance of this sequence is not known. The amino acid sequences of the alleles in 
phylogenetic order {Figure 4.4) illustrates the dramatic effect on the TM segment of a 
single base deletion in alleles *015 and *017 and a single base insertion in the A5.1 
alleles.
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Further distinct groups were identified which were sometimes associated with the same 
TM region eg. *001, *012, *018 (all A4) but sometimes not, eg. *007 (A4), *045 (A4) 
and *026 (A6). The majority of the A9 alleles clustered together apart from *015 which 
appeared in a different group. The alleles containing 6 GCT repeats (A6) were the most 
diverse, forming 3 separate groups; *004, *006, *009, *044 and *049 all grouped 
together, whereas *011 and *047 were in a separate group and *026 clustered apart from 
the other A6 alleles. This would indicate independent evolution of the TM region from the 
rest of the gene.
4.4.2 Associations of the MICA alleles with the disease groups
Fifteen of the MICA alleles were present in the studied populations. The MICA alleles 
*005, *006, *013, *014, *015 were not present in any of the patients or controls in the 
study. Some of the alleles could not be distinguished from each other such as *019/*033, 
*027/*048, *023/*028 and were therefore each considered as a single allele for the 
purposes of the analysis. Allele subtypes such as *00201 and *00202 were regarded as one 
allele (*002).
4.4.3 MICA Phenotype frequencies
The MICA phenotype frequencies in PsA, Type I psoriasis and controls are illustrated in 
Table 4.2 . The major results were:
•  M I C A  * 0 0 8  was the most common allele in all groups, both disease and control, with 
phenotype frequencies between 60 and 74%.
•  M I C A  * 0 0 2  was significantly associated with PsA (puncoir = 0.002, p COir = 0.03, OR 
2.32 (1.34-4.03)), with approximately twice the frequency in PsA than controls (31% 
vs 16%).
•  M I C A  * 0 1 7  was significantly increased in Type I Psoriasis in the 13IHW population 
including all the samples from the UK, Belgium, Italy and Germany (puncoir <0.0001, 
Pcorr<0.0015, OR 3.36 (1.74-6.48)) compared with controls.
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• A breakdown of the different countries that contributed to the 13 IHW on Type I 
psoriasis is given in Table 4.3. This illustrates that MICA *017 was significantly 
increased in the screened UK and unscreened Belgian populations, as well as in the 
group of patients with Type I psoriasis as a whole. The numbers were small in the 
German and Italian populations, although the German group followed the same trends. 
The Italian population appeared to be an exception, although the number of patients 
was too small to draw any firm conclusions. Only 8% of Italian patients with Type I 
psoriasis were MICA *017 positive compared with 10% of controls.
4.4.4 MICA A llele frequencies
The allele frequencies of MICA in patients with PsA, Type I psoriasis and controls are 
given in Table 4.4. Some of the alleles could not be independently identified in the 
presence of others, for example, MICA*018 in the presence of MICA*007 or MICA*001. 
These have therefore been omitted from the analysis and constitute the remaining allele 
frequencies of 0.003 -  0.04 that are unaccounted for in Table 4.4. The MICA allele 
frequencies for the patients with Type I psoriasis from the UK and other European 
countries is given in Table 4.5.
The major results were:
• MICA *002 was again found to be significantly increased in PsA (puncorr=0.0014,
Pcorr=0.021) with a resultant significant decrease in MICA *008 (puncon^O.0016,
Pcoit=0.024).
• MICA *017 was significantly increased in the Type I psoriasis group as a whole
(puncorr< 0 .0 0 0 1, pCoir<0.0015) as well as individually in the screened UK and 
unscreened Belgian populations (pCOrT= 0.012 and pcorr<0.0015, respectively). In the 
Belgian group, the increase in MICA *017 resulted in a significant decrease in MICA
*008 (pCOIT=0.02).
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4.4.5 Associations o f the MICA alleles by phylogenetic group
Examples of the agarose electrophoresis gels from analysis within Groups 1 and 4 are 
shown in Figures 4.5 and 4.6. If the MICA alleles are divided according to the five groups 
that are defined by the phylogenetic analysis, certain patterns emerge. The distribution of 
MICA alleles within each patient and phylogenetic group is shown in Table 4.6. The p  
values were corrected by a factor of five in view of the five phylogenetic groups.
In both psoriasis and PsA there was an increase in the number of alleles within Group 5 
and a compensatory decrease in the number of alleles in Group 1. This is largely due to an 
increase in MICA *017 (Group 5) in psoriasis, MICA *002 (Group 5) in PsA and a fall in 
MICA *008 (Group 1) in both groups.
4.4.6 Associations o f the MICA alleles with clinical characteristics
PsA
The increase in MICA *002 that was observed in the PsA group as a whole was also 
observed in the polyarthritis, oligoarthritis and spondyloarthritis subgroups. There was no 
significant association between any of the MICA alleles and the clinical subgroup of PsA 
that a patient belonged to. There was no association between the MICA alleles and the 
severity of PsA as indicated by the presence of erosions, DMARD use, PASI or tender and 
swollen joint counts in PsA. There were no associations with the presence or severity of 
nail disease.
Type I  psoriasis
MICA *017 was significantly associated with the presence of a high nail score (p=0.002). 
MICA *017 was also significantly associated with a younger age of onset of psoriasis 
(p<0.0001). There were no associations with the severity of psoriasis itself as represented 
by the PASI score.
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4.4.7 Stratification for HLA-Cw6
PsA
In order to test whether the association between MICA *002 and PsA was independent of 
HLA-Cw6, all HLA-Cw6 patients and controls were eliminated from the analysis. MICA 
*002 was then present in 32/93 (34%) patients with PsA compared with 22/122 (18%) 
controls. This result was still significant with a p  value of 0.006, suggesting that the 
association between MICA *002 and PsA is independent of HLA-Cw6.
Type I  psoriasis
In contrast, if the HLA-Cw6 positive patients were omitted from the analysis of the 
patients with Type I psoriasis (both UK and Belgian), the association with MICA *017 
was no longer significant.
4.4.8 Associations between the MICA alleles and the HLA Class II alleles
Two of the MICA alleles were found to be significantly associated with HLA-DR7 in the 
patients with PsA. MICA *004 was associated with HLA-DR7 with a p  value of 0.006, 
OR 4.3 (1.41-13.1). MICA *017 was strongly associated with HLA-DR7 (p<0.0001, OR
10.03 (3.76-26.78), due to its presence on the highly conserved 57.1 ancestral haplotype. 
There were no associations with the other HLA Class II alleles or the HLA-DRB1 shared 
epitope.
4.4.9 MICA Haplotypes from l&h workshop /  4AOH cell lines
The data available on the MICA haplotypes of homozygous cell lines from the 10th 
International Histocompatibilty Workshop (10EHW) was collated from published work 
(171) and is presented in Table 4.7. Many of the MICA alleles were present on conserved 
ancestral haplotypes or recombinant ancestral haplotypes. Confirmation of the haplotypes 
was determined by placing the data into the Arlequin programme. These reference 
haplotypes were utilised to define the haplotypes observed in the psoriasis population.
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4.4,10 MICA Haplotypes in Type I  Psoriasis
Data was available on the HLA typing at the Class I and II loci for the Type I psoriasis 
group from Belgium taking part in the 13IHW. HLA typing on the PsA, psoriasis and 
control samples from the UK and the other workshop samples is awaiting completion by 
the 13IHW in Seattle.
The MICA haplotypes that were observed in the Belgian population with Type I psoriasis 
are presented in Table 4.8. The frequency of the haplotypes together with estimations of 
the linkage disequilibrium between the components of the haplotype (D') are given. Some 
of the MICA alleles dispay a high degree of linkage disequilibrium with the HLA Class I 
and to a lesser extent Class II alleles indicating conservation of the haplotype through 
time. Some examples of strong linkage disequilibrium (D-1) are:
MICA *002 with HLA-B3801, HLA-B3901 
MICA *004 with HLA-B4901 and HLA-B4102 
MICA *007 with HLA-B2702, HLA-B2705
MICA *008 with HLA-B702, HLA-B1302, HLA-B40011, HLA-B4402
MICA *010 with HLA-B1501
MICA *011 with HLA-B1402
MICA *012 with HLA-B5501
MICA *017 with HLA-B5701, HLA-Cw0602
MICA *018 with HLA-B1801
These MICA haplotypes are represented in diagrammatic form in Figures 4.7-4.11 which 
illustrate some of the clear linkage patterns between the MICA, HLA-B and HLA-Cw 
alleles.
MICA A4 haplotypes (Fieure 4.7.)
Fifty percent of the haplotypes containing 4GCT repeats were MICA*007 and all but one 
of these was found in association with HLA-B27 (the other was found with B51-Cwl5). 
Although the overall increase in the A4 allele in the PsA population just failed to reach
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significance, the contribution of *007 was more difficult to elucidate due to some of the 
difficulties distinguishing *007 and *018. The other haplotypes observed in Type I 
psoriasis were *018-B18-Cw7, *018-B18-Cwl2 (AH 18.1), *001-B18-Cw5
(AH18.2),*012-B55-Cw3 (AH55.1), *012-B56-Cwl and *012-B55-Cw6.
MICA AS haplotypes (Fieure 4.8.)
The majority (10 out of 22) of the haplotypes containing 5GCT repeats were *010-B15- 
Cw3 (AH62.1). The other haplotypes observed were *016-B35-Cw4 (AH35.4/5), 
*027/048-B61 -Cw2, *027/048-B61-Cw3, *016-B35-Cw6, *019/033-B15-Cw8 and *010- 
B15-Cw2.
MICA A5.1 haplotypes (Figure 4,9,)
All of the alleles which contained 5GCT repeats with a G insertion were typed as MICA 
*008. The most common haplotypes were *008-B13-Cw6 (AH13.1), *008-B7-Cw7 
(AH7.1), *008-B8-Cw7 (AH8.1), *008-B44-Cw5 (AH44.1), *008-B44-Cw2, *008-B44- 
Cw7, *008-B37-Cw6 (AH37.1), *008-B47-Cw6 (AH47.1) and *008-B40-Cw3
(AH60.1/3).
MICA A 6 haplotypes (Fisure 4,10.)
There were fewer clearly dominant haplotypes and fewer recognised ancestral haplotypes 
seen with the MICA A6 alleles perhaps reflecting the disparate evolutionary distribution 
seen in the phylogenetic tree. The most frequent alleles were MICA *004 (10/26) and 
MICA *006 (10/26). Some examples of the haplotypes which emerged were *004-B44- 
Cwl6 (AH44.2/3), *004-B44-Cw4, *004-B49-Cw7, *004-B42-Cwl7 (AH42.1), *004- 
B41-Cwl7, *006-B51-Cwl5, *006-B35-Cw4, *006-B52-Cwl2 (AH52.1), *006-B51- 
Cwl5, *006/9/49-B45-Cw6, *006/9/49-B50-Cw6 (AH50.1) and *011-B14-Cw8
(AH65.1).
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MICA A 9 haplotypes (Fieure 4.11.)
The two MICA alleles with 9GCT repeats (A9 alleles) observed in the Belgian Type I 
psoriasis population were *002 and *017. The majority of patients who had an A9 allele 
were typed as MICA*017. This contrasts with the PsA population where the majority of 
patients with an A9 allele were typed as MICA *002.
In all 25 patients with Type I psoriasis and MICA *017, this allele was present on the AH
57.1 haplotype (HLA-B57, HLA-Cw6) which is reflected in the high D' values between 
MICA *017, HLA-B5701 and HLA-Cw6. One patient was HLA-B57 positive but had a 
MICA *002 not a MICA *017 allele. However, this was present on a different haplotype 
(B57, Cw7) and not the AH57.1 haplotype. Other haplotypes which were seen included 
*002-B38-Cwl2 (AH38.1), *002-B39-Cwl2, *002-B35-Cw4, *002-B58-Cw7 and *002- 
B58-Cw3.
MICA and HLA-DRB1 and HLA-DOB1 haplotypes in the PsA population
The data is not yet available for the HLA Class I typing for the PsA patients and this can 
therefore not be presented as haplotype data. However, the patients have been fully typed 
at the HLA-DRB1 and HLA-DQB1 Class II loci. The data was therefore entered into the 
Arlequin programme to elicit haplotype frequencies. D' values were calculated to obtain 
an estimate of the degree of linkage disequilibrium between the loci. The data is presented 
in Table 4.9. As would be expected from the higher genetic distance between the alleles, 
the D' values are generally lower than those seen with HLA-B and HLA-Cw. Higher 
numbers of patients within each haplotype would be needed before any definitive 
conclusions could be made about clear haplotypic patterns.
4.5 Discussion
There are two alleles of MICA that have been shown to be important in PsA and psoriasis. 
The MICA *002 allele was increased in frequency in PsA, whereas the MICA *017 allele 
was increased in Type I psoriasis. Both of these alleles contain 9 GCT repeats in their 5th 
exon and are therefore A9 alleles. The increase in MICA A9 that has been previously
142
demonstrated is therefore due to these two alleles. Some of the difficulties interpreting the 
relative contributions of MICA A9 in PsA compared with psoriasis may be explained by 
the different contributions of these two alleles.
The MICA alleles appear to be responsible for the susceptibility to rather than severity of 
PsA. There was no association with disease subgroup, tender and swollen joint counts or 
PASI.
The differences between the MICA *002 and *017 alleles are two-fold. Firstly a SNP at 
position 272 results in a change of amino acid at position 91. This is in the centre of the 
ala2 platform that interacts with the NKG2D receptor (Figure 3.1). A change of amino 
acid could significantly affect the affinity of the binding of MICA for its receptor, 
although this has not been formally tested with functional studies. The second change is 
the deletion of a guanine at position 823, at the very end of exon 4 in the MICA *017 
allele that does not occur in MICA *002. This results in a frame shift and a completely 
different transmembrane region in the MICA *017 allele. Instead of 9 alanines, the MICA 
*017 molecule has a hydrophobic polyleucine tail with truncation of the cytoplasmic 
segment. This could have significant effects on the function of the molecule. It could 
severely hamper the ability of the molecule to be expressed on the cell surface. The true 
functional effects of these polymorphisms are not known but both of the differences in the 
genetic sequence between MICA *002 and *017 could potentially result in significant 
changes of function of the molecule.
The association between MICA *002 and PsA is largely independent of HLA-Cw6. The 
majority of the haplotypes that contain MICA *002 do not contain HLA-Cw6. It may be 
that haplotypes containing MICA *002 (B38-Cwl2 (AH38.1), B38-Cw6, B39-Cwl2, 
B35-Cw4, B58-Cw6 and B58-Cw3) contain genes that are important in the development 
of arthritis or that MICA itself is the key gene. It is interesting to note that the frequency 
of HLA-B 3 8 and HLA-B 3 9 has been reported to be higher in patients with the peripheral 
polyarthritis subgroup of PsA.
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In contrast to MICA *002, there is a strong relationship between MICA *017 and HLA- 
Cw6, with the vast majority of MICA *017 alleles being present on the 57.1 ancestral 
haplotype. This would suggest that the association between MICA *017 and Type I 
psoriasis is not unique to the MICA region of the haplotype, but is an association with the
57.1 ancestral haplotype itself. The true association may therefore be any one of the 
closely linked neighbouring genes along the haplotype. It is also intriguing that the 57.1 
haplotype is frequently found in long term non-progressors in human immunodeficiency 
virus type I (HIV-I) infection (83; 84). This association may be related to the MICA *017 
allele which could alter the immune response to the virus by a change in structure and 
recognition by NKG2D receptors on NK and T cells. Whether MICA is a strong 
functional candidate in psoriasis would need to be investigated with further expression and 
functional studies.
This group-based PCR-SSP method for typing the most commonly occurring alleles of 
MICA is a rapid and efficient way of screening disease populations for possible 
associations with the MICA alleles. It is particularly suitable for Caucasian populations, 
where more is known about the frequencies of the MICA alleles. The study by Ahmad et 
al (117) demonstrated in a large UK population that only 13 of the currently recognised 54 
MICA alleles are present at a frequency greater than 1% and less than half of the alleles 
were present at all. It would therefore seem reasonable to approach MICA typing, at least 
in the initial stages, in a more efficient way than routinely testing all samples for the 
presence of all alleles with up to 70 primer pairs per sample.
The method described here is particularly suited to disease association studies where the 
transmembrane region (exon 5 microsatellite) has already been typed. Indeed, certain 
alleles can only be distinguished with knowledge of the TM region. This can also act as a 
check for the system since knowledge of the TM allele allows one to predict which group 
an allele is likely to belong to (eg. all A9 alleles are in group 5). The system picks up most 
of the common alleles by using an average of only 11-13 primer pairs per sample, 
although certain combinations of alleles cannot be distinguished. It is inexpensive in terms 
of patient material, reagents, time and equipment. However, as with all step-wise systems, 
one must be particularly aware of false negatives. The use of internal controls should
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prevent this, but there is no doubt that the use of such a simplified system will 
occasionally produce errors. However, if an allele is truly associated with a disease, this 
should be strong enough to withstand such potential problems. Knowledge of the TM 
alleles is particularly helpful in checking the correct allocation of the initial PCR groups, 
particularly where both alleles appear to be in the same group. The inclusion of known 
positives and negatives in each PCR run will also ensure good quality control.
The development of a typing technique based on the phylogenetic similarity of the known 
alleles of MICA provides a more meaningful approach to the definition of disease 
associated alleles and their haplotypes. The current nomenclature does not provide any 
insight into which alleles are more closely related through evolution than others. Distinct 
groups of alleles were identified which were sometimes associated with the same 
transmembrane region and sometimes not. The majority of the alleles with 9GCT repeats 
clustered together except *015 which appeared in a separate group. This allele has the 
same exon 4 deletion as *017 but was not seen in any of the samples studied in this 
workshop. The alleles with 6GCT repeats were the most disparate, although alleles *004, 
*006, *009, *044 and *049 were all very closely related.
The phylogenetic clustering of the alleles that were significantly associated with psoriasis 
(MICA *017) and PsA (MICA *002) suggests a common ancestral link between the two 
conditions. This is most likely to be a genetic factor that predisposes to psoriasis. This 
should be common to both haplotypes, either within the MICA gene itself (they both 
possess 9 GCT repeats in the transmembrane region of the gene) or further along the 
haplotype in a neighbouring gene. The two diseases, psoriasis and PsA, have then 
diverged as evidenced by the different alleles of MICA that are associated with each 
phenotype. MICA is known to play a direct role in the activation of T cells and NK cells 
via the NKG2D receptor. Both of these immune cells are present in the skin and synovium 
and appear to play a key role in the inflammatoiy process. The disease associations with 
MICA may therefore be primary rather than simply a marker for a disease gene present on 
the same haplotype.
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This method allows the rapid detection of the majority of MICA alleles that are present at 
a frequency of at least 1% in Caucasian populations. This should be sufficient for 
screening disease groups to see if any patterns emerge, particularly where an association 
with the less complex TM region of the gene has already been demonstrated. Further, 
more detailed, analysis can then be performed if any significant associations appear. Since 
the technique utilises a phylogenetic analysis, the grouping of the alleles is based more on 
evolutionary similarity than the current nomenclature of MICA. This may facilitate not 
only the recognition of disease associated alleles but also potential disease associated 
haplotypes.
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*001 A4 EVASP 100051Y 9135 18.2
*001 A4 DUCAF 100161R 9019 18.2
*00201 A9 YAR 100009X 9026 38.1
*004 A6 MOU 100058H 9050 44.3
*004 A6 RSH 100007B 9021 42.1
*006 A6 KAS116 100154N 9003 51
*00701 A4 BM92 10020IF 9092 51
*00801 A5.1 REE,GD 100044V 9132 8.1
*00801 A5.1 PLH 100064P 9047 47.1
*00901 A6 HARA 100065M 9142 52.1
*010 A5 BSM 100073N 9032 62.1
*010 A5 BOLETH 100072Q 9031 62.1
*011 A6 LWAGS 100002N 9079 65.1
*01201 A4 HOKKAIDO 100062T 9141 54.1
*015 A9 OMW 100204Z 9058 45
*016 A5 J0528239 100019U 9041 35.1
*017 A9 DBB 100084G 9052 57.1
*018 A4 D0208915 100050A 9008 18.1
*019
-
A5 CF996 100077D 9094 64.1
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Table 4.2. Phenotype frequencies (%) of the MICA alleles in Type I Psoriasis, PsA
and Controls
Allele Psoriasis Type I 
(13 IHW) 
(n=131)









*001 4 (3%) 1 (2%) 6 (4%) 4 (3%)
*002 29 (22%) 1 (2%) 49 (31%)1 24 (16%)
*004 14(11%) 7 (14%) 17(11%) 23 (16%)
*007 17(13%) 1 (2%) 16(10%) 10 (7%)
*007/018 2 (2%) 2 (4%) 11 (7%) 1 (1%)
*008 79 (60%) 35 (71%) 96 (61%) 109 (74%)
*009 24(18%) 11 (22%) 30(19%) 30 (20%)
*010 8 (6%) 5 (10%) 8 (5%) 19 (13%)
*011 3 (2%) - 1 (1%) -
*012 7 (5%) 2 (4%) 3 (2%) 5 (3%)
*016 10 (8%) - 3 (2%) 5 (3%)
*017 36 (27%)2 15 (31 %)3 29 (18%) 15(10%)
*018 7 (5%) 1 (2%) 13 (8%) 7 (5%)
*019/033 1 (1%) - 4 (3%) 2(1%)
*023/028 1 (1%) 1 (2%) 1 (1%) 1 (1%)
*027/048 4 (3%) - 2 (1%) 3 (2%)
1 Puncoir=0.002, pCorr=0.03, OR 2.32 (1.34-4.03) compared with controls
2 Puncorr<0.0001, pco^O.OOlS, OR 3.36 (1.74-6.48) compared with UK controls
3 Puncoir=0.001, pCOrr=0.015, OR 3.91 (1.74-8.78) compared with controls 
NB No ethnically matched control group for the 13IHW patients
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Table 4.3. Phenotype frequencies of MICA in Type I psoriasis from the European
























*001 1 (2%) 1 (1%) - 3 (12%) 5 (3%) 4 (3%)
*002 1 (2%) 13 (18%) 8 (24%) 8 (31%) 30(17%) 24 (16%)
*004 7 (14%) 6 (8%) 4 (12%) 4(15%) 21 (12%) 23 (16%)
*007 1 (2%) 8(11%) 6(18%) 3 (12%) 18(10%) 10 (7%)
*007/018 2 (4%) - 2 (6%) - 4 (2%) 1 (1%)
*008 35 (71%) 43 (60%) 20 (61%) 16 (62%) 114(63%) 109 (74%)
*009 11 (22%) 11 (15%) 8(24%) 5 (19%) 35 (19%) 30 (20%)
*010 5 (10%) 7 (10%) 1 (3%) - 13 (7%) 19(13%)
*011 - 2 (3%) - 1 (4%) 3 (2%) -
*012 2 (4%) 4 (6%) 1 (3%) 2 (8%) 9 (5%) 5 (3%)
*016 - 6 (8%) 1 (3%) 3 (12%) 10 (6%) 5 (3%)
*017 15 (31%)' 26 (36%)2 8 (24%) 2 (8%) 51 (28%)3 15 (10%)
*018 1 (2%) 6 (8%) - 1 (4%) 8 (4%) 7 (5%)
*019/033 - 1 (1%) - - 1 (1%) 2(1%)
*023/028 1 (2%) - 1 (3%) - 2(1%) 1 (1%)
*027/048 - 4 (6%) - - 4 (2%) 3 (2%)
1 Puncon-=0.001, pcoir=0.015, OR 3.91 (1.74-8.78) compared with controls
2 pxmcorr<0.0001, pcorrO.0015, OR 5.01 (2.44-10.28) compared with UK controls
3 Puncorr<0.0001, Pcor^O.OOlS, OR 5.01 (2.44-10.28) compared with UK controls 
NB. No ethnically matched control group for the 13 IHW patients
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*008 0.386 0.3671 0.493 0.413
*002 0.092 0.1682 0.081 0.113
*017 0.1473 0.092 0.051 0.100
*009 0.100 0.098 0.101 0.100
*004 0.058 0.057 0.078 0.064
*007 0.050 0.051 0.034 0.045
*010 0.036 0.025 0.064 0.041
*018 0.022 0.044 0.024 0.030
*016 0.028 0.009 0.017 0.019
*012 0.025 0.009 0.017 0.017
*001 0.014 0.019 0.014 0.015
*027 / *048 0.011 0.006 0.010 0.009
*019/*033 0.003 0.013 0.010 0.008
*023 / *028 0.006 0.003 0.003 0.004
*011 0.008 0.003 - 0.004
| Total 0.986 0.960 0.977 0.982
1 Puncoir=0.0016, pcorT=0.024 compared with controls
2 Puncorr=0 .0014, pCOrr=0.021 compared with controls
3 puncorr<0’0001, pCOIT<0.0015 compared with UK controls
NB. No ethnically matched control group for the 13IHW patients
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Table 4,5, MICA Allele frequencies in Type I Psoriasis from the European countries 
contributing to the 13th IHW




















*008 0.500 0.3301 0.364 0.346 0.386
*017 0.1632 0.1883 0.121 0.039 0.1474
*009 0.112 0.076 0.136 0.096 0.100
*002 0.020 0.090 0.136 0.173 0.092
*004 0.071 0.042 0.061 0.077 0.058
*007 0.010 0.056 0.091 0.058 0.050
*010 0.051 0.049 0.015 - 0.036
*016 0.042 0.015 0.058 0.028
*012 0.020 0.028 0.015 0.039 0.025
*018 0.010 0.042 - 0.019 0.022
*001 0.010 0.007 - 0.058 0.014
*027 / *048 0.028 - - 0.011
*011 0.014 - 0.019 0.008
*023 / *028 0.010 - 0.015 - 0.006
*019/*033 0.007 - - 0.003
Total 0.977
h ______ _____ _____ ---------
0.999 0.969 0.982 0.986
2
puncon-=0.0008, pcorr^O.012 compared with controls
3 puncoiT^ O.OOOl, pcorr< 0• 0015 compared with UK controls
4 puncon^O.OOOl, Pcorr<0.0015 compared with UK controls
NB. No ethnically matched control group for the 13 IHW patients
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Table 4,6. The number of alleles (%) within each of the phylogenetic groups in Type I
Psoriasis, PsA and controls
Group 1 Group 2 Group 3 Group 4 Group 5 Total
Type I Psoriasis 
(n=180)
167(46%)' 59(16%) 45(13%) 89(25%)' 360
PsA
(n=158)
133(42%)' 50(16%) 50(16%) 83(26%)" 316
Controls
(n=148)
176(59%) 54(18%) 27(9%) 39(13%) 296
1 puncoiT=0.0008, Pcorr= 0.004 compared with UK controls
2 PuncoiT=0.0002, pCOiT= 0.001 compared with UK controls
3 Puncorr<0.0001, pCOrr<0.0005 compared with controls
4 puncorr<0.0001, pco^O.OOOS compared with controls
NB No ethnically matched control group for the 13IHW Type I psoriasis patients
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Table 4.7. MICA Haplotypes observed in homozygous cell lines from the 10th 
International Workshop cells
I MICA MICA HLA-B HLA-C HLA-A Ancestral 10th IHW
TM allele allele Haplotype Cell
A4 *001 B*1801 Cw*0501 A*3002 18.2 DUCAF
A4 *001 B*1801 Cw*0501 A*0201 18 JVM
A4 *007 B*2705 Cw*0102 A*0201 JESTHOM
A4 *007 B*2705 Cw*0202
A4 *007 B*5101 Cw*0102 51 BM92
A4 *012 B*5401 Cw*0102 A*2402 54.1 LKT3
A4 *012 B*5501 Cw*0303 55.1
A4 *012 B*5601 Cw*0102
A4 *018 B*1801 Cw*0701 BM16
A4 *018 B*1801 Cw*1203 A*2501 18.1 DO208915
A5 *010 B*1501 Cw*0303 A*0101 62.3 CB6B
A5 *010 B*1501 Cw*0303 A*0217 15 AMALA
A5 *010 B*1501 Cw*0304 A*0201 62.1 BOLETH
A5 *010 B*3701 Cw*0602 A*0101 37.1 KAS011
A5 *010 B*4601 Cw*0102 A*0204 46.2 TAB089
A5 *010 B*4601 Cw*0102 A*0207 46.1 T7526
A5 *010 B*5201 Cw*1202 A*0101 52 E4181324
A5 *016 B*3502 Cw*0401 A*0101 35.1 J0528239
A5 *019 B*1401 Cw*0802 64.1 CF996
A5 *019 B*3801 Cw*1203
A5 *027/*048 B*4002 Cw*0202 40 CALGERO
A5.1 *008 B*0702 Cw*0702 A*0301 7.1 SCHU
A5.1 *008 B*0702 Cw*0702 A*2402 7.2 SA
A5.1 *008 B*0801 Cw*0701 A*0101 8.1 COX
A5.1 *008 B*1302 Cw*0602 A*0201 13 BER
A5.1 *008 B*1302 Cw*0602 A*3001 13.1 LBF
A5.1 *008 B*4001 Cw*0304 A*0201 60.2 SLE005
A5.1 *008 B*4001 Cw*0304 A*2402 60 DKB
A5.1 *008 B*4001 Cw*0304 A*6801 60.3
A5.1 *008 B*4402 Cw*0501 A*0201 44.1 WELAK
A5.1 *008 B*4701 Cw*0602 A*0301 47.1 PLH
A5.1 *023 B*3801 Cw*1203
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Table 4.8. The M ICA haplotypes present within the I31HW  Type 1 Psoriasis population
demonstrating the haplotype frequencies and D' values
Haplotype Freq HLA-A HLA-Cw HLA-B MICA HLA-DRB1 HLA-DQI
0.03488 A3 Cwl203 B3801 MICA*002 DR1 DQ501
D' 0.02 0.87 1 0.49 0.39
0.02326 A2 Cwl203 B3801 MICA*002 DR 13 DQ603
D’ 0.5 0.87 1 0.33 0.42
0.01163 A2 Cwl203 B5701 MICA*002 DR 1303 DQ301
D' 0.5 0.87 0.14 1 0.11
0.01163 A2 Cw702 B5701 M1CA*002 DR7 DQ301
D’ 0.5 0.03 0.14 - 0.11
0.01163 A2 Cw802 B3901 MICA*002 DR1 DQ402
D' 0.5 - 1 0.49 -
0.01163 A29 Cw702 B702 MICA*002 DR 14 DQ503
D' 0.26 0.03 0.07 0.11
0.01163 A1 Cw702 B4901 MICA*004 DR 13 DQ202
D' 0.16 0.23 1 - 1
0.01163 A24 Cw0701/06 B4901 MICA*004 DR 13 DQ604
D' 0.63 0.28 1 - -
0.01163 A24 Cw 1701/02 B4102 MICA*004 DR7 DQ303
D’ 0.63 1 1 1
0.01163 A1 Cw0303/04 B4002 MICA*007 DR 13 DQ503
D’ - 0.03 - - 0.13
0.01163 A2 Cw0701/06 B2702 MICA*007 DR4 DQ502
D' 0.21 0.09 1 0.68 -
0.01163 A2 Cwl601 B5701 MICA*007 DR 15 DQ301
D' 0.21 1 - - 0.47
0.01163 A3 Cw602 B5701 MICA*007 DR4 DQ502
D' 0.03 0.68
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0.01163 A1 Cw0303/04 B1517
D' - 0.62 1
0.01163 A30 Cw202 B4002
D' 0.31 0.31 0.65
0.01163 A31 Cw0303/4 B4002











Table 4.9 . The MICA haplotypes present within the PsA population at a 







































































0.02417 MICA*009 DR0301 DQ0201
D' 0.23 0.19
0.02744 MICA*017 DR0701-0702 DQ0303
D' 0.21 0.44
0.0122 MICA*017 DR0701 DQ0303
D' 0.38 0.44
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Fieure 4,1 , Polymorphic positions of the nucleotide sequence of MICA alleles in numerical order
E io n  3 Exon 4 Exon 5
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Figure 4.2a. Phylogenetic tree of the MICA alleles based on the nucleotide sequence 






















































Fieure 4.2b. Polymorphic positions of the nucleotide sequence of MICA alleles in phylogenetic order
Exon 2
1 4 6 7 7 0 6 9
1 7 0 9 0 7 7 8 2
G G T C A T G T A
MICA-017 * G - G - - G
MICA-020 * - G - G - - G
MICA-046 G - G - - G
MICA-023 * G - G - - G
MICA*00201 * G - G - - G
MICA*041 G - G G - G
MICA*047 * - G - G G - G
MICA-011 * G -  G - - G
MICA-030 ’ G - G - - G
MICA-014 ' - G - G - - G
MICA-015 * G - G - - G
MICA*013 ‘ - G - G - - G
MICA-036 * G - G - - G
MICA-00202 * G - G - - G
MICA-026 * - - - G - - G
MICA-00701 * - - G - - G
MICA*045 - - G - - G
MICA*029 * - G - - G
MICA-00702 * - - G - - G
MICA-043 * - G - - G
MICA-040 * -  G - - G
MICA-001 .  .  .
MICA-018 * .  . .
MICA-01201 * - .  .  .
MICA-01202 * - .  . .
MICA*021 ' * - .  . .
MICA*028 * - T G - A - G
MICA-032 T G - A - G
MICA-025 * C T G - A - G
MICA-031 - T G - A - G
MICA-034 - G - - G
MICA-038 * - G - - G
MICA-037 - - G - - G
MICA-039 • - - G - - G
MICA*035 * - G - - G
MICA-005 T G - A - G
MICA-006 • - T G - A - G
MICA-00902 • - T G - A - G
MICA*049 • - T G - A - G
MICA-00901 * - T G - A - G
MICA*004 - T G - A - G
MICA-044 • - - G - A - G
MICA*024 - T G - A - G
MICA-022 * - G - - G
MICA-042 - T G - A - G
MICA*019 * - T G - A - G
MICA-033 * T G - A - G
MICA-016 • - T G - A - G
MICA-010 c T G - A - G
MICA-00802 * T G - A - G
MICA-027 • T G - A - G
MICA*048 T G - A - G
MICA-00803 * T G - A - G
MICA-00801 * • T G - A - G
Exon ^
2 2 3 3 3 3 3 3 3 4 4 4 0 0 0 0  
5 7 1 3 4 6 7 7 8 2 5 6 1 2 2 4  
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E xon  4
0 0 0 0 6 6 6 6 0 6 6  / /  t / / 8 8 
4 7 7 9 1 1 2 2 3 4 6 4 5 5 6 6 1 2  
5 3 9 4 5 6 3 8 8 4 1 1 1 2 5 8 1 3  
T C C T T G A T C G G C C A G G C G
Exon S
8 8 8 6 8 8 8 8 8 8 8 8 8 8  
7 8 8 8 8 8 8 8 8 8 8 9 9 9  
9 0 1 2 3 4 5 6 7 8 9 0 1 2  
G C T G C T  G C T G C T
8 6 6 8 8 8 8 9
9 9 9 9 9 9 9 0
3 4 5 6 7 8 9 0
9 9 9 9 9 9 9 9 9 9 9 9 9 9  
0 0 0 0 0 0 0 0 0 1  3 3 6 7  
1 2 3 4 5 6 7 8 9 0 3 7 9 6  
A T C G G
- G - -
- G - -
.  G - -
.  G - -
.  G - -
- G - -
- G -  -
- G - -
.  G - -
- G - - - - G -
- G - -
- G G - - - G -
.  G - - - - G A
- G - -
.  G - -
- G - -
- G - -
- G - A
.  G - -
.  G - -
- G - -
- G - - - T - -
- G - - - T - -
.  G - - - T - -
-  G G -
- G - - - T - A
.  G - -
- G - -
.  G - -
-  G - -
-  G - -
- G - -
- G G -
G - G G - - - G A
G - G G - - - G A
G - G G - - - G A
G - G G - - -  G A
G - G G - - - G A
G - G G - - - G A
- G G - .  .  G -
- G G - - - G A
- G - - . . .  .
- G G - - - G A
T G G - - - G A
- G G - - - G A
- 6 6 - - - G A
- G G - - - G -
-  G G - - .  G -
- G G - - G -
•  6  G - - - G -
- G G - .  .  G -
C C A  
C C A  
C C A  
C C A  CCA 
- C A CCA CCA CCA 
CCA 
CCA 
C C A  
C C A  
C C A  
C C A  
C C A  
C C A  
C C A  
C C A  
C C A  
C C A  
C C A  
A C C A 
C C A
C - C 
C - C 
C T C  CTC CTC 
C - C 
C - C 
C -  C 
C - C 
C - C 
C - C 












G C T G C T . G C T G C T G C T G C T G C T G C T G C T  . . . - C T - - | A9
G C T G C T . G C T G C T G C T G C T G C T G C T G C T G C T - C T - - | A10
G C T G C T . G C T G C T G C T G C T G C T G C T G C T . . . - C T - - | A9
G C T G C T G G C T G C T G C T | A5.1
G C T G C T . G C T G C T G C T G C T G C T G C T G C T .  . - C T - - | A9
G C T G C T . G C T G C T G C T G C T G C T G C T G C T .  . . - C T - - | A9
G C T G C T . G C T G C T G C T G C T . . .  .  T - - I A6
G C T G C T . G C T G C T G C T G C T . .  T -  - | A6
G C T G C T  . G C T G C T G C T G C T G C T G C T G C T
GCTGCTGCTGCTGCTGCTGCTGCT
G C T G C T G C T G C T
G C T G C T  ............................
G C T G C T ............................
G C T G C T  ............................
G C T G C T  . G C T G C T
GCTGCTGCTGCTGCTGCT
GCTGCTGCTGCTGCTGCT
G C T G C T  G G C T G C T G C T
G C T G C T . G C T G C T G C T G C T
G C T G C T . G C T G C T G C T G C T
G C T G C T . G C T G C T G C T G C
G C T G C T . G C T G C
H
G C T G C T
G C T G C T . G C T G C
1- G C T G C T
G C T G C T . G C T G C T G C T
G C T G C T . G C T G C T G C T
G C T G C T . G C T G C T G C T
G C T G C T . G C T G C T G C T
G C T G C T G - - .  .  . - G C T
G C T G C T . G C T G C T G C T
G C T G C T . G C T G C T G C T






indicates identity with reference sequence (*001), "blank" indicates unpublished s e q u en c e ," *" with grey fill indicates a  deletion.
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Figure 4.3. Phylogenetic tree o f  the MICA alleles and polymorphic positions o f  exons 2,3,4 and 5 illustrating PCR-SSP Groups
Exon 2
1 1 1 2





2 2 3 3 3 3 3 3 3 4 4 4 5 5 5 5
5 7 1 3 4 6 7 7 8 2 5 6 1 2 2 4
Exon 4
5 5 5 5 6 6 6 6 6 6  
4 7 7 9 1  1 2 2 3 4
7 7  7  7 7 8 8 
4  5 5 6 6  1 2
1 8 6 6 8 8 8 6 8 6 8 8 6 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9  
> 8 8 8 8 8 9 9 9 9 9 9 9 9 9 9 0 0 0 0 0 0 0 0 0 0 1  3 3 6 7
1 7 0  9 0  7 7 8 2  6 7 2 4 6 0 4 0  3  5 4 1 7 7 3 6  2 5 3 9 4 5 6 3 8 8 4 1 1 1 2 5 8  1 3 3 4 5 6 7 8 9 0 1  2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0  3  7 9 6 T M Typing
MICA*001 O O T C A T G T A G  | G A G C G C A A A G A A A G G C | T c  C T T G A T C G G C C A G G C G | G C T G C T A T C G G G roup
MICA*017 G O • - G • | - G • • - • - G • - * .........................O C T G C T G C T G C T G C T • C T • • A9 5
MICA'020 • O - O ■ - G • | • G • • .............................1 ........................ G C T G C T G C T G C T G C T G C T - C T - - A10 5
MICA*046 • O • O • - G • | • G • • ........................ I .............................1 .........................O C T G C T G C T G C T G C T . C T - - A9 5
MICA*023 - G - O • - G - 1 - G • - . . . . . . .  | G ........................ O C T A5.1 5
MICA*00201 • • O O - • G - | . G . . .........................O C T G C T G C T G C T G C T . C T - - A9 5
MICA'041 • O . G O - G - | . G • - ........................ I ............................. 1 .........................O C T G C T G C T G C T G C T - C T - A9 5
MICA-047 G O G - G • | • G - • ....................G • | .........................G C T G C T - • T " • A6 5
MICA-011 ■ G • G • - G ■ | . G . . G ................... I . . . . .  G - | ........................ G C T G C T  . . . • . T . . A6 5
MICA-030 • G O - - G - | - G • - . . . . . .  I ....................G • I 5
MICA-014 - G - G - • G - | . . . .  A - - G • - ........................  1 2
MICA-015 • G O . ■ G • | . . . .  A - . G • - ........................&  1 .........................O C T G C T G C T G C T G C T - C T - . A9 5
MICA-013 • G • G - - G • | • G G  • . . o  . . .  | . . Q ■ • | 3
MICA-036 . G O - . G - - - - G A ■ • | ............................. 1 2
MICA-00202 • - G • G • • G • 1 . 0  . . ........................ I . t . . . . 5
MICA-026 • - - G • • G • 1 . G - * - T . . - - ............................. 1 ........................ G C T G C T A6 4
MICA-00701 • • - • G • - G • | • G • • T • • • • ............................. 1 .................... A4 4
MICA-045 . g - • G - | . G • • . T . - - - • G ....................| A4 4
MICA-029 - . - G ■ • G | ■ G - A .............................1 . . . . .  | A4 4
MICA-00702 * • • • G • - G • | • G ■ • * ........................ 1 4
MICA-043 • • • G • • G * | - G - • . o  . . . .  | . . . . T ■ ■ | . . I  . . A4 4
MICA-040 . . . G • - 0 - 1 ........................ I .............................1 4
MICA-001 - - • 1 . . . . . . .  | .................... A4 4
MICA-018 - - • 1 . G • • . . . .  - I . . . . . . .  j .................... A4 4
MICA-01201 • • • • 1 • G • • .............................1 .................... A4 4
MICA-01202 • • G * - . . .  A - - - | 4
MICA-021 C - • | . G . . .............................1 4
MlCA*028 • " T O * A - G - I • G O * . - G - - - j .............................1 G .........................G C T A5.1 2
MICA-032 • • T O  • A - G - | . G - - T • A • G | • ....................I 4
MICA-025 C - T G - A - G • 1 . 3  . . .............................1 4
MiCA-031 ... .  T G - A - G -  1 .............................1 4
MICA-034 - G • G • - G - | . G • - G ................... 1 - - - C C A • C • C . ............................. 1 5
MICA-038 . . . G - - G - | - G • - - C C A - C - c  - .............................1 4
MICA-037 . . . G - . G - | . G ■ - .................... ....  1 - - - C C A - C T C - - . G - - * - | 4
MICA-039 • • - G • - Q . | - G ■ • •...................- 1 • - - C C A - C T C C 4
MICA-035 • G O - - G • | . G - • • - C C A - C T C - • • G • • * - I 5
MICA-005 • • T G - ■ G - [ - G G - . . . .  C A -' C . c  - . . G • - - | 4
MICA-006 • • T O * A • G • | ................... G G G  ■ . • G A A • | . • C C A • c  • c  . ............................. 1 ........................ G C T G C T A6 2
MICA-00902 * • • T O  • A - G - | . . . T - G - G G - - G A - - | . . - C C A . c  . C . .............................1 .........................G C T G C T A6 2
MICA-049 - . T G - A • G • | ................... G • G G  ■ • • G A . - | - - - C C A • c  • c  - .............................1 ........................ G C T G C T A6 2
MICA-00901 • - T O - A • G - | ................... G - G G - - - G A • - | • • - C C A - c  - c  - .............................1 ........................ G C T G C T A6 2
MICA-004 • • T O * A • G • | ................... G • G G • • - G A • G | . - - C C A • c  - c  - . .  - ... - .  .  ( ........................ G C T G C T A6 2
MICA-044 • G • G ■ A • G • | ....................G - G G ■ • G A • G | • • C C A • C - C . .............................1 3,2
MICA-024 • • T G • A • G • | ■ G O  • . . 0  • • ■ | . • • C C A • c  • c  - .............................1 2
MICA-022 • G • G • • G • | - G Q • • • G A • • | • - r C C A - C T C - 3
MICA-042 • - T G • A • G • | - G • • • - - C C A ■ C T C . T . G • • • - | 4
MICA-019 • - T G - A • G • | ■ G O • • G A • • | - . - C C A C T C - . . G • • • - | .........................G C T .................... I A5 •
MICA-033 • • T G • A - G - | T G G • • • G A • • | - ■ C C A - C T C - • • G • • - • | ........................ G C T A5 1
MICA-016 - . T G • A • G - | • G G - • G A - • | - - - C C A - C T C C . . G - - - - | .........................G C T A5 1
MICA-010 C • T G • A • G - | ■ G G • - • G A • • | • - - C C A C T C - . . G - - - - | .........................G C T A5 1
MICA-00802 • • • T G • A • G - | - G G - . - G • . • | - - - C C A • C T C  • T - G - * - • | G .........................G C T A5.1 1
MICA-027 ■ • T G ■ A - G • | • G G  • - • G • • • | ■ - - C C A • C T C - - - G • - - - | ........................ G C T A5 •
MICA-048 • - T G • A • G - | . G G . . G - • - | • • - C C A • C T C - . . G • - - - | ........................ G C T • • - T - | A5 *
MICA-00801 • - T O - A - G - | - G O - . . c  - * • | C C A • C T C  • - - G . . . .  | G .........................G C T A5.1 1
MICA-00803 • • - T G • A G O - . . G . . . | • • A C C A - C T C - . - G - - - - | 1
indicates identity with reference sequence (* 0 0 l) , "blank" indicates unpublished seq uence," * " with grey fill indicates a deletion
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Figure 4.4. Amino acid substitutions at the polymorphic positions in the MICA alleles arranged in phylogenetic order
a  1 a  2 a  3 T M
i j 2 y 9 0 1 2 2 2 2 3 4 5 5 7 7 « 0 0 1 1 1 i I t , j J 2 2 2 r
Ami no  Aci d 6 4 4 6 6 1 5  4 2 4 5 9 0 2 1 6 3 6 1 6 8 0 J 5 1 6 ! 7 8 9 • 1 2 3 4 5 6 7 8 9 t 2 J 4 5 6 t  H » 0 1 ] 3 4 5 t - 8 « o 1 2  3 4 5 6 7 t 9 o t 2 3 4 M
Position R W T V c 0  R G L T K M P V M H K V T G Y W T S 0  R P V L v 1 9  s H W 9  T F H V s A V A A A A . . I F V 1 1 I F Y V R C  C K K K T s A A E G P







•020 - G A - E • - A A A A A A A A A A - C  - - - 10
•046 - G A - E - - A A A A A A A A A 9
*023 - G A • E • - A A G C  C  Y F C Y Y Y - L C P L L X 5.1
•00201 - G A - E - - A A A A A A X A A . c  - -  • 9
•041 - G A G - - E - - A A A A A A A A A 9
•047 • G A G - • E A - - A A A A A A - c  - - - 6
•O il - G A - E A - - A A A A A A - c  - - - 6
*030 - G A - E A
•014 - G A - - R - • E
•015 - G A - R - - E C W C F R V 1 G R H S M F L L L L L L L  L L 1 L  L F L L L L F S T s - V V R R - H Q L Q R V Q G A9
•013 - G A - E E
•036 - G A - E E
•00202 - G A - E
*026 - - A - E • - A A A A A A 6
*00701 - - A - E - - A A A A . . 4
•045 - - A - E - - A A A A . . 4
•029 - - A - E - - A A A A . . 4
•00702 - - A - E
•043 - - A - E - - A A A A . . 4
•040 - - A
•001 - K - - A •x A A . . 4
•018 - E - * A A A A . . 4
•01201 - E .  .  - .  L • - A A A A . . 4
•01202 - E L
*021 - E - - - - L
*028 - - A - E A G C  C  Y F C Y Y Y - L C P L 1 X 5.1
•032 - - A - E .  .  .  .  L
•025 P - A - E
•031 - - A
•034 • G A - E - R . T
•038 - ■ A - E - R - T
*037 - - A - E - R I T R -
•039 - - A - E - R I T  1 R -
•035 - G A - E - R 1 T R -
•005 - - A - E v  . . .  - - R - T R -
•006 - - A . . .  V - E V - - - - E S - R - T - - A A A A A A 6
"00902 - - A - Y . . .  v - E v  . . .  - E S S - R - T - - A A A A A A 6
•049 - - A - Y . . .  v - E V - - - - E s S - R - T - - A A A A A A 6
*00901 - - A - Y . . .  v • E v  - - - - E s s - R - T - - A A A A A A 6
"004 - - A - Y - - .  V - E v  - - . . E s - R s - R - T - - A A A A A A 6
•044 - G A - Y . . .  v - E V - • - - E s - R s - R - T
•024 - - A - Y - E v  .  .  .  - E - s - R - T
•022 - G A - E V - - .  • E s s - R I T R -
•042 - - A - Y - E s - R I T R -
•019 - - A - Y - E V - - - - E s s - R I T R - - - A A A A A .
•033 - - A - Y S E V • • - • E s s - R I  T R - - - A A A A A . 5
•016 - - A • Y • E v  .  .  - . E s s * R 1 T R - * - A A A A A . 5
•010 P - A - Y - E v  - - - - E s s - R I T R - - - A A A A A .
•00802 - - A - Y • E V - - - • E s - R 1 T R • - - A ■X G C  C  Y F C  Y Y Y - L < P L L X 5.1
•027 - - A - Y - E V - - - - E s - R 1 T R - - - A -x A A A . 5
•048 - - A - Y - E v  - - - - E s - R I T R - - - A A A A A . 5
•00801 - - A - Y - E V - - - - E s - R 1 T R - - - A A G C  C  Y F C Y Y Y - L c P L L X 5.1
*00803 - - A - Y - E v - .  .  - E s - R I T R *
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Figure 4.5. Agarose gel electrophoresis o f two primer pairs within Group 1
Row 1 : F10 + R17 
Product band : 841 base pairs 
Control band : 485 base pairs
Row 2 : F3 + R16 
Product band : 770 base pairs 
Control band 485 base pairs
Row 1 : F10 + R17 primer pair (*010) Row 2 : F3 + R 16 primer pair (*016)
Lane Sample Result
1 *010 control *010






















1 *010 control neg






















Figure 4.6. Agarose gel electrophoresis o f two primer pairs within Group 4
>
Lanes 1-16: F1+R12
Product band: 741 base pairs 
Control band : 485 base pairs
Lanes 17-32: F18+RI 
Product band: 617 base pairs 
Control band : 485 base pairs
Lanes 1-16 : FI + R12 (MICA *012) Lanes 17-32 : F18 + R1 (MICA *001)
Lane Sample Result
1 *012 control *012
















17 *012 control neg
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A5 *010 *016 *019/ *027/ 
*033 *048
15 35 61 3 2 4 6 8
—
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Figure 4.9. MICA A5.1 allele haplotypes in the 13IHW patients with Type I Psoriasis


































MIC A EC HLA B 11 LA Cw
* 0 0 4 * 009*011  44  49  42  41 51 52  35  50  45  14 16 4 7 15 17 1 2 14 12 6  8
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Figure 4 .11 . MICA A9 allele haplotypes in the 13IHW patients with Type I psoriasis
M ICA TIM M IC A  EC HLA B HLA C w


































The A9 allele of MICA has been associated with psoriasis and psoriatic arthritis in 
several small studies (50; 52; 67). The genetic study presented here confirms the 
association of MICA A9 and suggests a role for the *002 allele of MICA in PsA and 
the *017 allele in psoriasis. It is unclear whether these associations are primary or 
whether they are due to the presence of more functionally relevant genes along an 
extended haplotype. There are a number of reasonable functional candidate genes all 
present within a short distance of the chromosome that display a high degree of 
linkage disequilibrium to MICA. The task of distinguishing which of these are the key 
players in the susceptibility to PsA or psoriasis is clearly a difficult one. One factor 
that should be taken into consideration is the functional relevance of the gene product 
to the condition. In the case of MICA, its role in the stimulation of an immune 
response via the activation of a ubiquitous receptor on NK cells, CD8+ a@ T cells and 
yd T cells makes it a plausible candidate. However, if it could be demonstrated that 
MICA is expressed in the target tissues, ie. the skin and the synovium, and more 
specifically that the expression is in some way altered during the disease process, this 
would add considerable support to MICA being a strong candidate gene for these 
conditions.
Initial studies on the expression of MICA with monoclonal antibodies suggested 
specific expression on gastrointestinal epithelium in response to stress, with the only 
other site of expression being thymic cortical epithelium (131). It was later 
demonstrated that MICA was also expressed on a wide variety of tumours, including 
lung, breast, kidney, ovary, prostate and colon carcinomas (172). Recently, a more 
generalised expression pattern has been described using other monoclonal and 
polyclonal antibodies, with expression predominantly in epithelial tissues such as the 
skin and kidney (138).
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MICA is not always expressed by the cells in which it is transcribed. It was noted that 
several tumour cell lines lack surface expression of MICA despite the presence of 
abundant mRNA (173). Analysis of these cell lines showed that they were homozygous 
for MICA *010. This allele has a single amino acid substitution (proline for arginine) in 
the a l domain that appears to interfere with a stable protein fold. The frequency of 
MICA *010 in the population has been estimated at 5% in a Caucasian population (118) 
and 12.5% in a Japanese population (130). To date, no specific disease associations have 
been described with MICA *010 and these individuals appear to have a fully functional 
immune system.
Another allele, MICA 5.1, which is the commonest MICA allele in all populations 
studied, has a truncated cytoplasmic tail which alters expression. The resultant truncated 
MICA molecules have been shown to translocate to the apical surface of intestinal 
epithelial cells rather than to the basolateral surface as seen with all other alleles of 
MICA (133). The pathophysiological significance of this is not known, although several 
diseases have been reported to show associations with MICA 5.1.
The cytoplasmic tail (encoded by exon 6 of MICA) appears to carry important 
information for the sorting of MICA molecules and their subsequent transportation to the 
cell surface. The alleles, MICA *017 and *015, bear a single base deletion at the end of 
exon 4 that causes a shift in the reading frame. This results, not only in the production of 
a hydrophobic poly-leucine region, but also in the loss of the cytoplasmic tail. The 
surface expression of this allele has not been specifically studied, but it could be inferred 
from the previous studies that these alleles would also result in defective surface 
expression. The genetic study of MICA presented in this thesis has demonstrated a 
strong association between the MICA *017 allele and psoriasis. If the above hypothesis 
is correct, then the expression of MICA in the epithelium in psoriasis may be reduced 
due to altered transportation to the cell surface.
The MICA allele associated with PsA contains nine GCT repeats (A9) which are 
translated into nine alanines in the transmembrane region. On further analysis of the
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various alleles that contain 9 GCT repeats, the actual allele associated with PsA was 
MICA *002. This allele is identical to MICA *017 except for two single nucleotide 
polymorphisms. Firstly, it does not have the single base deletion at the end of exon 4 
and therefore has a normal cytoplasmic tail and no frameshift. Secondly, it has a 
substitution at position 272, which leads to a change of amino acid at position 91. This 
amino acid is at the heart of the crio2 platform that interacts with the NKG2D 
receptor. There may therefore be no reason for altered surface expression of MICA in 
PsA, but its interaction with the NKG2D receptor and therefore its ability to activate 
the immune response may well be altered. The significance of the number of alanines 
within the transmembrane region of MICA has not been studied in molecular models 
and therefore the consequences of the A9 allele on surface expression are not known. 
It would therefore be reasonable to assume that there is no clear reason why MICA 
should not be expressed on the cell surface in PsA. However, to date no study has 
examined whether MICA is expressed in the synovium.
Polyclonal antibodies have been produced which recognise MICA by immunising 
rabbits with short peptides from the cri (residues 42-60) and oQ domains (residues 
140-160) (174). These residues were chosen as they were in non-polymorphic regions 
of MICA and did not show appreciable cross-reactivity with the other members of the 
extended MHC Class I family. These antibodies have been used to immunoprecipitate 
a 62kDa band which appears to be the native MICA molecule. Western blotting has 
confirmed the presence of MICA in freshly isolated keratinocytes, monocytes, 
fibroblasts and umbilical vein endothelial cells. The MICA band was not present in 
peripheral blood CD4+, CD8+ or CD 19+ lymphocytes and was not upregulated by y- 
interferon. Flow cytometry has demonstrated that expression in keratinocytes and 
monocytes is predominantly within the cytoplasm and rarely on the cell surface. This 
contrasts with endothelial cells and skin-derived fibroblasts which show high levels of 
expression at the cell surface (175). The reason for this differential surface expression 
is not clear. It may be related to tissue-specific alternative splicing of the immature 
MICA RNA, a mechanism that has been described for HLA-G and MR1. It may be 
that surface expression of MICA is dependent on a tissue-specific transporting
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‘chaperone’ or surface binding ligand. Finally, surface expression may be influenced by 
the allele of MICA expressed by the cell.
The expression of MICA in a variety of tissues has been studied using indirect 
immunofluorescence. Several different polyclonal antibodies to MICA were utilised to 
demonstrate that MICA is expressed in the epithelial layers of the oesophagus, intestinal 
mucosa, liver, human neutrophils, glomeruli, testis and ovary (176). The strongest 
pattern of expression was observed with the antibody PERB11-5D. This antibody was 
produced following immunisation with a peptide from the a l domain (residues 57-67) of 
MICA. The same peptide was later used to make the polyclonal antibodies PERB11.1 
204 and 205 which were utilised in this study. The PERB11.1 antibodies were used to 
demonstrate the expression of MICA in the skin of patients with psoriasis in a small 
study that reported an association between the A9 allele of MICA and psoriasis (50). The 
expression of MICA was reduced in lesional skin specimens taken from 3 patients with 
psoriasis using indirect immunofluorescence. To date, there have been no further studies 
of the expression patterns of MICA in the skin in psoriasis or any other skin pathologies.
5.2 Alms of the study
Since polymorphisms of MICA are associated with psoriasis and psoriatic arthritis, the 
aim of this study was to evaluate the expression patterns of MICA in the skin and 
synovium. Disease-specific tissue expression patterns could be examined by 
immunohistochemistry following antigen retrieval. This technique would enable the use 
of archived paraffin-embedded, formalin-fixed sections from patients with known 
diagnoses that demonstrated clear histological patterns. The sections could then undergo 
antigen retrieval to ensure the MICA molecules became accessible for antibody staining 
(177). Expression patterns in normal skin and lesional psoriatic skin could then be 
compared to determine if there are any disease-specific changes. In addition, expression 
patterns in synovial sections from patients with PsA, RA, non-specific synovitis and
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normal synovium could also be examined to elucidate whether MICA is expressed in 
the synovium and, if so, whether there are any disease-specific patterns.
5.3 Methods
5.3.1 Polyclonal antibody production
The polyclonal antibodies used to detect MICA (PERB11.1 204 and 205) had been 
produced by the immunisation of different rabbits with a peptide derived from a 
sequence within the a l domain. The peptide was synthesised and conjugated to 
Diptheria toxoid (Chiron Mimotopes Pty Ltd, Victoria, Australia). The region of 
MICA chosen for the peptide synthesis was a conserved sequence not known to 
contain any polymorphism (residues 57-67 of the a l domain, Table 5.1). The 
immunisation procedure involved the injection of rabbits with the peptide-diptheria 
conjugate using Titremax adjuvant and harvesting serum after 9 and 14 weeks. The 
sera were tested for reactivity against the peptide using an indirect ELISA (176). The 
PERB11.1 204 and 205 antibodies would therefore be expected to show the same 
reactivity patterns as they were both derived from immunisation with the same 
peptide. However, they may differ in intensity depending on the quality of antibody 
produced by each rabbit.
5.3.2 Alignment o f  MICA amino acid sequence with other members o f  the EMCIF
Since the technique was developed to produce these polyclonal antibodies to MICA, a 
number of proteins related to MICA have been described in the literature and termed 
the ‘Extended MHC Class I Family’ or EMCIF (129; 178). An alignment of the amino 
acid sequences of the *008 allele of MICA with the other members of the EMCIF is 
illustrated in Table 5.1. The proteins within this family include MICB, HLA Class I, 
Zna2 glycoprotein, neonatal Fc receptor, CD1, MR1, HFE and the ULBPs. The MICA 
peptide used for the immunisation process does share some common residues with the 
other members of the family. The closest alignment is with MICB which shares 9/11 
residues with the peptide in MICA. The PERB11 antibodies would therefore be likely 
to recognise both MICA and MICB expression, and will hereafter be referred to as 
‘MIC’. The use of monoclonal antibodies to MICA and MICB may help delineate any
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differences in expression. None of the other amino acid sequences share more than 
5/11 residues of the PERB11.1 204 and 205 peptides. This would make it unlikely that 
there would be any significant cross-reactivity with the other members of the family.
5.3.3 Preparation o f  antibodies
The primary antibodies used for the immunofluorescence and immunohistochemistry 
studies included two polyclonal antibodies to MIC (PERB11.1 204 and PERB11.1 205), 
a monoclonal antibody to MICA (huMICA-M673) and an antibody to Class I HLA 
(W6/32) (Table 2.4). All antibodies were stored at 4°C as an undiluted stock solution. 
The optimal working dilutions of the antibodies was determined by testing sections with 
differing dilutions between 1:10 and 1:200. The optimal dilution for PERB11.1 204 and 
205 and W6/32 was 1:50 for both techniques. The monoclonal antibodies were only 
used for immunohistochemistry. They showed generally poor reactivity and a dilution 
of 1:10 was utilised. The antibodies were diluted just prior to use in antibody diluent 
(DAKO).
5.3.4 Selection ofpatient material fo r  immunohistochemistry
Skin and synovial sections were obtained from archived, paraffin-embedded, formalin- 
fixed tissue, stored in the Pathology Department of Sir Charles Gairdner Hospital, 
Perth, Australia. Permission for the tissue to be used was obtained from the Head of the 
Pathology Department and was within the remit of their Ethics approval.
5.3.5 Synovium sections
Sections from patients who had PsA, RA, non-specific synovitis and controls were 
sought. The pathology department database was searched by a Consultant 
Histopathologist for the words ‘psoriatic arthritis’, ‘rheumatoid arthritis’ and ‘non­
specific synovitis’ for appropriate synovial sections. Five sections representative of 
each diagnosis were retrieved. The diagnosis and histological features were confirmed 
by review of Haematoxylin and Eosin stained sections by a Consultant Histopathologist. 
The sections selected to show normal synovium were found to have a mild Grade I non­
specific synovitis on review of the histology, but were considered to be ‘normal’
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controls for comparison with the inflamed synovial sections. Fresh 5 pm  sections were 
cut from each paraffin-embedded block and placed onto glass slides and left to air-dry 
prior to use.
5.3.6 Skin sections
Five sections of skin from patients with psoriasis were obtained by searching the 
database for the word ‘psoriasis’. The histology was reviewed as above. Tissue was also 
available from normal skin which were used as controls. Fresh 5/mi sections were cut 
from each paraffin-embedded block and placed onto glass slides and left to air-dry prior 
to use.
5.3.7 Selection ofpatient material for immunofluorescence
Frozen sections of normal skin were obtained from the Centre for Molecular 
Immunology and Instrumentation in Perth. The sections had previously been used for 
localisation of the binding of different polyclonal MICA antibodies for which ethical 
approval was given. The frozen blocks were cut into 4/xm sections and placed on glass 
slides. They were then left to air-dry for 1 hour and fixed in ice-cold methanol. The 
slides were stored at -20°C until needed.
5.3.8 Immunofluorescence
The expression patterns of PERB11.1 204, PERB11.1 205 and W6/32 were examined 
by immunofluorescence on frozen sections of normal skin. The method is described in 
Chapter 2.5.2. The slides were examined for fluorescence using dark background 
microscopy. The sections were then photographed on slide film and the slides were 
scanned into a computer as .tif images.
5.3.9 Immunohistochemistry
The expression patterns of the PERB11.1 204 and PERB11.1 205 polyclonal antibodies 
to MIC, the MICA monoclonal antibody (huMICA-M673) and W6/32 were examined 
on the skin and synovial sections described above. The technique of ‘antigen retrieval’ 
by super-heating formalin-fixed slides is well described (177). This was achieved by
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microwaving the slides on a high power in a buffer solution. The technique had been 
optimised for routine use in the Immunohistochemistry department at the Sir Charles 
Gairdner hospital. The method is detailed in Chapter 2.5.3. Photographs of the slides 
following immunohistochemistry were taken with digital photography and the images 
were downloaded directly onto a computer.
5.4 Results
5.4.1 Immunofluorescen ce
Sections of normal skin were examined for the presence of MIC with the polyclonal 
antibodies PERB11.1 204 and 205 and the presence of HLA Class I with the W6/32 
antibody. PERB11.1 204 and 205 showed the same pattern of staining, although the 
intensity of staining with PERB11.1 205 was more intense. They both demonstrated a 
granular cytoplasmic pattern of staining of the basal layers of the epidermis. The 
expression was much less marked in the upper layers of the epidermis. Bright staining 
of the superficial keratin layer was seen and occasional staining of fibroblast-like cells 
in the dermis. Examples of the pattern of expression are shown in Figures 5.1, 5.2 and 
5.3. Comparison of the pattern of staining observed for MIC with the cell surface 
pattern of staining throughout all the layers of the epidermis with the antibody to HLA 
Class I (W6/32) serves to differentiate the two members of the EMCIF (Figure 5.4.). 
Although it is possible that there is some cross-reactivity between the expression of 
MIC and HLA Class I detected by the polyclonal antibodies, the basal epidermis 
staining would appear to be specific for MICA.
5.4.2 Immunohistochemistry
5.4.2.1 Normal Skin
There was a granular cytoplasmic pattern of staining throughout the cells of the 
epidermis. The comified layer stained strongly. There was no significant difference in 
the pattern of staining with the PERB11.1 204 or 205 antibody although staining was 
more prominent in the basal layer of the epidermis with PERB11.1 205. In the 
dermis, there was staining of the vascular endothelium, dermal fibroblasts and sweat 
ducts (Figure 5.5.). Immunohistochemistry using the monoclonal antibody to MICA
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(huMICA-M673) demonstrated a granular cytoplasmic staining of the basal layers of 
the epidermis in normal skin which was markedly reduced in the sections taken from 
patients with psoriasis {Figure 5.6). There was no staining of the keratin layer or 
dermis suggesting that the staining observed in these regions with the polyclonal 
antibodies was non-specific.
5.4.2.2 Skin from patients with Psoriasis
Staining of the expanded epidermal layer and hyperkeratotic comified layer in skin 
sections from patients with psoriasis was markedly reduced overall with both 
PERB11.1 204 and 205 {Figures 5.7 and 5.8). This was most apparent on the sections 
that contained both lesional and non-lesional skin, where the loss of staining within 
the pathological skin was striking. The loss of expression in the basal layers of the 
epidermis was the most evident. The pattern of staining in lesional skin was also 
different from that seen in normal skin in some of the sections. In these sections (3 out 
of 5), the cells of the stratum spinosum of the epidermis exhibited a strong cell 
membrane pattern not seen in normal skin. The pattern then returned to a 
predominantly granular cytoplasmic appearance in the upper stratum granulosum of 
the epidermis. Staining of dermal structures was no different from normal skin 
although any inflammatory cell infiltrate stained strongly. Staining with the 
monoclonal antibody to MICA demonstrated loss of expression in lesional psoriatic 
skin {Figure 5.9).
5.4.2.3 Control synovium
In Grade 0-1 synovitis, PERB11.1 204 and 205 antibodies stained the surface 
synoviocytes with a granular cytoplasmic pattern. Staining was also seen in the 
underlying connective tissue predominantly in the vascular endothelium {Figure 5.10). 
The monoclonal antibody to MICA (huMICA-M673) exhibited faint staining of the 
layer of surface synoviocytes {Figure 5.11). There was no staining of the underlying 
connective tissue or inflammatory infiltrate suggesting that some of the staining seen 
with the polyclonal antibodies was non-specific.
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5.4.2.4 Synovium from patients with PsA
The inflamed synovium was thrown into multiple frond-like villi with an expanded 
layer of surface synoviocytes which stained strongly with the PERB11.1 antibodies. 
The underlying connective tissue contained increased amounts of heavily staining 
vascular tissue. There did appear to be an increased intensity of staining in inflamed 
compared with non-inflamed synovium (Figure 5.12.).
5.4.2.5 Synovium from patients with RA
The synovial samples from patients with RA showed similar changes to those seen in 
the inflamed PsA synovium (Figure 5.12). There were no apparent differences in 
either the intensity or the pattern of staining with either PERB11.1 204 or 205.
5.4.2.6 Synovium from patients with non-specific synovitis
The non-specifically inflamed synovial samples showed the same distribution and 
intensity of staining for MIC as the sections from patients where a specific diagnosis 
of PsA or RA had been made.
5.4.2.7 Control sections
A section of human brain was used as a negative tissue control as MICA is not 
expressed in the central nervous system. This was confirmed by the lack of staining 
with the PERB11.1 204 and 205 antibodies (Figure 5.14). An antibody control was 
also created by staining a synovial section with a polyclonal antibody to glial fibrillary 
acid protein. There confirmed the expected lack of staining of the section as 
demonstrated in Figure 5.15.
5.5 Discussion
Immunohistochemistry following antigen retrieval has been successfully utilised to 
evaluate the binding of the PERB11.1 204 and 205 antibodies to the corresponding 
proteins in the skin and synovium. These antibodies predominantly bind to MICA but
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may show some affinity for the gene products of the other members of the Extended 
MHC Class I Family (EMCIF), particularly MICB which is the most closely related.
This study has shown that expression of MICA was reduced in psoriatic skin and 
displayed a different pattern of staining from normal skin. Expression of the MICA 
protein appeared to be almost lost in the basal layers of the skin. In some examples of 
psoriatic skin, MICA was expressed predominantly on the cell surface of the spiny 
cells of the stratum spinosum and in a reduced amount within the cytoplasm of the 
upper stratum granulosum and the cells of the comified layer. In other examples of 
psoriatic skin, the staining was reduced in all layers, particularly in the basal layers, 
but the pattern of staining was predominantly cytoplasmic throughout. This is 
interesting as it may represent differential expression patterns of the MICA alleles. 
The two alleles which have been associated with psoriasis are the transmembrane 
alleles MICA A5.1 and A9 (50; 52). The A5.1 allele has a guanine insertion in exon 5 
which causes a frameshift and a truncated protein which may well affect the surface 
expression. The A9 allele which has been associated with psoriasis in this study 
(MICA *017) also has a frame shift due to a guanine deletion at the end of exon 4 
(179). This causes the production of a hydrophobic, long leucine-rich region and 
premature termination in the cytoplasmic tail which may in turn lead to altered 
expression patterns. Typing the MICA allele of the patients from whom the samples 
were taken would help to clarify the patterns seen and aid in their interpretation. The 
reason why a reduction in the expression of MICA is seen in psoriatic skin is not clear. 
It may simply be a function of the altered cell dynamics in psoriasis as the cells 
differentiate through the layers of the epidermis. The consequences of this apparent 
reduction of MICA are not known, but it is possible that it may result in a reduced 
capacity of psoriatic skin epithelial cell MICA molecules to interact with NK cells and 
T cells. This may ultimately affect the ability of the skin to respond to stresses such as 
injury or infection.
Expression of MICA in the synovium has not been previously reported. The 
expression was predominantly seen within the cytoplasm of the surface synoviocytes
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but also in the underlying vascular connective tissue. The use of monoclonal 
antibodies to MICA suggests that the more specific staining is with the surface 
synoviocytes. There was no clear change in the pattern of staining between PsA, RA 
and non-specific synovitis. All pathologies which resulted in an inflamed synovium 
caused an increase in the intensity of staining. Thus, MICA expression may be 
upregulated in inflamed synovium, but, so far, no disease specific patterns have 
emerged. Further examples of synovium from a number of different pathologies will 
help to establish whether any disease-specific changes can be found.
The possibility of cross-reactivity of the polyclonal antibodies with other members of 
the extended MHC Class I family has to be considered. It is very likely that PERB11.1 
204 and 205 detect both MICA and MICB since the peptide used for the production of 
the antibodies share 9/11 residues. Much less is known about the function and 
expression of MICB than MICA. It does appear to be less polymorphic than MICA 
and no specific disease associations have been described.
The peptide used for the production of PERB11.1 204 and 205 does share 5/11 
residues with HLA-Class I, the neonatal Fc receptor and ULBP1. HLA Class I 
molecules are ubiquitously expressed in most tissues. However, the pattern of 
expression obtained using antibodies specific for HLA Class I (W6/32) is clearly 
different from that obtained with PERB11.1 204 or 205. The neonatal Fc receptor is 
responsible for the shuttling of maternal IgG from the intestinal lumen into the 
bloodstream. Although it is possible that it is expressed in the skin or synovium, it 
would seem unlikely.
Another possible cross-reactivity is with ULBP1. This interesting protein is one of 
three binding proteins that bind to the human CMV protein UL16. The ULBPs, like 
MICA, bind to the stimulatory NKG2D receptor that is expressed on NK cells and T 
cells. It is possible that the CMV protein, UL16, avoids destruction by NK and T cells 
by binding to the ULBPs, preventing them from activating the host’s immune 
response. The ULBPs are widely expressed on T and B cells, a variety of tissues and
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are possibly upregulated in tumour cell lines. Their expression in the skin and 
synovium has not been reported. The sharing of the NKG2D receptor by MIC 
molecules and the ULBPs is intriguing and may suggest some complementary role in 
the regulation of the immune response to viral or other pathogens. A study of the 
expression patterns of the ULBPs would help to resolve some of these problems.
Further insight into the possibility of a functional role for MICA in the skin and 
synovium will require the investigation of more histological specimens from differing 
pathologies. These should include skin sections from other conditions which cause a 
‘psoriasiform reaction’ as well as other inflammatory skin conditions such as eczema. 
In addition, the utilisation of other antibodies, including monoclonal antibodies, 
produced by a range of techniques will help delineate which of the patterns of staining 
are specific and which are due to cross-reactivity or background staining. A better 
understanding of the functional consequences of the allelic variants of the molecule 
will help determine whether any of the different expression patterns observed are due 
to an individual’s genetic background. Until more is known of the nature and function 
of all the members of the EMCIF, it would be appropriate to interpret some of the 
minor expression patterns seen with these antibodies with caution. However, it would 
appear that MICA is expressed in the skin and synovium and expression patterns differ 
between the disease and control samples studied here. Although further work needs to 
be done, these preliminary findings would support a role for MICA in psoriasis and 
PsA.
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Comparison of the patterns of expression of MICA (using PERB11.1 204 
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Expression of MICA in normal skin demonstrated with a polyclonal antibody to
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Expression of MICA in psoriatic skin demonstrated with a polyclonal (PERB11.1
204) and monoclonal antibody (Immunex) to MICA
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Fieure 5.7.
Psoriatic lesional skin, 
low power view
Immunohistochemistry 
using PERB1I.1 204  
antibodies
Loss o f  expression o f  
MICA in the basal 
layers o f  the expanded 
epidermis.
Cell surface pattern o f  
staining in the central 
‘stratum spinosum ’.
Cytoplasmic 
expression in the 
upper layers o f  the 
epidermis
Fieure 5.8.
High power view o f  
psoriatic lesional skin 
stained with polyclonal 
antibodies to MICA 
(PERB11.1 204).
Loss o f  basal layer 
expression and change o f  
pattern to cell surface 
expression in the middle 
layers o f  the epidermis
Fieure 5.9.
Low power view  o f  
psoriatic lesional skin 
stained with monoclonal 
antibodies to MICA 
(Immunex).
Loss o f  expression o f  MICA 
in psoriatic skin in both the 
basal layer and the keratin 
layer
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Expression o f MICA in normal synovium demonstrated with polyclonal
(PERB11.1 204) and monoclonal antibodies (Immunex) to MICA
Fieure 5.10.
High power view o f  normal 
synovium
The section is stained with the 
polyclonai antibody for MICA, 
PERB11.1 204.
Expression o f  MICA is 
detected in the surface 




High power view o f  
normal synovium
The section is stained 
with monoclonal 
antibody for MICA 
(Immunex).
Expression o f  MICA 
is confined to the 
surface synovial cell 
laver
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Expression of MICA in synovium taken from one patient with PsA and one patient 
with RA
Fieure 5.12.
Low power view o f  inflamed 
synovium taken from a patient 
with Psoriatic arthritis.
The section is stained with the 
polyclonal antibody, PERB11.1 
204
Expression o f  MICA is clearly 
demonstrated along the surface o f  
the frond-like synovium
Fieure 5.13.
High power view o f  inflamed 
synovium taken from a patient 
with Rheumatoid arthritis.
The synovium is stained with the 
polyclonal antibody, PERB11.1 
204.
There is marked cytoplasmic 
expression o f  MICA in the 
expanded synovial layers and the 
inflammatory cell infiltrate
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Negative controls for immunohistochemistry experiments
Fieure 5.14.
Tissue control
A section o f  
human brain 
stained with 





A section o f  
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CHAPTER 6 THE ROLE OF THE 




The role of the MHC Class II loci in PsA has been much less widely studied than the 
MHC Class I loci. The MHC Class II loci, particularly HLA-DR4, are known to be 
strongly associated with RA, but their role in PsA remains controversial. The strongest 
HLA association with PsA does appear to be with HLA-Cw6, although the components 
of the extended haplotypes containing HLA-Cw6 (AH 13.1, 37.1 and 57.1) have also 
been implicated (61; 63; 180).
Several MHC Class I alleles have been independently associated with PsA and confer 
additional contributions to disease susceptibility and presentation. For example, HLA- 
B16 and its splits HLA-B38 and HLA-B39 have been associated with a peripheral 
distribution of PsA (62; 63). In contrast, HLA-B27 seems to be associated with 
sacroiliitis and axial disease (61; 62), DIP joint disease and oligoarthritis (63) and a 
later age of onset of arthritis (63). However, the correlation between HLA-B27 and 
spondyloarthritis is far less in PsA than AS. In one study of patients with PsA 
spondyloarthritis, grade 2 or higher sacroiliitis was present in 38% of HLA-B27 
positive patients, but also 27% of HLA-B27 negative patients (63). HLA-B17 has been 
associated with early age of onset of both psoriasis and PsA(63; 181). HLA-B7 has 
been correlated with a milder form of PsA with fewer deformed joints (63; 182). There 
is additional evidence that some of the MHC Class I genes may modulate the severity of 
PsA. In particular, HLA-B27 and HLA-B39 have been shown to have a role in disease 
progression (183).
The situation with regards to the role of the MHC Class II locus in PsA is less clear. 
Most studies have not compared the frequencies of the Class II alleles with 
uncomplicated psoriasis, thus it is difficult to ascertain the relative contributions to the 
skin and the joint disease. The frequency of HLA-DR7 has been shown to be increased 
in both psoriasis and psoriatic arthritis (62; 184). This may well be related to its 
presence on ancestral haplotypes containing HLA-Cw6 (AH 13.1 and 57.1). One study
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suggested an increased association between HLA-DR7 and more severe peripheral disease 
(62), whereas another has reported an association with milder disease (63). However, in 
some populations, HLA-DR7 is no more frequent in PsA than in the general population 
(64). This would suggest different contributions of the MHC to disease in various ethnic 
populations and confirms the inherent difficulties encountered when studying such a 
complicated condition.
The role of HLA-DR4 in PsA remains controversial; contradictory associations have been 
reported in diverse as well as similar ethnic populations. Two initial studies did report an 
increased frequency of HLA-DR4 in PsA (182; 185), but the numbers of patients studied 
were small. The more recent and larger studies have failed to find any increase in HLA- 
DR4 over and above the control population (63; 181; 186-188). HLA-DR4 has been 
reported to be associated with peripheral arthritis resembling RA by some (63; 63; 182; 
185) but not others (64). There is also some evidence to suggest that HLA-DR4 is 
associated with erosive disease (62) but this has yet to be confirmed (63).
The association between RA and HLA-DR4 has been confirmed in many ethnic 
populations. Those patients who are not HLA-DR4 positive frequently carry HLA-DR1, 
HLA-DR6 or HLA-DR10. Closer analysis between these MHC Class II alleles revealed 
sequence homology between alleles *0101, *0102, *0401, *0404, *0405, *0408, *1001 
and *1402 in the area encoding five amino acids at positions 70-74 
(QKRAA/QRRAA/RRRAA) on the third hypervariable region of the HLA-DRB1 p chain. 
Thus the concept of the ‘shared epitope’ (SE) emerged (97). Furthermore, there is 
evidence that these shared sequences may be associated with disease severity in 
rheumatoid arthritis (189; 190) rather than disease susceptibility. This is particularly seen 
if the number of copies of a SE allele is considered; the presence of two SE alleles of the 
same or different type has been linked with more severe erosive disease, inferring a 
synergistic effect between the alleles (191-193).
The subtypes of HLA-DR4 in PsA have been further explored in a study of 90 patients 
with PsA, 90 patients with RA and 90 controls who were all HLA-DR4 positive (188).
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The HLA-DR4 alleles present in the patients with PsA were less likely to be SE alleles 
than those present in RA. Patients with PsA were also less likely to carry two copies of 
a SE allele. HLA-DRB1*0401 was significantly less common in PsA than RA and the 
non-SE allele, HLA-DRB 1*0402 was found significantly more often in PsA than RA. 
The study did not examine the clinical characteristics of the patients with PsA who were 
SE positive.
6.2 Aims of the study
A detailed study of HLA-DRB 1 alleles in PsA has been undertaken in order to 
investigate the frequencies of these alleles in the disease group as a whole. The possible 
associations with clinical subgroup, characteristics and disease severity will also be 
explored. The role of HLA-DR4 and the SE alleles will be determined to see whether 
they help define a particular subgroup, perhaps those with more severe, peripheral, 
erosive disease resembling RA. The role of HLA-Cw6 and HLA-B27 will also be 
investigated, to examine whether these HLA Class I alleles define any particular clinical 
subgroup or disease pattern.
6.3 Materials and Methods
6.3.1 Study Population
One hundred and fifty eight patients were recruited from the specialist PsA clinic at the 
RNHRD in Bath, as detailed in Chapter 2.2. All patients were Caucasian, had psoriasis 
either at the time of follow-up or in the past confirmed by a physician, an inflammatory 
arthropathy and were mostly sero-negative for RF at initial assessment. Three patients 
had low titre positive RF when they were initially seen. There were 78 females and 80 
males, the mean age was 56 years and the mean duration of arthritis was 21 years 
(Table 6.1). The patients were divided into disease subgroup as originally described by 
Moll and Wright (2), except that oligoarthritis was strictly defined as four or less 
involved joints and polyarthritis as five or more involved joints at the point of 
assessment. Patients with radiological sacroiliitis and predominant axial symptoms, 
with or without peripheral arthritis were designated as spondyloarthritis. Patients with 
classical clinical and radiological features of arthritis mutilans were placed in a separate
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group. Two patients had involvement of only one knee and were classified as 
monoarthritis and one patient had involvement of the distal interphalangeal joints only. 
Thus, the patient subgroups were as follows: polyarthritis (n=83), oligoarthritis (n=56), 
spondyloarthritis (n=ll), arthritis mutilans (n=5), monoarthritis (n=2) and DIP only 
(n=l), (Table 6.1.). The control population consisted of 250 healthy Caucasian blood 
donors from the Bath area. Whilst the controls were subject to the routine screen for 
blood donors, mild psoriasis, which occurs in approximately 2% of the population may 
have been present.
6.3.2 Outcome Measures
Data was collected annually and recorded on a database as described in Chapter 2.2. 
The information used for this study included a modified Ritchie tender and swollen 
joint count (modified to include the terminal interphalangeal joints), the psoriasis area 
severity index (PASI), a psoriatic nail severity score, the Health Assessment 
Questionnaire (HAQ) and inflammatory markers (PV or CRP). If the data had been 
collected on more than one occasion, a mean of the values recorded at different visits 
was used in this analysis. With regards to subgroup allocation, the subgroup which best 
categorised the patient on the most recent hospital visit was used. Antero-posterior 
radiographs of the hands and feet taken at the most recent visit were scored for the 
presence or absence of erosions and this was used as the main radiological outcome 
measure.
6.3.3 HLA-DRB 1 typing and HLA-DR4 subtyping
Blood samples were collected from the patients following informed consent. DNA was 
extracted as described in Chapter 2.3.3. The samples were initially typed for the HLA- 
DRB 1 alleles using the method described in Chapter 2.4.3. Any patients who were 
positive for HLA-DR1 and HLA-DR4 were subtyped for the SE alleles as described in 
Chapter 2.4.3.
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6.3.4 HLA-B27 and HLA-Cw6 typing
The methods used for typing for these MHC Class I alleles is described in Chapter 
2.4.4.
6.3.5 Statistical Analysis
The frequencies of the HLA-DRB 1 alleles and SE alleles were compared between the 
patient and control populations using the Chi squared test with Fisher’s exact test when 
necessary. A result was considered to be significant if the p  value was less than or equal 
to 0.05. The Bonferroni correction was used to control for multiple comparisons (the p  
value was multiplied by the number of alleles/subgroups tested in each example). The 
results were also expressed as Odds Ratios. When performing the subgroup analysis, a 3 
degrees of freedom (3df) global test was performed in addition to standard pair-wise 
comparisons between subgroups and controls. The patients from the smaller subgroups 
were combined to give a third “other” subgroup containing the patients with 
monoarthritis, DIP joint disease and arthritis mutilans. A 3 degrees of freedom global 
test was then performed using a 4*2 table and Chi squared test to examine the 
hypothesis that none of the 3 groups differed from the control population. A further test 
using a 2*2 table comparing the oligoarthritis subgroup and all other PsA subgroups 
combined was also performed.
6.4 Results
6.4.1 Associations ofHLA-Cw6 with PsA and psoriasis
HLA-Cw6 was significantly associated with PsA (65/151 (43%) HLA-Cw6 positive 
PsA patients compared with only 26/131 (20%) controls, p<0.0001, OR 3.05 (1.79- 
5.22)). HLA-Cw6 was associated with a younger age of onset of psoriasis (p=0.003) 
and a higher median nail score (p=0.002), but there was no difference in the median 
PASI between HLA-Cw6 positive and HLA-Cw6 negative patients. There were no 
other clinical associations such as subgroup, DMARD use or presence of erosive 
disease. There was a significant association between HLA-Cw6 and HLA-DR7 due to 
their occurrence on the same ancestral haplotypes (p<0.0001, OR 6.28 (3.01-13.10)).
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There were no associations between HLA-Cw6 and HLA-DR1, DR4 or the shared 
epitope.
6.4.2 Associations o f HLA-B27 with PsA
Overall, the frequency of HLA-B27 was not increased in PsA compared with controls. 
There was no association between HLA-B27 and any of the clinical subgroups. HLA- 
B27 was not significantly associated with any other clinical parameters of disease 
severity. HLA-B27 was significantly associated with HLA-DRB1 *0101 (p=0.006) due 
to their presence on the same ancestral haplotypes. There were no associations between 
HLA-B27 and the HLA Class II alleles or the HLA-DRB 1 SE.
6.4.3 Associations o f HLA-DRB 1 alleles with PsA
There was an increased frequency of HLA-DR7 within the PsA population as a whole 
compared with controls (41% vs 25%, pUncorr=0..001, OR 2.02, pcorT =0.01) (Table 6.2). 
There was a trend towards an increased frequency of HLA-DR1 in PsA but this did not 
reach significance. There was a decreased frequency of HLA-DR2 and HLA-DR4 in 
PsA with the former only reaching statistical significance if uncorrected for the number 
of tests performed (puncon- =0.03, OR 0.59).
6.4.4 Associations o f HLA-DRB 1 alleles with PsA subgroups
There were no significant associations between disease subgroups and the HLA-DR 
alleles. HLA-DR4 was equally prevalent in both the polyarthritis and oligoarthritis 
subgroups (present in 25% of each group). HLA-DR1 was slightly more common in the 
polyarthritis group than the oligoarthritis group (34% vs 20%). HLA-DR3 was the most 
common allele in the spondyloarthritis group being present in 5 out of 11 patients (45%) 
and HLA-DR7 was the most common allele in all subgroups except the 
spondyloarthritis group.
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6.4.5 Associations o f the SE alleles with demographic and clinical characteristics 
There was no association between the sex of the patients and presence of the SE (50% 
of the SE positive patients were male and 50% female). There was no difference in the 
age of onset of psoriasis, age of onset of arthritis, family history of psoriasis/arthritis, 
Health Assessment Questionnaire, joint score, PASI, nail score or mean plasma 
viscosity between SE positive and SE negative patients {Table 6.3).
6.4.6 Associations o f the SE alleles with PsA
All SE alleles were detected in the patient and control populations except *1402 due to 
its low frequency in Caucasians. Overall there was no difference in the number of 
patients who were SE positive compared with controls (48% vs 54%, Table 6.4). The 
most frequent SE allele in the PsA group was *0101 (22%) followed by *0401 (17%). 
The *0404 allele was the only allele to be significantly different in its prevalence 
between the patient and control populations, present in only 3.8% of PsA patients 
compared with 10% of controls ( p uncorr =0.02, OR 0.34, pcolT =NS).
6.4.7 Associations o f the SE alleles with PsA subgroups
The SE was present in all disease subgroups although only the oligoarthritis and 
polyarthritis groups were large enough for analysis. The prevalence of the SE in the 
polyarthritis subgroup was not increased compared with controls (49% vs 54% in 
controls, Table 6.5). However, there was a reduction in the frequency of the SE in the 
oligoarthritis subgroup compared with controls (38% vs 54%, p=0.02, OR 0.32 using a 
pair-wise comparison). This difference failed to reach significance if the oligoarthritis 
subgroup was compared against all other PsA patients (p=0.202) or if a 3 df test was 
performed comparing the oligoarthritis group with the polyarthritis group, a group 
combining the spondyloarthritis, arthritis mutilans, monoarthritis and DIP only patients 
and controls (p=0.134).
6.4.8 Double dose phenomenon
Two copies of a SE allele were found in 9.6% of the control population. There was no 
significant difference in the number of PsA patients with a double dose compared with
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controls (6.3% vs 9.6%). The double dose phenomenon was seen more often in the 
polyarthritis subgroup (8.4%) and less often in the oligoarthritis subgroup (3.6%) but 
the groups were too small to reach significance.
6.4.9 SE and radiological erosions
One hundred and fifty one patients had radiographs of the hands and feet available for 
scoring for the presence of erosive disease, of whom, 76 had erosions and 75 did not. 
Erosive disease was most prevalent in the polyarthritis subgroup (73%) compared with 
30% of the spondyloarthritis subgroup and 16% of the oligoarthritis subgroup. Those 
patients who were SE positive were significantly more likely to have erosive disease 
than those who were SE negative (60% (39/65) vs 43% (37/86), p=0.03, OR 2.11, Table 
6.6). The presence of erosions was not more strongly associated with any particular SE 
allele than another. There was no relationship between any overall HLA-DR subtype 
(including HLA-DR1 and HLA-DR4) and erosive disease. Of the 76 patients with 
erosions, 39 (51%) were SE positive compared with only 26 out of 75 (33%) of the 
patients with no erosions.
6.5 Discussion
Since psoriatic arthritis can vary dramatically in its clinical course, any factor which 
may help identify patients who are more likely to develop severe or erosive disease 
would be of great benefit in patient management. This study has investigated the 
influence of the SE on the clinical course of PsA by determining its prevalence in each 
disease subset and whether it is associated with any particular clinical or radiological 
characteristic. The study also examined the frequency of HLA-Cw6 and HLA-B27 in 
PsA and its clinical subgroups.
The associations of HLA Class I antigens with psoriasis and PsA are probably better 
understood than those with the HLA Class II antigens. In the population studied, the 
frequency of HLA-Cw6 was significantly increased compared with controls. HLA-Cw6
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was associated with a higher nail score but not with a higher skin score. The reasons for 
this are not clear. As expected HLA-Cw6 was associated with a younger mean age of 
onset of psoriasis, confirming similar reports in published studies. There were no other 
clinical or disease subgroup associations with HLA-Cw6. In contrast, HLA-B27 was 
not found to be increased in the PsA population as a whole, nor was it increased in any 
of the disease subgroups. Some studies have reported associations between the 
spondyloarthritis subgroup and HLA-B27, but this was not confirmed here.
More is known about the role of the SE in RA where it has been studied predominantly 
in early disease. There is mounting evidence that the SE exerts its effect in RA on 
disease severity as well as disease susceptibility (194). The majority of studies have 
investigated the role of the SE as a predictor of outcome in patients presenting with 
early synovitis. These studies have provided somewhat conflicting results (195; 196) 
but, in general, possession of the SE does appear to be associated with more severe 
disease particularly in relation to the presence of erosive damage and extra-articular 
features (190).
In RA, the increased prevalence of HLA-DR4 and HLA-DR1 has been well established 
and confirmed in many populations. However, a study of HLA-DR4 in newly diagnosed 
community based patients with RA did not find any association, suggesting that it is 
more important in the severity and persistence of RA than the susceptibility (194). 
There have been several reports of HLA-DR associations with PsA and its subgroups 
(61). This study has confirmed some of these but did not find some of the associations 
reported by others. In this group of patients with PsA, there was an increased prevalence 
of HLA-DR7 compared to a control population. In contrast to some reports of an 
increased prevalence of HLA-DR4 in psoriatic arthritis, particularly in the polyarthritis 
subset (63), a non-significant reduction of HLA-DR4 has been demonstrated in this 
population. The frequency of HLA-DR2 in the PsA population as a whole was reduced. 
There were no associations of HLA-DR subtypes with any of the disease subsets.
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The frequency of the SE in a population with established RA (mean disease duration of
15.4 years) was recently found to be 76% (192). The frequency has been reported to be 
as high as 95% (197). However, as approximately 50% of the normal population carry 
at least one SE allele, its use as a predictive test is limited by low specificity and low 
positive predictive value. The test is probably better applied to patients known to have 
RA to help identify those at increased risk of severe disease (198). The frequency of the 
SE in this population of patients with PsA was 48%, with a control frequency of 54%. 
The most frequent SE allele in the patient population was *0101 followed by *0401. 
The frequency of *0404 was lower in patients than in controls and clearly different from 
the frequencies reported in RA where it is often one of the most common alleles. There 
was no association between different SE alleles and disease subgroup or markers of 
severity unlike RA where *0401 and *0404 have been linked with more severe disease 
(199). Another point of interest is that the SE was equally prevalent in male and female 
patients with PsA, whereas in RA it has been reported to be more frequent in men (200).
It could be hypothesised that the SE may be found at a higher frequency in those 
patients who develop a polyarthritis resembling RA. However, the frequency of the SE 
in the polyarthritis subset was found to be no different from the normal population. 
There was a reduction in the frequency of the SE in patients who remained in the 
oligoarthritis subset. This may suggest that, in the absence of the SE, patients are less 
likely to progress to polyarticular disease or that other genetic influences are more 
important in oligoarthritis. This study is based on patients with well-established disease 
with a mean duration of arthritis of 21 years. Although it is recognised that patients do 
move between subsets (95), the majority of patients in this study are likely to be 
correctly classified in view of the length of their disease process. The genetic 
associations with disease subsets in this study are therefore less prone to classification 
difficulties than in studies where the disease duration is shorter.
The influence of the SE on the development of radiological erosions in patients with 
PsA is another important finding of this study. Seventy-three percent of patients in the 
polyarthritis group had erosive disease of the hands and feet, compared with only 16%
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of the oligoarthritis group and 30% of the spondyloarthritis group. When considering 
the proportions of patients in each subgroup with erosions, the influence of the SE was 
not so significant, but looking at the population as a whole, patients who were SE 
positive were significantly more likely to develop erosions than those who were SE 
negative (60% vs 43%, p=0.03, OR 2.11). This suggests that the SE may influence 
disease severity in PsA as well as RA. It is interesting that there is mounting evidence 
that the predominant influence of the SE on erosive disease in RA appears to be in 
patients who are seronegative for RF. This has been found in both early synovitis (201; 
202) and established RA populations (203). In one of these studies (201), it was found 
that the SE had no influence on the likelihood of disease persistence in an early 
synovitis population and only a modest effect on functional disability. The most 
obvious effect was on the development of erosions (RR 1.9) and restricted to those who 
were seronegative for RF. No effect on the severity of radiological damage defined by 
the total Larsen score or number of eroded joints was noted.
It is possible that the SE allele copy number influences disease severity in RA (199; 
204). The presence of two identical or two different SE alleles is known as the double 
dose phenomenon. A study in RA found an increased relative risk for RA in patients 
who were compound heterozygous for SE alleles (RR 11.7) over those who were 
homozygous (RR 4.3) for the same SE allele (192). Some 25% of the patients with RA 
had a double dose of the SE. In this study, only 6.3% of the PsA population as a whole 
carried two copies of a SE allele compared with 9.6% of the control population. There 
were no clear associations between the dose of the SE, homozygosity or compound 
heterozygosity and the disease subset or development of erosions, although fewer 
patients in the oligoarthritis subgroup had a double dose (3.6% vs 9.6% in controls, 
NS).
In conclusion, the frequency of SE alleles in this population of patients with PsA was 
similar to that found in a control population. There was no increase in the frequency of 
the SE in the polyarthritis subset. There was a lower frequency of the SE in patients 
who remained in the oligoarthritis subset. As only 16% of the oligoarthritis subset were
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erosive, the lower frequency of the SE in this subset may simply reflect the association 
of the SE with erosive disease. It would seem that the greatest influence of the SE in 
PsA is in the development of erosions. It is possible the SE influences severity in RA 
via the development of erosions and this may be a feature in common between the two 
arthritis populations. However, the clear differences in the prevalence of the SE in our 
population and its subgroups and published data in RA further delineate the differences 
between patients with PsA and RA. The data presented here adds to the genetic 
evidence that PsA is a distinct clinical entity and argues against those who view the 
polyarthritis subgroup as simply a form of RA with psoriasis. Further genetic studies, 
both within and outside the HLA region, will hopefully provide more information on 
genetic classification and severity markers in psoriatic arthritis.
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Table 6.1. Demographic and clinical characteristics of the PsA population
Characteristic n or age (yrs)
Number of patients 158
Polyarthritis ( >5 involved joints) 83




DIP joint disease only 1
Sex (Male:Female) 80M:78F
Mean age, yrs (+/- SD) 56(14)
Mean age of onset of psoriasis, yrs (+/- SD) 29(15)
Mean age of onset of PsA, yrs(+/- SD) 37(14)
Mean duration of PsA, yrs(+/- SD) 21 (13)
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HLA-DR 1 47 (30%) 53 (21%) 0.059 1.57 NS
HLA-DR2 30(19%) 71 (28%) 0.034* 0.59 NS
HLA-DR3 36 (23%) 52 (21%) 0.71 1.12 NS
HLA-DR4 44 (28%) 92 (37%) 0.067 0.66 NS
HLA-DR5 23 (15%) 48 (19%) 0.28 0.72 NS
HLA-DR6 35 (22%) 59 (24%) 0.81 0.92 NS
HLA-DR7 64 (41%) 63 (25%) 0.001* 2.02 0.01**
HLA-DR8 12 (8%) 13 (5%) 0.40 1.50 NS
HLA-DR9 3 (2%) 4 (2%) 0.99 1.19 NS
HLA-DR 10 2(1%) 2(1%) 0.64 1.59 NS
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Table 6.3. Clinical and demographic features of PsA patients with and without the
SE
SE present SE absent
Females 35 43
Males 35 45
Mean age of onset of psoriasis, yrs (+/-SD) 29(15.2) 29(15)
Mean age of onset of PsA, yrs (+/-SD) 36 (14.2) 37(14)
Positive Family History of psoriasis 43% 45%
Mean HAQ at latest follow-up (+/-SD) 10.9 (5) 7.7 (7)
Mean joint score at latest follow-up (+/-SD) 17.5 (16) 15.4(16)
Mean PASI at latest follow-up (+/-SD) 3.2 (4) 3.4 (3.4)
Mean nail score at latest follow-up (+/-SD) 6.0 (7) 5.4 (5.4)
Mean PV at latest follow-up (+/-SD) 1.81 (0.2) 1.81 (0.2)
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Puncorr V a lu e
(* if p<0.05)
OR pcorr value I
(NS ifp>0.05)
*0101 35 (22%) 46(18.4%) 0.37 1.26 NS
*0102 3(1.8%) 4(1.6%) 0.99 1.19 NS
*0401 27(17%) 54 (21.6%) 0.31 0.75 NS
*0404 6 (3.8%) 25 (10%) 0.02* 0.36 NS
*0405 2(1.3%) 1 (0.4%) 0.56 3.19 NS
*0408 1 (0.6%) 3 (1.2%) 0.99 0.52 NS
*1001 2(1.3%) 2 (0.8%) 0.64 1.59 NS
Total 76 (48.1%) 135 (54%)
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Table 6.5. The association of PsA subgroups with the presence of the SE
Disease Subgroup SE present SE absent
Polyarthritis (n=83) 41 (49%) 42 (51%)
Oligoarthritis (n=56) 21 (38%)* 35 (63%)
Spondyloarthritis (n= ll) 5 (45%) 6 (55%)
Arthritis Mutilans (n=5) 1 (20%) 4 (80%)
Monoarthritis (n=2) 1 (50%) 1 (50%)
DIP joint disease only (n=l) 1 (100%) 0 (0%)
Controls _____ 135_(54%)_ 115(46%)
* Puncon-=0.027, OR 0.32 following pair-wise comparison between the oligoarthritis 
group and controls. If the groups are considered as 3 subgroups due to the small sizes of 
some groups (ie. polyarthritis, oligoarthritis and ‘other’), the Bonferroni adjusted pcorr 
value would be 0.081 (3 x 0.027). A global 3df test to test the hypothesis that none of 
these three groups differs from the control population gives a p value of 0.134. A 
comparison of the oligoarthritis group with all other PsA patients yields a p value of 
only 0.202.
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Table 6.6. The association between the presence of the SE and the presence of 
radiological erosions








*p=0.03, OR 2.11 when comparing the presence of erosions in SE positive and SE 
negative patients
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The presence of anti-perinuclear autoantibodies in the sera of patients with RA was first 
described by Nienhuis and Mandema in 1964 (205). The antibodies were found to stain 
keratohyaline granules surrounding the nucleus of human buccal mucosal cells (206). 
These antibodies were not only highly specific for RA, they also seemed to indicate 
more severe erosive disease, especially in seronegative patients (207). Indeed, several 
studies have reported that they were more specific for RA than RP (208). They also 
appear very early in disease, thus aiding the diagnostic process (209). However, 
difficulties standardising the assay procedure precluded its routine use in clinical 
practice. The other major problems were related to the subjective and labour-intensive 
immunofluorescence technique, the availability of suitable buccal cell donors and 
interlaboratory standardisation (210).
Some of these problems were overcome with the development of an immunoblotting 
technique (211; 212). However, the quantitative and qualitative interpretation of the 
results was still reliant on subjective judgment and the sensitivity was poor. The use of 
native filaggrin extracted from human epidermis as the antigen for the technique 
provided a poorly standardised substrate due to variations in charge and deimination 
(213). A technique using synthetic peptides as the antigen for the RA autoantibodies 
was therefore developed.
The antigen recognised by the anti-perinuclear antibodies was initially thought to be 
profilaggrin, a structural protein expressed on differentiated epithelial cells (206). 
However, more recent studies have shown that the antigen is in fact filaggrin, a 
cytokeratin filament aggregating protein in the human epidermis, rather than its 
precursor (214). The same target is also recognised by the related autoantibodies 
originally described as anti-keratin antibodies (209). Anti-perinuclear antibodies and 
anti-keratin antibodies are therefore more correctly referred to as anti-filaggrin 
antibodies.
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Purified human epidermal filaggrin has been used in an Enzyme Linked Immunosorbent 
Assay (ELISA) to quantify anti-filaggrin antibodies (AFA) in RA sera. The 
immunodominant epitopes on filaggrin are peptides containing the modified amino acid 
citrulline (98; 215). This amino acid is believed to arise in native proteins as a result of 
post-translational deimination of an arginine residue by the enzyme peptidylarginine 
deiminase (PAD).
Deimination produces structural changes which lead to the denaturation of proteins
(216). Antibodies to several synthetic citrullinated peptides have been described in RA 
sera with high disease specificity (98). However, an ELISA utilising these citrullinated 
peptides to recognise AFA (more accurately described as anti-citrullinated peptide 
antibodies) was not sensitive enough for the development of a routine serological test. 
The ELISA was therefore adapted to employ a modified peptide variant {cyclic 
citrullinated peptide (CCP)) that was recognised by the RA autoantibodies (anti-CCP 
antibodies) with relatively high sensitivity in a convenient and reliable test format
Cyclic peptides adopt a more stabilised conformation in solution that is more 
representative of the antigenic site in the native protein. The use of cyclic (cfcl-cyc) 
instead of linear (cfcl) citrullinated peptides resulted in an increased sensitivity for RA 
(49% to 68%) without compromising the specificity (217). Control peptides where the 
citrulline was substituted with arginine were not reactive with RA sera.










X = citrulline 
R = arginine
The sensitivity of the test was further increased following the development of the CCP2 
ELISA. This test was developed by screening libraries of citrulline-containing peptides 
for reactivity with RA sera. Novel peptides were then incorporated into the ELISA 
resulting in an increased sensitivity for RA of 82% (218). This ELISA is now 
commercially available.
7.1.1 Anti-CCP antibodies in conditions other than RA
The anti-CCP ELISA has been evaluated in a number of rheumatological and non- 
rheumatological conditions to examine its specificity for RA. Schellekens et al (217) 
assessed the anti-CCP ELISA in patients with a variety of rheumatological conditions, 
infectious diseases and healthy individuals. The anti-CCP ELISA was positive in only 
2% of patients with rheumatological conditions other than RA. These included primary 
Sjogrens (1/50), SLE (1/60), systemic sclerosis (3/62), polymyositis/dermatomyositis 
(0/60), mixed connective tissue disease (1/47), vasculitis (1/30), reactive arthritis (1/40) 
and osteoarthritis (0/27). These results compared with a relatively high positivity (14%) 
for an IgM RF ELISA in the same group. Only 2% of the sera from patients with 
infectious diseases were positive for anti-CCP antibodies compared with 13% positivity 
for RF. In the healthy control group, less than 1% were positive for the anti-CCP 
ELISA. Anti-CCP antibodies were not present in ulcerative colitis, Crohns disease or 
multiple sclerosis. The ELISA was also tested on 19 patients with psoriasis, who were 








(APF) detected by indirect immunofluorescence has been reported in a small study of 
patients with PsA (n=76). APF was found to be increased in PsA (7.9%), compared 
with 2.6% of uncomplicated psoriasis and 1% of healthy controls (219).
Anti-CCP antibodies have also been examined in juvenile idiopathic arthritis (JIA). No 
evidence of an association was reported: the prevalence of the antibody was between 
2% (220) and 5% (221). There was no correlation with anti-nuclear antibodies, 
inflammatory response, erosions or disease subset. A further study has shown a positive 
correlation between anti-CCP antibodies and IgM RF positive patients with 
polyarticular JIA (juvenile RA) (222). These patients had significant radiological 
damage but the anti-CCP antibodies did not add any further information than the 
presence of RF.
The prevalence and clinical significance of anti-CCP antibodies has also been evaluated 
in palindromic arthritis (223). Anti-CCP antibodies were detected in 56% of patients, a 
similar frequency to that found in their RA population. There were no significant 
clinical differences between the patients with palindromic arthritis who were positive 
and those who were negative for anti-CCP antibodies.
7.1,2 The specificity and sensitivity o f  anti-CCP antibodies
The specificity of the anti-CCP ELISA for RA has been widely reported. One study 
examined the usefulness of the ELISA in an early arthritis clinic to predict RA (217). 
After 1 year, 31% of patients had developed RA, 27% undifferentiated arthritis, 10% 
crystal arthritis, 6% sarcoidosis, 5% psoriatic arthritis and 21% had other causes of an 
inflammatory arthritis. The specificity of the anti-CCP ELISA for RA was 96% 
compared with 91% for the IgM RF ELISA. The positive predictive value of the anti- 
CCP ELISA for RA was 84% compared with 74% for the IgM RF ELISA. The 14 
‘false positive’ anti-CCP patients included 10 with undifferentiated arthritis, 2 with 
palindromic arthritis, 1 with sarcoidosis and 1 with pseudogout. After 2 years, four of 
the undifferentiated arthritis patients fulfilled the criteria for RA and three had 
developed erosive disease.
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The sensitivity of the anti-CCP ELISA was found to be quite low: 48% compared with 
54% for the IgM RF ELISA. After 1 year of follow-up, the sensitivity of the anti-CCP 
ELISA for RA increased marginally to 53% and the IgM RF ELISA decreased to 49%. 
Thus the anti-CCP ELISA changes very little during the disease process and appears to 
be present early in disease. A small proportion of patients can convert from positive to 
negative (3%) and from negative to positive (8%).
More recently, the specificity and sensitivity of the CCP2 test for RA has been reported. 
In a large multicentre trial, 79% of RA patients, 0% of healthy controls and 5% of 
disease controls were positive for anti-CCP antibodies compared with 78%, 15% and 
50%, respectively, for RF (224). This high specificity and sensitivity has been 
confirmed in two further studies on the CCP2 test, where the sensitivity of the test was 
comparable to RF (80-82%) but with a much higher specificity; only 1% of healthy 
controls and 2% of disease controls were positive (218; 225).
There is no evidence that the presence of anti-CCP antibodies increases with age, as 
seen with the RF test. A recent study has shown that only 1/300 elderly subjects were 
positive for anti-CCP antibodies and this subject was the one person who also happened 
to have RA (226).
7.1.3 Anti-CCP antibodies are present early in disease
A further study of 379 patients with inflammatory arthritis of less than 3 years duration 
confirmed the findings that anti-CCP antibodies are found early in the disease process 
(227). They noted that in many cases the occurrence of RF and anti-CCP antibodies 
were independent. The optimal criterion for the distinction of RA from undifferentiated 
polyarthritis was a combination of the two antibodies, with a combined sensitivity of 
55% and specificity of 96.7%. Other studies have confirmed the presence of anti-CCP 
antibodies early in the disease process, often before disease manifestations become 
apparent (228-230). A study using the CCP2 test has demonstrated that anti-CCP
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antibodies are actually present several years before the onset of RA by the retrospective 
testing of blood donors (231).
7.1.4 Anti-CCP antibodies predict erosive disease
The association between anti-CCP antibodies and the development of erosive disease in 
RA has been widely examined. In one study, anti-CCP antibodies were positive in 65% 
of erosive but only 39% of non-erosive patients with RA at the initial consultation
(217). Thus the detection of anti-CCP antibodies at presentation was a significant risk 
factor for erosive disease (OR 2.95). After 2 years of follow-up, 76% of the patients 
with RA had erosive disease: the positive predictive value of anti-CCP antibodies for 
the development of erosions was 91%.
Further studies have shown that anti-CCP antibodies are predictive of erosive disease 
both in established disease (232) and early in the disease process (233). The latter study 
demonstrated an increase in total Sharp score (OR 2.5) and higher mean scores for 
radiographic damage, joint space narrowing and erosions at 0, 3 and 5 years in patients 
who were anti-CCP positive. Kroot et al found an association between anti-CCP 
antibodies and erosions at 6 but not 3 years of follow-up (229). Some studies have also 
demonstrated an increased functional disability and absence of clinical remission in 
anti-CCP positive patients (234).
7.1.5 Anti-CCP antibodies are associated with the HLA-DRB 1 SE
Although the HLA-DRB 1 ‘shared epitope’ (SE) is well known to be a major genetic 
contributer to RA, surprisingly few studies have examined or reported an association 
between anti-CCP antibodies and the SE. However, two studies have documented an 
association between these markers of RA. This is particularly interesting in light of the 
emerging evidence for the presentation of citrullinated peptides by the shared epitopes 
of HLA DR4 molecules (229; 230).
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7.1.6 Possible immunopathological role for anti-CCP antibodies
It remains unclear whether the anti-CCP antibodies have any pathogenic role in the 
development of inflammatory arthritis. One group has studied the response of peripheral 
blood mononuclear cells (PBMC) to stimulation with filaggrin and found no response in 
RA or controls (OA, PsA) (235). This was in contrast to a proliferative response 
generated by PBMC and synovial T cells from patients with RA after stimulation with 
A2/RA33, another antigen known to produce autoantibodies in RA.
Immunohistochemistry using polyclonal antibodies has demonstrated the presence of 
citrullinated proteins in the synovial membranes of patients with RA (236). The same 
proteins appeared to be absent in control synovium. Interestingly, monoclonal 
antibodies to filaggrin show that filaggrin is not present in the synovium. However, 
affinity-purified anti-filaggrin antibody reactivity co-localised with the anti-citrulline 
activity. This would suggest that citrullinated proteins rather than filaggrin itself are the 
triggers for the autoimmune response.
Plasma cells actively secreting anti-filaggrin antibodies have been demonstrated in the 
synovial membrane of patients with RA (237). In addition, anti-CCP antibodies are 
present and secreted by B cells in the synovium and synovial fluid of patients with RA 
(238). This active production of IgM anti-CCP antibodies was only seen in patients who 
had anti-CCP antibodies detectable in their serum. The presence of cells actively 
secreting these antibodies in the synovium provides some evidence for an antigen- 
driven maturation of specific B cells at the site of inflammation in RA. The antibodies 
certainly seem to be locally produced as they constitute a greater proportion of the IgG 
in synovium than serum. Since filaggrin itself is not found in the synovium, the identity 
of this citrullinated autoantigen is not yet clear. It should possess deiminated epitopes 
that are recognised by both anti-CCP and anti-filaggrin antibodies.
One such autoantigen has recently emerged as a strong candidate: deiminated alpha and 
beta chains of fibrin (239). These two proteins, p64-78 and p55-61, were shown by 
immunoblotting to be specifically targeted by anti-filaggrin antibodies. Interestingly, it
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was demonstrated 40 years ago that intra-articular injection of heterologous fibrin could 
induce chronic arthritis in a rabbit (240). Thus, autoimmunisation against deiminated 
fibrin may be a critical step in RA pathogenesis. The question remains, however, 
whether deimination of synovial fibrin is specific for rheumatoid arthritis or whether it 
occurs in other inflammatory arthritides.
The enzyme responsible for deimination of proteins is peptidylarginine deiminase or 
PAD. Deimination is known to interfere with observed in vitro protein-protein 
interactions and enzymatic processes. Five isotypes of PAD are recognised. PAD2 is 
found in macrophages and PAD4 in granulocytes. Recently, a particular haplotype of 
PAD4 was found to be strongly correlated with RA (241). This haplotype may result in 
functional differences within the enzyme that lead to increased citrullination of proteins.
The PAD enzymes are inactive in normal physiological conditions as intracellular Ca2+ 
concentrations are too low (242). However, following the death of a cell, loss of the cell 
membrane integrity allows Ca2+ to enter the cell. In addition, PAD enzymes may leak 
out of the cell where the Ca2+ concentration is high enough to allow citrullination of 
extracellular proteins such as fibrin. Citrullination of intracellular proteins such as 
histones and vimentin has been described in granulocytes and macrophages, 
respectively (243). Vimentin is certainly present in the synovium and many of the 
synovial lining cells are macrophages. Thus calcium influx into a dying macrophage 
may induce citrullination of vimentin. Interestingly, the Sa-antigen appears to be 
identical to citrullinated vimentin (244). The polyclonal anti-CCP response would 
suggest that there are additional citrullinated antigens that have yet to be identified in 
the synovium.
Citrullination of synovial proteins would not appear to be a process specific for RA. It is 
known to occur in murine models of non-specific inflammatory arthritis (245). Yet, the 
production of anti-CCP antibodies does seem to be highly specific for human RA. There 
is some evidence that the antibody response may be genetically determined by HLA 
subtypes bearing the HLA-DRB1 SE (97). The prevailing subclass of anti-CCP
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antibodies is IgGl (246) suggesting T cell involvement in the antibody production. 
Recent molecular modeling has shown that peptides containing citrulline but not 
arginine are bound by HLA-DRB 1*0401 molecules (99). HLA-DRB1*0401 transgenic 
mice produce a proliferative T cell response following stimulation with peptides that 
contain citrulline but not arginine. This data is supported by the observed co­
segregation of the SE and anti-CCP antibodies in clinical studies of RA (229; 230).
Citrullination is one of the post-translational modifications known to occur during 
apoptosis. Cell death may follow oxidative stress in an inflamed synovium following a 
relatively minor insult. This can then lead to the release and activation of PAD enzymes 
and the citrullination of intracellular and extracellular proteins. In the right genetic 
environment, these modified “self ” proteins may then be presented by HLA molecules 
to T cells causing perpetuation of the initial inflammatory response. The anti-CCP 
antibodies will also form immune complexes with citrullinated proteins to further 
stimulate the production of pro-inflammatory cytokines. Thus, in certain pre-disposed 
individuals, a relatively minor self-limiting trigger can result in a chronic inflammatory 
disease.
If the process of autoimmune recognition of deiminated proteins is central to the 
pathogenesis of RA then clearly there is potential for new therapeutic targets. 
Interestingly, anti-CD20 therapy (rituximab) has been shown to reduce circulating 
levels of anti-CCP antibodies (247). A better understanding of the immunological and 
genetic background of individual patients with inflammatory arthritis should allow more 
appropriate targeting of such therapies. The presence or absence of anti-CCP antibodies 
may be one such factor.
The prevalence and prognostic value of anti-CCP antibodies in PsA is not known. The 
aim of this study was therefore to determine whether anti-CCP antibodies defined any 
particular clinical subgroup of patients with PsA. If anti-CCP antibodies were 
associated with more severe disease, then the test would be of value in the identification 
of patients who would benefit from early and aggressive treatment.
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7.2 Hypothesis
Anti-CCP antibodies may be present in those patients with PsA who develop a more 
aggressive, erosive form of arthritis that is phenotypically similar to RA.
7.3 Study design
The study was designed to test a cohort of patients with PsA for the presence of anti- 
CCP antibodies using the second generation CCP2 ELISA test. Two control groups 
were used for comparison: normal controls (random blood donors) and patients with 
seropositive RA. The aims were to assess the prevalence of anti-CCP antibodies in PsA 
and to evaluate the clinical and genetic characteristics of any anti-CCP positive patients.
7.4 Methods
7.4.1 Patient recruitment
Patients with PsA (n=126) were recruited from the specialist PsA clinic at the RNHRD, 
Bath. Ethical approval was given by the Bath Local Ethics Council. A blood sample 
was taken from each patient following informed consent and sent to the laboratory 
where the serum was extracted and frozen until needed. Clinical and radiological 
information was collected on the patients participating in the study as described in 
Chapter 2.2. Control serum samples (n=40) were available from random blood donors 
and were matched for age and sex (20 male: 20 female, mean age 52 yrs). Serum 
samples from patients with seropositive RA (n=40) were used as positive controls. The 
patient and control serum samples were tested for the presence of anti-CCP antibodies 
using a commercially available ELISA (CCP2, Axis Shield, Scotland).
7.4.2 Statistical analysis
Direct comparisons between patients and controls were made using the Chi-squared test 
with Fisher’s Exact test when necessary. A median of the outcome measures (eg. PASI, 
tender and swollen joint counts) was calculated from each of the consecutive visits that 
the score was recorded. These values were compared between groups using the Mann
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Whitney U test. A p  value <0.05 were considered to represent a significant difference 
between two groups.
7.4.3 Principle o f  the Enzyme-linked Immunosorbent assay (ELISA)
The wells of microtitre strips are pre-coated with highly purified specific peptides. 
During the first incubation, specific autoantibodies in diluted serum bind to the antigen- 
coated surface. The wells are then washed to remove unbound components. In the 
second incubation, an enzyme-labelled monoclonal antibody to human IgG binds any 
surface bound autoantibodies. After further washing, specific autoantibodies are traced 
by incubation with a substrate. Addition of a stop solution terminates the reaction, 
resulting in a coloured end product. The amount of autoantibody bound is then 
quantified by measuring the absorbance of light at a certain wavelength by the coloured 
solution and a comparison is made with reference controls.
7.4.4 The anti-CCP ELISA
The specific method utilised for the anti-CCP ELISA is given in Chapter 2.6.2. Each 96 
well plate provides enough wells to test 40 samples together with the reference controls. 
All samples and controls were tested in duplicate and some samples were repeated on 
separate plates to assess intra-assay and inter-assay reliability. The concentration of 
anti-CCP antibodies present in each sample was calculated directly from the absorbance 
readings by the software attached to the plate reader (Multiskan Ascent, Labsystems, 
Finland). A cut off value of >6U/ml was used to indicate a positive result. This slightly 
higher value was used as 6/40 (15%) of controls had values between 5U/ml and 6U/ml. 
Using a cut off value of 6U/ml resulted in a control frequency of 0/40 which was a 
better approximation to the published range for controls of 0-1%.
7.4.5 Rheumatoid Factor ELISA
The samples were also tested in duplicate using a commercial ELISA for Rheumatoid 
Factor (Sigma Diagnostics, St Louis, USA) as described in Chapter 2.6.3.
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7.4.6 HLA-DRB1 shared epitope
All patients were tested for the presence of the HLA-DRB1 shared epitope (HLA- 
DRB1*0101, *0102, *0401, *0404, *0405, *0408, *1001), as described in Chapter 
2.4.3.
7.4.7HLA-Cw6 andB27 testing
The samples from patients with PsA were tested for the presence of HLA-B27 and 
HLA-Cw6 as described in Chapter 2.4.4.
7.5 Results
7.5.1 Anti-CCP antibodies in PsA, RA and controls
The number of patients with PsA positive for anti-CCP antibodies did not differ 
significantly from the control population (7/126 (5.6%) vs 0%, p=0.198). The titres of 
anti-CCP antibodies found in the 7 positive PsA patients ranged from 6.5U/ml to 
>100U/ml, with 5/7 patients showing titres of >20U/ml. All but one of the patients with 
RA were positive for anti-CCP antibodies, with 36/40 (90%) showing a titre of 
>20U/ml. Rheumatoid factor was positive in 8.7% of patients with PsA, 100% of 
patients with RA and 5% of controls (Table 7.7).
7.5.2 Rheumatoid factor and anti-CCP antibodies
Anti-CCP antibodies were not always associated with the presence of rheumatoid 
factor. Although both tests are commonly positive in patients with RA, it has been well 
described that some patients are positive for one but not the other. A positive test for 
both has a higher predictive value for RA. In the patients with PsA, it was uncommon 
for both tests to be positive (Table 7.1). Only 2 patients with PsA were positive for both 
anti-CCP antibodies and RF. Neither of the RF positive controls was positive for anti- 
CCP antibodies. All 40 patients with RA were RF positive and 39/40 were positive for 
anti-CCP antibodies.
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7.5.3 Characteristics o f the anti-CCP positive PsA patients
The sex ratio and age of the patients with PsA who were positive for anti-CCP 
antibodies was no different from the anti-CCP negative patients (Table 7.2). The 
distribution of subgroups was similar between the two groups. Of the 7 positive 
patients, 4 had a polyarthritis (> 4  involved joints) and 3 had an oligoarthritis (<4 
involved joints). One anti-CCP positive patient (14%) had a spondyloarthritis in 
combination with a polyarthritis. Spondyloarthritis was slightly more frequent in the 
anti-CCP negative group, where 27 (23%) of the patients had clinical or radiological 
features of spondyloarthritis (not significant). Of these, only 2 patients had a pure 
spondyloarthritis and the rest were present in combination with either a polyarthritis 
(19/27) or oligoarthritis (6/27).
Patients who were anti-CCP positive were more likely to be on a disease modifying 
drug (DMARD) (100% vs 61%, /?=0.049) and had a higher median swollen joint count 
(p=0.01). There were no other demonstrable differences in the PASI, nail scores or 
tender joint counts.
7.5.4 Anti-CCP antibodies and the HLA-DRB1 shared epitope in PsA
All 7 patients with PsA who were positive for anti-CCP antibodies possessed at least 
one copy of the HLA-DRB1 SE (3 patients were HLA-DRB1*0101 positive and 4 
patients were HLA-DRB1*0401 positive, including one *0401 homozygote). This was 
highly significant compared with the anti-CCP negative PsA patients (7/7 vs 48/119, 
p=0.0036). A comparison of HLA-DR4 between anti-CCP positive and anti-CCP 
negative PsA patients failed to reach significance (4/7 vs 28/119, p=0.069). HLA-DR1 
was present in the same proportion of anti-CCP positive and negative patients (3/7 vs 
32/119, p=0.396). There were no associations between Class IHLA antigens (HLA-B27 
and Cw6) and anti-CCP antibodies. All 7 anti-CCP positive patients were negative for 
HLA-B27 (0/7 vs 24/119, /?=0.35) and 4/7 were HLA-Cw6 positive (4/7 vs 46/119, 
p=0.43).
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7.5.5 Anti-CCP antibodies and the HLA-DRB1 shared epitope in RA
All but one patient with RA was positive for anti-CCP antibodies. Fifty percent of the 
patients had titres >100U/ml, 90% had titres >20U/ml and only 3 patients had titres 
<10Uml. Seventy percent (28/40) of patients carried at least one copy of the HLA- 
DRB1 SE. The titre of anti-CCP antibodies was not associated with the presence of the 
SE: 65% of those with titres >100 U/ml were SE positive compared with 69% of those 
with titres of 20-100 U/ml and 100% of those with titres <10 U/ml.
7.5.6 Anti-CCP antibodies and erosive disease in PsA
All of the anti-CCP positive patients had erosive disease on radiographs of the hands 
and feet (7/7 vs 68/111, /?=0.047). Six out of the seven patients also exhibited at least 
one characteristic radiographic feature of PsA such as new bone formation, DIP joint 
involvement or sacroiliitis. Review of the radiographs by two independent observers 
concluded that radiographically these patients had PsA not RA.
A summary of the features of the anti-CCP positive patients is presented in Table 7.3.
7.5.7 Characteristics o f the RF positive and RF negative patients with PsA
Rheumatoid factor was more common in the older patients with PsA (Table 7.4). The 
sex ratio was the same for RF positive and RF negative patients. There were no 
differences in the subgroup distribution, with 4/11 RF positive patients presenting as an 
oligoarthritis and 1/11 with a spondyloarthritis. Unlike anti-CCP antibodies, RF was not 
associated with the HLA-DRB1 SE (6/10 RF+ SE+ vs 49/109 RF- SE+,/?=0.51). There 




To date, there are no serological tests for PsA or the severity of PsA. Most research 
groups define their PsA cohorts as inflammatory arthritis in the presence of psoriasis 
and the absence of a RF. The latter is not an absolute criterion as approximately 8% of 
the general population are RF positive, particularly if >60 years of age. Indeed, most 
classification criteria for PsA suggest that the majority of patients will be negative for 
RF but that a diagnosis of PsA can be made in the presence of an incidental RF (2; 63) 
There are certain clinical and radiological features which are classic for PsA. Therefore, 
even if the RF is positive, a diagnosis of PsA can be made. For this reason, any RF 
positive patients with classical PsA have not been excluded from this study.
There is not a strong correlation between the presence of RF and the presence of anti- 
CCP antibodies in PsA; most patients who are positive for one are negative for the 
other. This would be in agreement with studies of seronegative RA where a high 
proportion have anti-CCP antibodies, although the absolute numbers in PsA are lower. 
The two antibodies probably identify slightly different subgroups of RA patients who 
may have different prognoses. Both have independently been associated with erosive 
disease in RA, but this would appear to be stronger with anti-CCP antibodies. In PsA, 
presence of RF was not associated with any clinical, radiological or genetic 
characteristics. This suggests that RF is simply an incidental finding of no relevance to 
the outcome of PsA. In contrast, several correlations between the presence of anti-CCP 
antibodies and the genotype and phenotype of PsA have been demonstrated.
A strong correlation between the presence of the HLA-DRB1 SE and anti-CCP 
antibodies has been demonstrated in this study. This has been reported in studies 
involving patients with RA (229; 230). We have previously shown that presence of the 
SE in patients with PsA correlates with erosive disease, suggesting that this genetic 
charcteristic may define a subgroup of patients with a worse prognosis (248). In this 
study, all 7 anti-CCP positive patients possess at least one copy of either HLA- 
DRB1*0101 or HLA-DRB 1*0401. The mechanism for the association may be related
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to the ability of the SE alleles to present peptides containing citrulline but not arginine 
to T cells. Thus, those patients with this particular genetic background will produce 
anti-CCP antibodies in response to an injured cell converting its arginine residues to 
citrulline. The antibodies may then play a direct pathogenic role in the perpetuation of 
the immune response, leading to the development of a chronic inflammatory disease.
Anti-CCP antibodies were also associated with the presence of radiographic erosions in 
patients with PsA. This association has been widely reported in RA where anti-CCP 
antibodies predict the future development of erosive disease. The mechanism for this 
remains unclear although it is possible that the antibodies, by sustaining the 
inflammatory response, are directly involved in joint damage.
Patients with PsA who are positive for anti-CCP antibodies also have a higher mean 
number of swollen joints than anti-CCP negative patients. This would suggest that they 
may be a marker for or indeed a contributory factor in more severe disease. All anti- 
CCP positive patients required treatment with a DMARD compared with only 61% of 
anti-CCP negative patients. It would not be unreasonable to hypothesise that all anti- 
CCP positive patients should present with a polyarthritis. However, there were in fact 
equal numbers of patients with an oligoarthritig and a polyarthritis. In view of the higher 
overall number of swollen joints seen in the positive group, this would suggest that even 
if <4 joints are involved they are likely to be chronically swollen. In addition, all of the 
anti-CCP positive patients with oligoarthritis had erosive disease and required treatment 
with a DMARD. This suggests that these patients fall within the more severe end of the 
spectrum of oligoarthritis. There was also one patient with features of an associated 
spondyloarthropathy in the anti-CCP positive group. Therefore, anti-CCP antibodies are 
present throughout the clinical spectrum of PsA and do not appear to be simply related 
to a phenotype resembling RA.
The key question here is whether these anti-CCP positive patients truly represent 
patients with PsA with a more severe prognosis or whether in fact they represent 
patients who actually have RA. In the latter scenario, the associations with erosive
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disease, the SE, DMARD use and higher number of swollen joints may simply reflect 
the widely accepted view that RA carries a worse prognosis than PsA. There are, 
however, several reasons for categorising these patients as true PsA. Firstly, only 2 of 
these patients were also positive for RF and even these 2 patients had clinical and 
radiological evidence to support PsA. Secondly, 3 patients had a true asymmetrical 
oligoarthritis and one of the polyarthritis patients had an associated spondyloarthritis 
with radiological sacroiliitis. Most patients (6/7) had radiological features of PsA such 
as new bone formation, DIP joint involvement and asymmetry. All patients had 
confirmed psoriasis of the skin and nails, 50% had a family history of psoriasis but none 
had a family history of RA and there was an equal sex incidence.
Even if the definitive diagnosis remained in doubt, the evidence presented here suggests 
any patient with PsA who has anti-CCP antibodies falls into a poor prognostic category. 
The presence of the antibodies may represent some phenotypic overlap with RA or 
indeed the antibodies may directly affect the disease process to modify the presentation. 
We have shown that these patients all develop erosions and all require DMARD 
therapy. Therefore, if a patient has anti-CCP antibodies, DMARD therapy should be 
initiated early in the disease process.
There is no evidence from this study that the presence of RF is associated with a more 
severe outlook. RF was also found more frequently in the older patients, although this 
did not reach significance. There was no association between RF and erosive disease, 
DMARD use, subgroup, the number of swollen joints or the presence of the SE. This 
would suggest that the presence of RF in patients with PsA does not define a group of 
patients who have RA or indeed more severe disease. In those patients with classical 
clinical and radiological features of PsA, the presence of RF should not be regarded as a 
barrier to making the correct diagnosis. For the sake of purity such patients are often 
excluded from research studies, although one could argue that the evidence presented 
here suggests that this may not be necessary.
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A number of studies have confirmed the presence of anti-CCP antibodies in RA early in 
the disease process, indeed often preceding the diagnosis by many years. Although they 
do appear to strongly predict the development of RA, it should be noted that a small 
proportion will develop PsA. The presence of anti-CCP antibodies does not therefore 
always mean that a patient with early synovitis will develop RA and can therefore not 
be used as a test to exclude PsA in diagnostic criteria. If a patient does have PsA, then 
they are likely to represent the more severe end of the spectrum. This has also been 
shown in seronegative RA, where the presence of anti-CCP antibodies is strongly 
associated with the development of erosions.
Although the CCP2 ELISA is an excellent technique, it cannot really be justified as a 
prognostic test in a PsA population as it will only pick up a small number of the more 
severe patients. It is probably more useful in a group of seronegative early arthritis 
patients (that will include some PsA patients) where it can predict those patients most at 
risk of progressive disease. It should be remembered that many patients with PsA who 
do not have anti-CCP antibodies will still develop a chronic debilitating arthritis. Thus, 
there remains a need for a test that will detect the majority of patients who will 
experience a more severe outcome. PsA is no longer regarded as a benign condition: it 
carries an increased mortality and considerable morbidity with many patients 
progressing rapidly to a destructive arthropathy. Perhaps clues for a prognostic 
immunological or genetic marker will come, not from studies based on RA, but from a 
better understanding of the immunopathology specific to PsA. The development of such 
a marker will facilitate more targeted and aggressive disease modifying therapy for 
those patients who will truly benefit.
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Table 7.1. Anti-CCP antibodies and RF in the patient and control populations
PsA (n=126) RA (n=40) Controls (n=40)
Anti-CCP positive 7 (5.6%) 39 (97.5%) 0 (0%)
RF positive 11 (8.7%) 40 (100%) 2 (5%)
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p  value RR (95% Cl)
Female : Male 4 F : 3 M 62F : 57 M NS
Age (yrs) (median, range) 59 (55-72) 59 (33-87) NS
Polyarthritis 4 (57%) 67 (56%) NS
Oligoarthritis 3 (43%) 48 (40%) NS
Spondyloarthritis 1 (14%) 27 (23%) NS
Median PASI (range) 2.0 (0-7.3) 1.0 (0-13.8) NS
Requirement for DMARD 7 (100%) 73 (61%) <0.05 1.6 (1.4-1.9)
Median number of 7.5 (3-16) 2.0 (0-17) <0.02
swollen joints (range) 
Median number of tender 5.5 (0-17) 4.0 (0-34) NS
joints (range) 
Presence of erosions 7 (100%) 68 (61%) <0.05 1.6 (1.4-1.9)
HLA-DRB1 SE 7 (100%) 48/112(43%) <0.005 2.3 (1.9-2.9)
HLA-DR4 4 (57%) 28/119(24%) NS
HLA-DR1 3 (43%) 32/119(27%) NS
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Table 7.3. Features of the anti-CCP positive patients with PsA
Anti-CCP titre RF titre HLA-DRB1 Erosions DMARD Subgroup
Patient 1 33 <6 *0101 Y V± Polyarthritis
Patient 2 90.3 39 *0401 Y Y Polyarthritis
Patient 3 48.2 <6 *0401, Y Y Polyarthritis and
*0401 Spondyloarthritis
Patient 4 >100 <6 *0101 Y Y Polyarthritis
Patient 5 >100 15 *0401 Y Y Oligoarthritis
Patient 6 9 <6 *0401 Y Y Oligoarthritis
Patient 7 6.5 <6 *0101 Y Y Oligoarthritis
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Table 7.4. Characteristics of RF positive and RF negative patients with PsA
RF positive RF negative p  value
patients (n= 11) patients (n= 119)
Female : Male 6 F : 5 M 60 F : 55 M
Age (yrs) (median, range) 64 (47-87) 59 (33-85) <0.06
Polyarthritis 7 (64%) 64 (56%) NS
Oligoarthritis 4 (36%) 47 (41%) NS
Spondyloarthritis 1 (9%) 27 (23%) NS
Median PASI (range) 0.42 (0-6) 1.0 (0-13.8) NS
Requirement for DMARD 8 (73%) 72 (63%) NS
Median number swollen joints (range) 5.0 (0-10) 2.2 (0-17) NS
Median number tender joints (range) 8(0-33) 4 (0-34) NS
Erosions 4 (40%) 69 (64%) NS
HLA-DRB1 SE 6/10 (60%) 49/107 (46%) NS
HLA-DR4 3/10 (30%) 29/107 (27%) NS




8.1 The challenges of researching the MHC in complex diseases
Over the last 30 years, more than 100 diseases have been associated with the HLA 
complex on chromosome 6. Despite the enormous resource and effort that has been 
expended in the characterisation of these associations, we are, in most cases, little 
further on in our understanding of the pathology of these diseases. Two clear exceptions 
are the HFE gene in haemochromatosis and the 21 hydroxylase genes in adrenal 
hyperplasia. The majority of HLA-associated conditions are linked to the Class II 
region (eg. DRB1*04 with rheumatoid arthritis, DRB 1*1501 with multiple sclerosis, 
DQB 1*0302 with Type I diabetes). Three notable exceptions are Psoriasis 
Vulgaris/PsA, ankylosing spondylitis and Behcets disease which are all primarily 
associated with Class I genes (HLA-Cw6, B27 and B51, respectively). It is interesting 
that these diseases also break the rule of female preponderance that is such a feature of 
many of the ‘autoimmune’ conditions associated with the Class II MHC region. In the 
absence of a viable explanation for the direct involvement of the Class I alleles in the 
disease process, the search for the key genes has strayed to those which closely 
neighbour the associated region.
A major problem with the study of any disease that is associated with the MHC is the 
strong evolutionary conservation of genes along segments of ancestral haplotypes (36). 
Large segments of the MHC are therefore inherited “en bloc” through many generations 
without the occurrence of any recombination events, although there are certain 
recombination hotspots that must be accounted for within any haplotype analysis. 
Dissecting out which alleles along an ancestral haplotype are more important than 
others can be a major challenge. One way is to assess the functional relevance of certain 
mutations. The impact of a given SNP on secondary protein structure or gene 
expression levels offers support for the functional relevance of a given allele associated 
with disease. The gene of interest should therefore be expressed in the target tissue and 
fulfil a potentially important function within the pathogenesis of the disease.
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Some of the difficulties identifying a gene responsible for a complex disorder relate to 
preconceptions about genetic associations with disease. It is widely assumed that the 
genetic contribution to complex disease is due to relatively high frequency SNPs which 
have subtle effects on protein function (249). This may not always be the case, as has 
recently been shown in Crohn’s disease where a low frequency frameshift mutation of 
the CARD 15 gene on chromosome 16 is strongly implicated in disease susceptibility 
(73; 250). CARD 15 has also been associated with PsA in one study (72), although this 
has yet to be confirmed (75). Interestingly, a similar frameshift mutation occurs in the 
allele of MICA that has been found to be associated with psoriasis, MICA *017, 
resulting in a polyleucine repeat like CARD15.
It is widely believed that if a gene is truly responsible for disease susceptibility, the 
association should be replicable in many different populations. However, it is clear that 
different genes take on different roles in diverse populations. For example, the 
associations between MICA and the TNF alleles with psoriasis / PsA in Caucasian and 
Asian populations are very different (51) (52) (67) (69) (70) (251). In addition, HLA- 
Cw6 bearing haplotypes are associated with psoriasis in Caucasians whereas HLA-Cw7 
bearing haplotypes are associated with psoriasis in the Japanese. Similarly, in Type II 
diabetes, the CAPN10 haplotype confers different risks in different populations (252).
Therefore, the results of genome wide screens and high density mapping of potential 
disease susceptibility sites from one population can not necessarily be applied to all 
populations. One of the largest genome-wide screens and fine mapping for the PSORS1 
gene was undertaken in the Japanese population (40). Similar techniques applied to a 
UK population led to the proposal of a different susceptibility region bordering that 
described in the Japanese population (41), suggesting that adjacent genes could be 
implicated in the same disease in different populations. Within a certain population or 
ethnic group these approaches can be extremely helpful in narrowing down the target 
area. Case control studies investigating genes that are in the correct position and have 
functional relevance to a disease remain a very effective tool in the search for candidate
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genes. However, it should be remembered that the importance of different candidate 
genes may well vary between populations.
A further assumption in most association studies is that a single or a few closely related 
SNPs is responsible for disease. In complex diseases this would seem too simplistic. It 
is more likely that several SNPs in several genes are important. There is no reason to 
assume that adjacent genes may not play equal roles in disease susceptibility. Indeed, it 
may be the combination of a number of alleles along a disease-associated haplotype that 
places an individual at risk, particularly if these genes potentially interact with each 
other. In addition, certain genes may be important in disease susceptibility whereas 
others (which may be close-by) could interact in order to affect the severity of disease. 
An example might be the association of a particular haplotype with psoriatic arthritis 
that contains a certain allele of TNF, MICA and Comeodesmosin. This would be 
similar to the idea of a ‘superlocus’ in Insulin Dependent Diabetes Mellitus (IDDM) 
(253). It should also be noted that the consequences of SNPs may differ according to 
which haplotype they are on due to modulation by intronic sequences. Therefore, it is 
increasingly recognised that the disease-associated haplotype is of paramount 
importance, rather than the individual SNPs.
8.2 The challenges of studying PsA
There has been a reluctance to study PsA within the research community due to the 
considerable challenges it presents. There is therefore a relative lack of published 
research on PsA either from clinical or scientific studies. This contrasts with the wealth 
of studies investigating the aetiology, treatment and clinical assessment of other 
conditions with an equivalent prevalence such as systemic lupus erythematosis (SLE) 
and AS. There are several reasons that PsA is a difficult disease to study.
Firstly, it is a very heterogeneous disease. This has led to difficulties in the 
classification criteria which have yet to be agreed upon by the international community.
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There have been several proposals for the division of patients into subgroups which 
would appear to have different prognoses, treatments and aetiologies. The most widely 
used classification follows that originally proposed by Moll and Wright (2), but it is 
increasingly recognised that patients can move between subgroups, most commonly 
from oligoarthritis to polyarthritis (95). The numbers of patients with involvement of 
just the DIP joints appears to be quite rare. Equally, the separation of monoarthritis and 
arthritis mutilans as distinct groups would be unhelpful for the majority of studies. It is 
therefore most likely that researchers will classify their patients into those with a 
peripheral arthritis and those with a spondylarthritis with or without peripheral joint 
disease. The patients for the studies presented here have been divided into three main 
groups -  polyarthritis, oligoarthritis and spondyloarthritis.
A further difficulty in studying the genetics of PsA is dissecting out which genes are 
responsible for psoriasis and which for PsA. There will clearly be some genes that are 
important for both, but there are likely to be others that are more specific for the joints 
or the skin. The best way to address this is to examine patients who have psoriasis but 
no arthritis and compare them with patients with PsA. However, there are also some 
pitfalls in the recruitment of psoriasis controls. Firstly, the arthritis may not develop for 
many years after the psoriasis, thus some patients w ho are in the ‘no arthritis’ group will 
be bound to develop arthritis at a later date. This effect can be minimised by recruiting 
patients with a long disease duration. A further factor is the well recognised 
complication of asymptomatic sacroiliitis. Even though these patients may never 
complain of any symptoms and indeed may have totally normal spinal movements, they 
should be excluded from any group claiming to be ‘arthritis free’ as they are likely to 
share at least some of the genes that contribute to the inflammatory arthritis. Ethical 
approval to perform sacroiliac radiographs on asymptomatic patients can sometimes be 
difficult and therefore not all patients will be adequately screened. We did get ethical 
approval to perform sacroiliac radiographs on our psoriasis patients and found the 
incidence of asymptomatic sacroiliitis to be as high as 25% (96).
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8.3 The challenges of studying MICA as a candidate gene
The MICA gene lies in the heart of the MHC region between HLA-B and the TNF 
genes. This places the gene close to the area that has been proposed as a susceptibility 
region for psoriasis (PSORS1) (39). There have been several reports of associations 
with PsA and the TNF genes (69) (70) and HLA B alleles (63). Not only does MICA 
lie in a good position for a candidate gene for psoriasis and PsA but it is also one of the 
most polymorphic genes in the MHC Class III region. The most extensive 
polymorphism lies within exons 2-4 that encode the extracellular portion of the 
molecule. There is a strikingly high level of non-synonymous mutations, a feature 
reminiscent of the MHC genes themselves. However, the reason for this level of 
variation between individuals remains unclear as many attempts have failed to detect 
any ligand binding. However, most of the polymorphism lies within the region of the 
molecule which directly interacts with its receptor, NKG2D. This lectin-type activatory 
receptor is found on NK cells as well as CD4 and CD8 positive T cells. Certain 
polymorphisms have been shown to affect the affinity of binding to the NKG2D 
receptor by up to 50 fold. It is possible therefore that the variation within MICA results 
in altered NK and T cell activation which may lay the host open to infection, tumour 
cell invasion or other attack.
The majority of clinical association studies have examined the microsatellite 
polymorphism within exon 5 that encodes the TM region of the molecule. There are six 
microsatellite alleles which vary in the number of GCT repeats encoding up to 10 
alanines. However, the functional significance of this elongated TM region is unclear. It 
would seem unlikely that increasing the number of alanines in the TM region from four 
to ten would have any significant bearing on the ability of the molecule to interact with 
its receptor. However, there are some interesting polymorphisms which result in a very 
different TM region of the protein. This, in turn, may affect the ability of the MICA 
protein to locate to the cell surface. One such allele is the A5.1 allele which has 5 GCT 
repeats together with an insertion of an additional guanine causing a frameshift and 
premature termination of the protein. This results in abnormal localisation of the protein 
on the cell surface. The full impact of this on the function of the MICA/NKG2D
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interaction is not known. However, it is intriguing that it is this allele that is uniformly 
the most common MICA allele within most populations. Another interesting allele of 
MICA, MICA *017, has 9 GCT repeats together with a single base deletion at the end 
of the 4th exon which also results in a frameshift. In this case, the TM region becomes 
hydrophobic due to the production of a polyleucine rather than a polyalanine repeat. It 
is this allele that is strongly associated with Type I psoriasis. A similar mechanism is 
found in the CARD15 allele that is strongly associated with Crohn’s disease (72).
A method for the detection of the microsatellite repeat of MICA has been devised for 
the study of PsA and psoriasis using a Genescanner to separate double stranded PCR 
products on the basis of their size. The method was simple to use and the results could 
be obtained rapidly. The technique had the ability to distinguish PCR products that 
varied by only one base pair. However, this proved to be less reliable in the detection of 
heterozygotes where each allele only varied by one base pair, such as an A5 and A5.1 
allele. This particular combination was sometimes difficult to distinguish with 
confidence from either A5 or A5.1 homozygotes. This could be resolved by further 
typing of the extracellular portion of the molecule.
Few disease association studies have examined the more complicated and polymorphic 
region of MICA encoded by exons 2,3 and 4, the region which makes direct contact 
with the NKG2D receptor. This is largely because of the number of SNPs involved and 
the complexity of the alleles. However, it would seem more likely that polymorphisms 
that affect the extracellular portion of MICA have the potential to cause disease. In 
order to rationalise the typing of the SNPs, a method using sequence-specific primers 
(PCR-SSP) was devised which was based on a phylogenetic analysis of the MICA 
alleles. The primers were then applied in a group-wise fashion to avoid unnecessary 
testing of every sample with every available primer pair. Although there were some 
alleles that could not be distinguished with this technique, it proved to be a simple and 
reproducible method which could easily be applied to other disease association studies.
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8.4 The role of MICA in PsA
A major focus of this thesis has been the role of MICA in PsA. There is good evidence 
for the involvement of T cells and emerging evidence for the involvement of NK cells 
in both psoriasis (55) (56) (57) and PsA (23) (24) (94). Thus any factor which affects 
the stimulation of these immune cells within the joint or skin could have a potential role 
in disease pathogenesis. MICA is therefore a good candidate gene due to its interaction 
with the NKG2D receptor on T and NK cells leading to cellular activation and cytokine 
release.
The investigation was divided into three main areas.
• The identification of which microsatellite alleles within exon 5 (encoding the TM 
region of MICA) were associated with PsA and psoriasis.
• The development of a PCR-SSP method to identify the SNPs within exons 2,3 and 4 
of MICA. This technique was then applied to determine the associations of the 
MICA alleles with PsA and psoriasis.
• The analysis of skin and synovial biopsies from patients with psoriasis and PsA 
using immunohistochemistry to determine the expression of MICA within the 
tissues in the presence and absence of disease.
The main conclusion of the microsatellite study was that the MICA A9 allele was 
strongly associated with PsA.
To determine whether this association was primarily with psoriasis or a true association 
with PsA, several populations of patients with Type I psoriasis were examined. The 
patients from the 13IHW from Belgium, Germany and Italy with Type I psoriasis had 
not been screened for the presence of a complicating arthritis. In this group as a whole, 
the MICA A9 allele was also significantly increased compared with the control 
population. However, the UK population with Type I psoriasis that had been fully 
screened for arthritis failed to show any significant increase in the MICA A9 allele. 
This may have been because of the smaller population size or because the true 
association was actually with PsA not psoriasis. The findings of this study confirm the
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published smaller studies (67) (66) (68) in Spanish and Jewish populations of an 
association between MICA A9 and PsA. Interestingly, in one of these studies (67), the 
association was seen only with PsA and not with psoriasis, although the numbers were 
small and the psoriasis population unscreened.
The second phase of the investigation was aimed at defining the SNPs within exons 2-4, 
so that the alleles of MICA associated with disease could be identified. There are 
several alleles of MICA that carry 9 GCT repeats in exon 5, each defined by unique 
SNPs within exons 2-4. A method was therefore devised to identify the most common 
of the 54 known alleles of MICA based on the detection of SNPs with sequence-specific 
primers.
A method had been published using PCR-SSP to identify the MICA alleles, but at this 
point only 16 of the now recognised 54 alleles were known (116). The primers were 
therefore updated and new primers introduced to identify novel alleles. The current 
nomenclature of MICA is largely based on the time that particular alleles were 
discovered and bears little relation to sequence similarity. A phylogenetic analysis of 
the MICA alleles was therefore undertaken in order to identify evolutionarily similar 
alleles that could be grouped together for the purpose of genetic analysis.
The phylogenetic tree of MICA alleles revealed some interesting features. The alleles 
fell into 2 groups, based largely on the presence of a particular sequence in exon 4. The 
significance of this sequence is not known. Further distinct groups were identified 
which were sometimes associated with the same TM region eg. *001, *012, *018 (all 
A4) but sometimes not, eg. *007 (A4), *045 (A4) and *026 (A6). The majority of the 
A9 alleles clustered together apart from *015 which appeared in a different group. The 
alleles containing 6 GCT repeats (A6) were the most diverse, forming 3 separate 
groups; *004, *006, *009, *044 and *049 all grouped together, whereas *011 and *047 
were in a separate group and *026 clustered apart from the other A6 alleles. This would 
indicate independent evolution of the TM region from the rest of the gene.
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Primer pairs were utilised which recognised the alleles falling into one of five mutually 
exclusive phylogenetically based groups. A second stage PCR was then performed to 
elicit the major alleles within each group. The majority of patient samples could be 
typed for MICA using an average of nine primer pairs per sample. This was clearly an 
advantage over the two recently published PCR-SSP techniques for MICA (117) (170), 
both of which use blanket testing of all samples with all primers and need over 50 
primer pairs per sample. Indeed, the study which examined the MICA alleles in 
inflammatory bowel disease tested in excess of 900 samples and found that only 13 of 
the possible 54 alleles were present at a frequency of >1%, with many not being 
detected at all. There is therefore a high level of redundancy in testing every sample for 
every allele.
For this reason a group based approach is clearly preferable and certainly less wasteful 
of time and resources. However, there are disadvantages to the simpler, step-wise 
technique employed here. Firstly, some of the alleles could not be adequately 
distinguished from each other. Secondly, certain heterozygote combinations were 
unable to be typed with confidence, such as *018 in the presence of *007. Thirdly, since 
fewer combinations of primers are utilised there are fewer opportunities for double­
checking results and errors may therefore occur.
However, as the alleles had also been independently typed for the micro satellite alleles, 
this provided a method of checking results, particularly with certain heterozygote 
combinations. It is possible that some of the rarer alleles were present in the patient and 
control samples, but these were not detectable with the technique that was used. If 
higher resolution is required, a third stage PCR could be introduced to the groups to 
exclude the rarer alleles with confidence. However, it was decided for the purposes of 
this study that medium resolution typing would pick up any major associations with 
disease.
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The major findings of the MICA PCR-SSP study were:
• MICA *002 was significantly associated with PsA but not Type I 
psoriasis
• MICA *017 was significantly associated with Type I psoriasis but not 
PsA
Both of these alleles contain 9 GCT repeats in exon 5. However, the differences 
between the MICA *002 and *017 alleles are two-fold:
• Firstly a SNP at position 272 of exon 2 of MICA *017 results in a change of 
amino acid from glutamine to arginine at position 91. This is in the centre of the 
a la 1 platform that interacts with the NKG2D receptor.
• Secondly, the guanine at position 823, at the very end of exon 4, of the MICA 
*017 allele is deleted. This deletion does not occur in MICA *002. The deletion 
results in a frame shift and a completely different transmembrane region in the 
MICA *017 protein. Instead of 9 alanines, the MICA *017 molecule has a 
hydrophobic poly-leucine tail with truncation of the cytoplasmic segment.
Both of these SNPs could therefore have potentially significant effects on the function 
of the MICA molecule. The alteration of the transmembrane region and truncation of 
the cytoplasmic segment could severely hamper the ability of the molecule to be 
expressed on the cell surface. This feature is of interest with regards to the observations 
from immunohistochemistry using antibodies to MICA on sections of skin with 
psoriasis. It would appear that the normal pattern of expression of MICA in the basal 
layer of the epidermis is lost in psoriasis with reduced expression. It is possible that the 
altered structure of the MICA protein in the *017 allele affects cellular expression. The 
second SNP is directly in the middle of the MICA platform that interacts with NKG2D. 
Although the functional consequences of this SNP have not been assessed in terms of
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the 3-dimensional structure of MICA and its binding affinity with the receptor, it is 
certainly of potential importance.
It would appear that MICA *002 is a susceptibility rather than a severity gene for PsA. 
A detailed analysis of the prospectively collected clinical and radiological data on the 
patients with PsA failed to reveal any associations between MICA *002 with disease 
subset, swollen or tender joint counts, use of DMARDs or the presence of radiological 
erosions. Therefore the frequency of MICA *002 is markedly increased in PsA as a 
whole but there would not appear to be any association with markers of disease 
severity.
It is possible that MICA *002 and *017 share a common evolutionary ancestor. 
Through time, some individuals have branched off with the development of new 
mutations which predispose them to develop PsA whereas others follow the branch 
which leads to the development of uncomplicated psoriasis. The common ancestor may 
in fact be the A9 allele from which *002 and *017 have diverged.
8.5 MICA Haplotype analysis
The MICA *017 allele is highly conserved on the 57.1 ancestral haplotype and is in 
strong linkage disequilibrium with HLA-Cw6. If the association between MICA *017 
and Type I psoriasis is stratified for HLA-Cw6, the MICA *017 allele is no longer 
significant. A component of this may be that the numbers involved once all HLA-Cw6 
patients have been removed become much smaller. Greater numbers of patients would 
therefore be needed to demonstrate any independent association of MICA *017 with 
psoriasis.
However, the association between MICA *002 and PsA is independent of HLA-Cw6. 
Thus either the MICA gene itself is the key contributor to the association or it is a 
marker for a further disease-associated haplotype. The latter would seem less likely as 
*002 exists on many different haplotypes, with no clear alternative haplotype emerging 
as a strong contender. More information of the other alleles of neighbouring genes that
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are found on MICA *002 haplotypes, such as the TNF genes, may help distinguish the 
importance of the potential candidate genes.
8.6 Studies of the expression of MICA
Although several studies have investigated the role of MICA in a variety of 
rheumatological conditions, there is no published data concerning the expression of 
MICA in the synovium. The aims of the expression study were:
• To determine whether MICA was expressed in the synovium
• To establish whether there was any pattern of expression that was specific to PsA by 
examining synovial biopsies from patients with other inflammatory arthritides
• To extend the limited knowledge of the expression of MICA in the skin and 
examine whether the pattern of expression differed between psoriatic and normal 
skin
A technique was developed to enable the use of archived histological material from 
patients with a clear diagnosis of PsA and psoriasis. Formalin-fixed, paraffin-embedded 
sections were prepared for immunohistochemical analysis by a process called antigen 
retrieval. Polyclonal antibodies specific for MICA had been produced by immunising 
rabbits with a peptide from the extracellular a\ domain of the MICA molecule. 
Monoclonal antibodies to MICA were also utilised to enhance the specificity for MICA.
One of the problems encountered with the immunohistochemistry analysis was the 
background staining and potential cross-reactivity with the polyclonal antibodies to 
MICA. There are a family of proteins which share a proportion of the amino acids with 
MICA that could potentially be recognised by the polyclonal antibodies. It is likely that 
the antibodies detect MICB as well as MICA, since the peptide used in the formation of 
the antibodies shares 9/11 residues between MICA and MICB. The other members of 
the extended MHC Class I family share much lower numbers of residues and cross­
reactivity is therefore possible but not likely. This would be supported by the very 
different staining pattern observed with antibodies to MHC Class I molecules (W6/32)
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compared with that observed with the MICA antibodies, despite MICA and MHC Class 
I proteins sharing 5/11 residues in the immunisation peptide. Some of the difficulties 
were addressed by the use of a monoclonal antibody to MICA, provided by a 
collaborating laboratory. Although the monoclonal antibody did not work optimally 
with the technique used, it was helpful in the determination of which patterns of 
staining were likely to be specific to MICA.
The main findings of the immunohistochemistry study were:
• MICA was expressed in the synovium. Expression was predominantly in the 
cytoplasm of the surface synoviocytes, although some more non-specific staining 
was also seen in the underlying vascular endothelium and inflammatory cell 
infiltrate. The monoclonal antibodies confirmed expression in the surface 
synoviocytes.
• The intensity of the expression was increased during inflammation, but the pattern 
and intensity of expression did not appear to differ between pathologies (PsA, RA 
and non-specific synovitis).
• MICA was found to be expressed in the skin, predominantly in the cytoplasm of the 
cells within the basal layer of the epidermis of normal skin. This was confirmed 
using the monoclonal antibody to MICA. However, in lesional psoriatic skin, the 
expression of MICA in the basal layer was reduced and in some cases lost.
• There was also a different pattern of staining observed in psoriatic skin. In 3 out of 
5 sections, the cells of the stratum spinosum of the epidermis exhibited a strong cell 
membrane pattern not observed in normal skin. The pattern then returned to a 
predominantly granular cytoplasmic appearance in the upper stratum granulosum of 
the epidermis. Thus MICA expression was lost in the basal layers of the epidermis 
and then was found on the cell surface in the central epidermal layers. The reason 
for these changes remains unclear. It is of interest that the MICA allele that is
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associated with psoriasis, MICA *017, results in a faulty protein with a hydrophobic 
transmembrane region and a shortened cytoplasmic tail. If the patients from whom 
the sections were taken that exhibited these altered staining patterns possessed 
MICA *017, this could explain some of the findings. Further work using skin 
sections from patients who had been genotyped for MICA would help to resolve 
this.
The expression study has provided some interesting results. The confirmation of 
expression of MICA in the synovium complements the case for the consideration of 
MICA as a candidate gene in PsA. Further work would need to be performed on a larger 
number of synovial sections from differing pathologies before any definite conclusions 
could be drawn with regards to any patterns of expression that may be unique to PsA. 
There were no obvious differences in this preliminary study. Equally, greater numbers 
of skin samples would need to be examined to elucidate the true nature of the intriguing 
changes in expression pattern observed in this study. Some fascinating insights into the 
expression patterns observed with different MICA genotypes could be gained if DNA 
and biopsy material were available from the same patient.
8.7 What are the potential functions for MICA?
The potential role of the MIC genes in histocompatibility has recently been explored. 
HLA compatibility is clearly a key factor in haematopoietic transplants and has been 
shown to improve survival in kidney transplants. The degree of complication following 
transplantation is directly related to the degree of histocompatibility. However, it has 
become clear that matching for alleles other than classical Class I and Class II HLA 
genes can improve outcome. In bone marrow transplantation, clinical results improve 
significantly if the donor and recipient are matched for haplotype (from a family 
member) rather than just for the HLA antigens (from an unrelated individual) (254). 
MIC would certainly be a good candidate for histocompatibility, particularly in view of 
the widespread expression on epithelial cells. A recent study has demonstrated the 
presence of antibodies to MIC in rejected ‘histocompatible’ kidney transplants (139). 
Further analysis of the genetic and outcome data from patients who have undergone
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transplantation should help to address what role MIC has to play in transplantation but it 
would certainly seem to be of some importance.
There is evidence that MICA may be aberrantly expressed and therefore possibly non­
functional in certain individuals. The commonest allele of MICA, A5.1 results in a 
truncated molecule with no cytoplasmic tail. This has been shown to result in abnormal 
localisation of the molecule on the apical rather than the basolateral surface of intestinal 
epithelium. It is possible that this has resulted in some evolutionary advantage 
culminating in the high frequency of this particular allele in almost every population 
studied. Perhaps the native MICA molecule lies dormant and requires certain factors, 
either genetic or environmental, to become active. Certain polymorphisms may then 
alter the expression and function of the molecule which may then stimulate the immune 
response and produce disease.
It is also clear that some individuals can function without any MIC genes whatsoever. 
The so-called MIC ‘null’ haplotype (AH48.1) contains a complete deletion of both the 
MICA and MICB genes (130). This haplotype is extremely uncommon outside 
southeast Asia with the exception of some Amerindians. In southeast Asia, the AH48.1 
is relatively common with a frequency o f  3.2% and an expected homozygous carriage 
of 0.1%. So far, 8 individuals homozygous for the MIC null haplotype have been 
reported in the literature. Ostensibly, these individuals have no clinical symptoms and a 
limited exploration of their NK and T cell repertoires has proved unremarkable. This 
would suggest that the function of the MIC genes may be replaced in these individuals 
by functional homologues.
8.8 MICA and NK cells
Another factor in the functional role of MICA may be the repertoire of receptors on an 
individual’s NK and T cells. Each NK cell bears many different types of both activatory 
and inhibitory receptors. There are two man types of NK cell receptors -  the lectin-type 
receptors like NKG2D and the killer immunoglobulin-like receptors (KIRs). It has
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recently emerged that there is a high degree of polymorphism and complexity in the 
genes that encode the KIRs on chromosome 19, resembling the MHC complex. A 
particular KIR haplotype will therefore encode a distinct set of receptors for an 
individual’s NK cells. It is possible, therefore, that the presence of a particular MICA 
allele in the context of a particular KIR haplotype and HLA haplotype may influence 
the response of that individual to infection, cell damage or tumour cells.
There have been two recent publications examining the role of the KIR genes in the 
development of PsA and psoriasis. Both studies reported an association between the 
activating KIR2DS1 receptor and PsA (255) and psoriasis (256). Interestingly, the 
association between KIR2DS1 and PsA was only found if the HLA ligand for the 
corresponding inhibitory receptor (KIR2DL1) was absent. This may suggest one 
mechanism by which the presence of certain HLA Class I molecules, such as HLA- 
Cw6, can influence the NK cell response. It could be therefore that HLA-Cw6 and 
HLA-B27 are not simply markers for neighbouring disease-associated genes but are in 
fact directly involved in the immune response of an individual. Furthermore, which 
MICA allele an individual possesses may also influence NK cell activation via its 
interaction with the stimulatory NKG2D receptor.
8.9 HLA associations with PsA
The majority of the patients with PsA were typed for HLA-Cw6, HLA-B27 and HLA- 
DRB1 to examine any relationships to disease subset, clinical characteristics and 
disease severity. All the samples will be fully typed at all HLA Class I and II loci as 
part of the 13IHW but this work has yet to be completed.
The frequency of HLA-Cw6 was significantly increased in the PsA population 
compared with controls. HLA-Cw6 was associated with a higher nail score but not with 
a higher skin score. The reasons for this are not clear. As expected HLA-Cw6 was 
associated with a younger mean age of onset of psoriasis, confirming similar reports in
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published studies. There were no other clinical or disease subgroup associations with 
HLA-Cw6.
In contrast, HLA-B27 was not found to be increased in the PsA population as a whole, 
nor was it increased in any of the disease subgroups. Some studies have reported 
associations between the spondyloarthritis subgroup and HLA-B27, but this has not 
been confirmed by others and was not confirmed here.
Overall, the only HLA Class II allele to be associated with PsA was HLA-DR7. This 
has been reported in previous studies (63) and is most likely to represent its presence on 
HLA-Cw6 containing ancestral haplotypes such as AH13.1 and AH57.1. There were no 
particular clinical characteristics associated with HLA-DR7. The prevalence of HLA- 
DR1 and HLA-DR4 was no greater than a control population, but a sub-analysis of the 
HLA-DRB1 SE alleles *0101, *0102, *0401, *0404, *0405, *0408 and *1001 has 
revealed some interesting associations within PsA.
8.10 The HLA-DRB1 shared epitope in PsA -  what does it mean?
The HLA-DRB1 SE alleles have been consistently shown to be one of the strongest 
genetic associations with RA, particularly with the development of erosive disease. The 
frequency and relevance of these alleles in PsA has never been studied. It might be 
hypothesised that the SE alleles may be associated with a subset of PsA that resembles 
RA, perhaps with polyarthritis and erosive disease. The aims of this study were 
therefore to examine:
• The prevalence of the SE alleles in PsA
• Whether the presence of SE alleles was correlated with any particular clinical 
subgroup or phenotype of PsA
• Whether the SE alleles were associated with the presence of radiological erosions
The main findings of the study were:
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• Overall the prevalence of the SE alleles was no different in PsA than in a control 
population
• There was no increase in the frequency of the SE in the polyarthritis subset
• There was a lower frequency of the SE in patients who remained in the oligoarthritis 
subset.
• A significantly greater number of patients with PsA who developed radiological 
erosions were SE positive (60% vs 43%, p=0.03, OR 2.11)
The findings add further evidence for the clear distinction between patients with PsA 
who have a polyarthritis and patients who have RA. It is possible that the SE influences 
the severity of RA as well as susceptibility to RA by contributing in some way to the 
development of erosions. It is interesting that the only significant association between 
the SE and PsA was in the development of erosions. This may therefore be a feature in 
common between the two arthritis populations. It is possible that the SE alleles are one 
of the genetic contributors to the severity of PsA.
8.11 Anti-CCP antibodies - are they a useful serological marker in PsA?
The development of an ELISA to detect the presence of anti-CCP antibodies in patients 
with early inflammatory arthritis has increased the specificity and sensitivity for 
diagnosing RA. Anti-CCP antibodies certainly seem to be superior to RF in their 
specificity for RA particularly with regards to other connective tissue diseases such as 
Sjogrens syndrome and SLE. However, there has been very little data on the prevalence 
of anti-CCP antibodies in PsA. It could be hypothesised that anti-CCP antibodies may 
be found in a subgroup of patients with PsA with more severe, erosive disease 
resembling RA. The aims of this study were therefore:
• To assess the prevalence of anti-CCP antibodies in PsA
• To elicit any associations with disease subset
• To elicit any associations with markers of disease severity
• To investigate any HLA associations including HLA-DRB1 and the SE
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• To investigate whether the presence of RF had any impact on disease subset or 
severity
Overall the prevalence of anti-CCP antibodies was no higher in PsA than in a control 
population. However, there were some interesting features in the 7 patients (5.6%) who 
were positive for anti-CCP antibodies. Firstly, there was a significant association 
between anti-CCP positivity and DMARD use and number of swollen joints, indicating 
that it may be a marker for severity. In addition, there was a significant association with 
the presence of erosions similar to that seen in RA. The mechanism for the production 
of erosions is still poorly understood but it is possible that the anti-CCP antibodies play 
a role in the process possibly by the perpetuation of the immune response. There was no 
association between the presence of anti-CCP antibodies and clinical phenotype with an 
even distribution of polyathritis, oligoarthritis and spondyloarthritis in the positive 
patients. Thus, when present in PsA, anti-CCP antibodies would appear to be associated 
with indices of more severe disease.
There was a strong association between the presence of anti-CCP antibodies and the SE 
in all 7 positive patients. This is interesting and may relate to the pathology within the 
joint. It has recently been demonstrated that the SE alleles present peptides containing 
citrulline but not arginine to T cells. Thus, SE positive patients are able to produce anti- 
CCP antibodies in response to an injured cell converting its arginine residues to 
citrulline. The antibodies may then play a direct pathogenic role in the perpetuation of 
the immune response, leading to the development of a chronic inflammatory disease. 
Patients with PsA who are positive for anti-CCP antibodies also have a higher median 
number of swollen joints than anti-CCP negative patients. This would suggest that they 
may be a marker for or indeed a contributory factor in more severe disease.
One of the most important questions to resolve is whether the anti-CCP positive patients 
truly represent patients with more severe PsA or whether the patients really have RA. 
Some might see the associations with erosive disease, the SE, higher DMARD use and 
greater number of swollen joints as support for a diagnosis of RA. However, only 2/7
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patients were also positive for RF. In addition, 3/7 patients had a true asymmetrical 
oligoarthritis and one of the polyarthritis patients had an associated spondyloarthritis 
with radiological sacroiliitis. Most patients (6/7) had radiological features of PsA such 
as new bone formation, DIP joint involvement and asymmetry. All patients had 
confirmed psoriasis of the skin and nails, 50% had a family history of psoriasis but none 
had a family history of RA and there was an equal sex incidence. However, more 
patient numbers would be required to improve the chances of establishing a definite 
conclusion. Even if the definitive diagnosis remained in doubt, any patient with PsA 
who has anti-CCP antibodies falls into a poor prognostic category and should be treated 
aggressively. However, the small proportion of patients who are positive for anti-CCP 
antibodies would not justify the routine testing of all patients with PsA. The test is most 
likely to be informative in an early arthritis setting as a predictor of persistence and 
severity of inflammatory arthritis.
Another interesting result of this study was that, in contrast to anti-CCP antibodies, 
there was no evidence that the presence of RF in PsA was associated with a more severe 
outlook. There was no association between RF and erosive disease, DMARD use, 
subgroup, the number of swollen joints or the presence of the shared epitope. Therefore, 
the presence of RF should not exclude patients from research studies on PsA. Neither 
should it be regarded as a barrier to making the correct diagnosis on the basis of classic 
clinical and radiological characteristics of PsA.
In summary, there are many challenges in the study of a complex heterogeneous disease 
such as PsA. Clear definition of clinical phenotype and prospective collection of data 
over extended periods of time should limit some of the variability. Another challenge is 
dissecting those factors that are predominantly involved in the development of psoriasis 
from those that predispose to a complicating inflammatory arthritis. Thus, the study of a 
control population with psoriasis who have been screened clinically and radiologically 
for the presence of arthritis is vital in the search for factors involved in the aetiology of 
PsA. This study has presented some significant immunogenetic associations with both 
PsA and psoriasis. Some of the associations are common to the two diseases whilst
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others are independent and specific for the development of an inflammatory arthritis. 
Further work on these factors will hopefully establish why some patients with psoriasis 
develop arthritis whilst others never do.
8.12 Future work
8.12.1 Patien t m aterial
The significance of the genetic results from this study would be enhanced by higher 
patient numbers. There are considerably more patients with PsA who have been added 
to the database at the Royal National Hospital for Rheumatic diseases in Bath, many of 
whom have had DNA extracted to allow an extension of this study. In addition, it is 
hoped that ethical approval will be granted to allow the collection of DNA and 
demographic data from family members of the patients with PsA. There is a definite 
need to increase the numbers of patients with Type I psoriasis who have been screened 
for arthritis and recruitment from a further General Practice will hopefully commence 
soon.
8.12.2 Immunohistochemistry
The immunohistochemistry study presented in this thesis demonstrates some interesting 
preliminary results. Analysis of further samples is needed to establish clear expression 
patterns for MICA. The technique will need to be optimised for the monoclonal 
antibody to MICA so that some of the problems encountered with the polyclonal 
antibodies can be minimised. The use of further antibodies to MICB, other members of 
the extended MHC Class I family, NK cell receptors and T cell receptors will 
complement the results seen with MICA.
In addition, the collection of fresh skin and synovial samples from patients whose 
clinical details are known and whose DNA is available for analysis would be preferable 
to the use of archived material. Comparison of the expression patterns of MICA with 
the genotype of MICA will provide more information on whether there is any allele- 
specific expression.
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8.12.3 Further genetic analysis
A major addition to the genetic analysis will be the availability of the results of the full 
HLA Class I and II typing on the patient and control samples. This will allow analysis 
of haplotypes of MICA and comparison of haplotype frequencies between patient and 
control populations. There is additional data available on polymorphisms of the TNF 
genes within the same population. This would allow the construction of extended 
haplotypes of MICA, TNF and the HLA Class I and II alleles. Further work is planned 
to elucidate the KIR haplotypes of the same patients. This could provide a fascinating 
insight into the interactions between MICA and NK cells and the roles they may play in 
the aetiology of PsA.
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T e l: 01225 465941
Fax: 01225 473435
PATIENT INFORMATION SHEET FOR PATIENTS WITH 
PSORIASIS AND ARTHRITIS 
Markers of outcome in Psoriatic Arthritis Study
Introduction
This information sheet is for patients who have Psoriatic Arthritis. We would like you to take 
part in a research project. This is absolutely voluntary and if  you would prefer not to take part 
your decision will be accepted without question. You would not have to give a reason and your 
future care would certainly not be affected in any way.
What is the purpose of the study ?
Arthritis associated with psoriasis is a very variable condition and affects patients in different 
ways. We are interested in finding out if  there are any factors which influence why some 
patients develop more severe arthritis than others. In order to do this we would like to take a 
small sample o f your blood to look for the presence of particular genes and a new antibody in 
the blood which may help us to understand why some people develop psoriatic arthritis and 
why some people have more problems from their joints than others.
Why have you been chosen ?
You have been asked to participate because you have arthritis associated with psoriasis.
Who is organising the study ?
Dr McHugh, Dr Korendowych and Dr Ravindran are organising the study which is funded by 
the Royal National Hospital for Rheumatic Diseases in Bath.
What will happen if you take part ?
We would ask you to give one small blood sample ( approximately 15mls or 3 teaspoons).
The blood will only be taken on one occasion. You will not need to make any special trips to 
the hospital to take part. If you agree to take part the blood sample will be taken at the end o f  
your normal clinic appointment. We would also ask that you take a minute or two to fill in a 
short questionnaire. The doctor who sees you for your normal clinic appointment may take a 
little extra time examining your joints so that we have an accurate picture o f how your arthritis 
affects you. Studies have also suggested that a proportion of patients with psoriasis and 
arthritis may have inflammation and arthritis in the spine and in some patients this may occur 
in the absence o f any particular symptoms. We would also like to investigate this further and 
would also ask you to have an x-ray o f your lower spine.
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What are the possible benefits of taking part ?
The results o f this study will not be o f benefit directly to you but may eventually benefit others 
by increasing our understanding o f the condition.
What are the possible risks of taking part ?
The insertion o f a needle into a vein for collection of blood may produce minor pain, bruising 
or bleeding at the insertion site. There is a small risk o f an infection at the site.
What will happen to my blood sample ?
Your sample will be kept in secure storage at the Bath Institute for Rheumatic diseases. The 
sample will be used to test for the genes and a new antibody we are interested in for this 
project. Some o f this project involves working closely with a laboratory in Australia which 
has specialist facilities to look at certain genes. Dr Korendowych has been awarded a 
fellowship to travel to Australia to use their facilities. A small amount o f your blood sample 
will also be transported to Australia where storage will be similarly rigorous to Bath and the 
sample will only be used by Dr Korendowych and then destroyed The sample will be kept for 
a further 10 years and then destroyed. The sample will only be used for the purposes o f the 
tests described in this sheet. If any further tests are required in the future you will be informed 
and asked to give your permission before these could be carried out.
Confidentiality -  who will know you are taking part ?
Data collected for this research will be treated as confidential information. Your GP will be 
informed that you have agreed to take part. Your blood sample will be allocated a study 
number and your name will not be on the sample. Only Dr McHugh, Dr Korendowych and Dr 
Ravindran will know that your study number applies to you. The results o f the study on your 
blood will not be given to you. The overall results of the many patients who take part in the 
study will increase our understanding of psoriatic arthritis as a whole but will not be o f benefit 
for individual patients. Summary results o f this research may be published in the scientific 
literature but you will never be individually identified in any publication.
Will anybody benefit financially from the study ?
No
Ethics Approval
This study has been approved by the Bath Local Research Ethics Committee.
What happens now ?
You are free to choose whether you would like to take part. If you would like to take part you 
will be asked to complete and sign a consent form. If you do not it will not affect your usual 
care in any way. Thank you for reading this information sheet. If you have any questions about 
the study please ask the doctor who sees you in the clinic or Dr Ravindran/ Dr Korendowych 
who can be contacted in the clinic or at the Royal National Hospital for Rheumatic Diseases 
on telephone 01225 465941. Please keep this information sheet.
Thank you very much
Dr Ellie Korendowych and Dr Jaya Ravindran 
Research Fellows to Dr McHugh
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INFORMED CONSENT FORM : Markers of outcome in psoriatic arthritis
Have you read the patient information sheet ? Yes / No
Have you had an opportunity to ask questions and discuss this study ? Yes / No 
Have you received satisfactory answers to all your questions ? Yes / No
Have you received enough information about the study ? Yes / No
Who have you spoken to ?
Do you understand that you are free to withdraw from the study :
• At any time
• Without having to give a reason
• Without affecting your future care Y e s /N o
Do you agree to take part in this study ? Y e s /N o
Signed Date
Name in block capitals
Signed ( Researcher) Date
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Clinic date: | | | /  | | | /  | | | | | Study no: | B | P j S [A |
r
Appendix 3. Psoriatic Arthritis Follow-up form
jorename (s) I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
>OB I I I / I I I / 1 I I I I
lospital No I I I I I I I I I I
Jew NHS No. I I I I I I I I I I I I
'elephone no
lection 1 -  J o in t  Scores
Right Left RightA Left
D</) Q)<D 5 3
o_J (/> w (0 % 3
f o^_ . t p  D)
o * 3
. to Q? o « 3a. 2 . £ » » »
= o 5
® 3 |
3 O 0)a  = (Q n> 2  w 1  = 0 .
3  O 5Q. = <Q (o ® ro -i = a
Temp. mand. Q □  □ □ Hips
Stemo. Clav. Q □  □ □ Knees □  □ □ □  □ □
Aero. Clav. □  □ □ □  □ □ Ankles □  □ □ □  □ □
Shoulders □  □ □ □  □ □ Tarsi □  □ □ □  □ □
Elbows □  □ □ □  □ □ MTP1 □  □ □ □  □ □
Wrist □  □ □ □  □ □ MTP2 □  □ □ □  □ □
CMC □  □ □ □  □ □ MTP3 □  □ □ □  □ □
MCP1 □  □ □ □  □ □ MTP4 □  □ □ □  □ □
MCP2 □  □ □ □  □ □ MTP5 □  □ □ □  □ □
MCP3 □  □ □ □  □ □ Toes(PIP)l □  □  □ □  □ □
MCP4 □  □ □ □  □ □ Toes(PIP)2 □  □  □ □  □ □
MCP5 □  □ □ □  □ □ Toes(PIP)3 □  □  □ □  □ □
PIP1 □  □ □ □  □ □ Toes(PIP)4 □  □  □ □  □ □
PIP2 □  □ □ □  □ □ Toes(PIP)5 □  □  □ □  □ □
PIP3 □  □ □ □  □ □ Toes(DIP)2 □  □  □ □  □ □
PIP4 □  □ □ □  □ □ Toes(DIP)3 □  □  □ □  □ □
PIP5 □  □ □ □  □ □ T o e s ( D I P ) 4 n n n □  □ □
DIP1 □  □ □ □  □ □ Toes(DIP)5 □  □  □ □  □ □
DEP2 □  □ □ □  □ □
DIP3 □  □ □ □  □ □ Total Tender Joints
DIP4 □  □ □ □  □ □
DIP5 □  □ □ □  □ □
Total Swollen Joints
TotalD am aged Joints
Total Involved Joints
[ection 2 -  C lin ical su b g ro u p , S chobers, DAS an d  H A Q  scores
a) Which subgroup best fits the current □  Mutilans □  Mono □  Oligo | | Poly | | Spond | | Dip 
c lin ica l nicture?p
b) Schobers
c) DAS score
c) HAQ raw score





Total Nail Score (max 40)
R T H U M B  LTH UM B
(1) (2) (3) (4) (5) (1) (2) (3) (4) (5)
Section 4 -  P A S I sco re
E x te n t: <10% 1929%  3 0 4 9 %  506 9 % 70-89% 90-100% S e v er ity : Nil Slight M oderate S e v e r e V ery se v e r e
E x te n t s c o r e :  1 2 3 4 5 6 S e v e r ity  s c o r e :  0 1 2 3 4
Extent { SEVERITY
Skin Area Score Total Extent E ryth em a Infiltration D e sq u a
Head □ x 0 .1 = [ I ] ’[ I ] □ + □ + □
Arms □ x 0 . 2 = d - n □ + □ + □
Trunk □ x 0.3= [ d  ' d l □ + □ +  □
Legs □ x < > .* = □ ■ □ □ +  □ +  □
T otal
Severity
Total Extent x 
Total Severity
m-n m-n
PASI (PsA Skin Index) = extent x severity (max score 72)\
Section 5 - Investiga tions
a) Research bloods requested:
b) Xrays requested:
If other please specify:
□  Y e s  □  N o □  N/A
□  H and s | | F ee t □  H ee ls  | | C sp in e  □  l sp in e  □ O ther
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Section  6 -  M ed ica tio n  since la st visit
DMARDS
N a m e  S tart d a te
a) Methotrexate 1 / 1 I / I
b) Sulphasalazine ___ J / 1___ / 1______
c) Leflunomide i / i I / I
d) Hydroxychoroquine L i / l I / I
e) Anti-TNF i / i L - 1 / 1
f) Azathioprine / I I / I
g) Cyclosporine i / l I / I
h) IM Gold / I / I
i) Prednisone i / l I / I
j) Other U / U I/ I
If other please specify: 1 1 M i l
E nd d a te  R e a s o n  for  s to p p in g
L_U /  L_U /  L_U I I I I I I
Reasons for stopping codes:
SR=Skin rash H=Hepatic R=Renal N=Neurologic P=Pulmonary
I=Ineffective N = Not drug related IR=In remission U=Unknown 0= 0ther
Section 7 - H o sp ita l A dm issions (related to arthritis since last clinic visit)
Section 8 -  A d d itio n a l com m ents
Clinic date: | | | /  | | | /  | | | Study no: | B  | P | S 1A  1 1 1 1
Appendix 4. Psoriatic Arthritis Initial form
Forename (s) 1 | |  I | | | | | .........................................................................
Surname 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
DOB 1 1 1/ 1 1 1 /1 1 
Hospital No 1 1 1 1 1 1 1 1 
N ew N H S N o. 1 1 1 1 1 1 1 1 




1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
| | | | | | | | | | | | |
Telephone no | | | | | I I I
Section 1 - A rthritis
a) What was the time course o f  onset | | After o n s e t  of p soriasis  I [ B efore o n s e t  o f p so r ia sis  | | At s a m e  tim e a s  p sor iasis  
o f  arthritis?
b) Mode o f  onset I I Mutilans I I Mono Q o iig o  | |Poly | | Spond | |Dip
Section 2 - Psoriasis
a) Has Psoriasis ever been present? e h  Yes n  n°
b) Has there ever been any nail EH Y e s  EH No
involvement?









b) Any tender enthesis □ □ □
c) Diffuseenthesispain □ □ □
d) Chest wall pain □ □ □
e) Inflammatory heel pain □ □ □
f) Clinical sacroliitis □ □ □
g) Inflammatory lower back pain □ □ □
h) Inflammatory thoracic back pain □ □ □
i) Inflammatory neck pain □ □ □
j) Iritis □ □ □
k) Clinical small joint □ □ □
1) Inflammatory bowel disease □ D ’ 2 □
Section 4 -  Medical History
DM ARDS
N a m e S tart d a te
a) Methotrexate i / l i / i
b) Sulphasalazine i / l / i
c) Leflunomide i / l i / i
d) Hydroxychoroquine l / U /
e) Anti-TNF / i i /
f) Azathioprine ___ i / ___ i / i
g) Cyclosporine i / i i / i
h) IM Gold / i /
i) Prednisone i / i i / i
j) Other ...j i /  _ / i
E nd d a te
i / i i i / i
i / i /
i / i i i / i
/ i / i
/ i / i
i / i i i / i
i / i i i / i
i / i /
i / i i i / i
i / i i / i
R e a s o n  for  s to p p in g
If other please specify:
Reasons for stopping codes:
SR=Skin rash H=Hepatic R=Renal N=Neurologic P=Pulmonary
I=Ineffective N= Not drug related IR=In remission U=Unknown 0= 0th er
Section 5 -  Lab data





D ate  ta k en
I l l / l l 1 I / I  1
r e su lt
1 1 1 1 1 1 1 1 1
1 I / I  1 / I  1 1 1 1 1 1 1 1 1 1
1 I J / M U / U 1 I I  1 1 1 1 1 1 1
1 I / I  I / I 1 I I  1 I I  1 I I  1
Section 6 -  X-rays
Have any X-rays been taken?
Yes Result
a) C spine EH 1 I
b) L spine EH I_ _ _
c) Pelvis EH I_ _ _
d) Hands EH I_ _ _
e) Feet EH I— I—
f) Heels □  i I .
g) Other EH I_ _ _
If other please specify: | I
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ection 7 -  Joint Scores
Right Left Right LeftA
o_i w 0)
? % 3 3 O B)
H W toi  % 35 o CD
{/) w
® % 3 3 O CD
( \ D
-< S %s I ia  = (q 5 2 cd■« 3 Q. CD |  |
a  = CQ <D O (D-1 3 Q-
Q. — <QCD 2 2 -n 3 Q.
Temp. mand. Q □  □ □ Hips
Stemo. Clav. Q ] [ □  □ □ Knees □  □ □ □  □ □
Aero. Clav. □  □ □ □  □ □ Ankles □  □ □ □  □ □
Shoulders □  □ □ □  □ □ Tarsi □  □ □ □  □ □
Elbows □  □ □ □  □ □ MTP1 □  □ □ □  □ □
Wrist □  □ □ □  □ □ MTP2 □  □ □ □  □ □
CMC □  □ □ □  □ □ MTP3 □  □ □ □  □ □
MCP1 □  □ □ □  □ □ MTP4 □  □ □ □  □ □
MCP2 □  □ □ □  □ □ MTP5 □  □ □ □  □ □
MCP3 □  □ □ □  □ □ Toes(PIP)l □  □  □ □  □ □
MCP4 □  □ □ □  □ □ Toes(PIP)2 □  □  □ □  □ □
MCP5 □  □ □ □  □ □ Toes(PIP)3 □  □  □ □  □ □
PIP1 □  □ □ □  □ □ Toes(PIP)4 □  □  □ □  □ □
PIP2 □  □ □ □  □ □ Toes(PIP)5 □  □  □ □  □ □
PIP3 □  □ □ □  □ □ Toes(DIP)2 □  □  □ □  □ □
PIP4 □  □ □ □  □ □ Toes(DIP)3 □  □  □ □  □ □
PIP5 □  □ □ □  □ □ Toes(DIP)4 □  □  □ □  □ □
DIP1 □  □ □ □  □ □ Toes(DIP)5 □  □  □ □  □ □
DIP2 □  □ □ □  □ □
DIP3 □  □ □ □  □ □ Total Tender Joints
DIP4 □  □ □ □  □ □ Total Swollen Joints
DIP5 □  □ □ □  □ □ Total Damaged Joints
Total Involved Joints
Section 8 -  Nail score
R T H U M B  LTH UM B
(1) (2) (3) (4) (5) (1) (2) (3) (4) (5)
Pitting
Onycholysis
Hyperkeratosis _ _ _ __
Severe nail deformity
Total Nail Score (max40)
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Section 9 -  PASI score
E x ten t: <10% 1029% 3 0 4 9 %  5 0 6 9 % 70-89%  90-100% S e v e r ity : Nil Slight M oderate S e v e r e Very se v e r e
E x te n t s c o r e :  1 2 3 4 5  6 S e v e r ity  s c o r e :  0 1 2 3 4
Extent { S E V E R IT Y  } Total Total Extent x
Skin Area Score Total Extent E ryth em a Infiltration D e sq u a m a tio n  Severity Total Severity
Head □ x o . i = D - D □ + □ + □  = m m - n
Arms □ x 0 . 2 = D - [ I □ + □ + □  = m m - n
Trunk □ xo .h u  a □ +  □ + □  = m m a
Legs □ x o H H O □ + □ + □  = m
PASI (PsA Skin Index) = extent x severity (max scote 72>
Section 10 -  Clinical subgroup, Schobers and HAQ scores
a) Which subgroup best fits the current | | Mutilans | |Mono | |01igo | |Poly | |Spond | |Dip
clinical picture?
b) Schobers
c) HAQ raw score
Section 11 - Investigations
a) Research bloods requested: Q  Y e s  Q  N o Q  n /a
b) Xrays requested: □  H ands □  F e e t □  H ee ls  □  C sp in e  □  L sp in e  □  O ther
If other please specify:
Section 12 -  Additional comments
i i i  i i i i i i  i i i i  i ii i i i i i i i i i i i i i i i i i i i i i
i i i i i i i i i i i i i i i  i i  i i i i i
........................................ ......................... .... ......................................................
i i i i i i i i i i i i i i i i  i i i i i i i i  i i i i i i i i i i i i i
i i i i i i i i i i i i i i i i i i i i i i i i i  i i i i i i i i i i i i
i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i  i i i i i i i
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Appendix 5. Psoriatic Arthritis Background information






I I  1 1 1 1 1 1 1
1 1 1 1 1
1 1 / 1 1 / 1 1
1 1 1 1 1 1
1 1 1 1 1 1 1
1 11
Telephone no
Section 1 - Background data
1. Are you currently working? □  Y e s
If yes what is your current occupation? 1 I I 
If no what was you last occupation? 1 1 I




What is your marital status? 
What is your ethnic group?
□  Married ]  S in g le  | D ivorced □  S ep a ra ted  □  W idow ed
I I W hite & Black  
'— ' Caribbean
White: □  British 
Asian or Asian British:
Black or black British: □  Indian 
Chinese or other: □  C h in ese  
(if other please give details)\ | | |
□  Irish □  O ther
^  African* B 'aCk D  W hite S  A sian  C H  o th er
□  Pak istani B an g lad esh i □  Other 
O ther
Have you ever drunk alcohol?
If yes then please provide details:
□  Y e s  □  No
I 1 1 currently drink alcohol | | I u sed  to drink alcohol
J  A v erage  num ber o f units per w eek
Have you ever smoked?
If yes then please provide details.
□  Y e s  □  No
□  I currently sm o k e □I u sed  to sm o k e
1 1 1 2 9 6  | l 1 1 1 |
_ |  No. P er d ay  [ _ |  Y ears sm o k ed 1 Y ears  s in c e  sm ok ed
Section 2 - A rthritis
1. What year did the symptoms o f  arthritis start?
2. What year was your arthritis diagnosed?
3. Which joint was first affected by arthritis?
Section 3 - Psoriasis
1. What year did the symptoms o f  psoriasis start?
2. What year was your psoriasis diagnosed?
Section 4 -  Past medical history




Cardiac problems [_ □ U
Pulmonary problems [_ □ □
Liver problems [ □ □
(If other medical problems then please provide details below)
Section 5 -  Past jo in t surgery
I f  you have had any joint surgery then please provide details below:-
Section 6 -  Family history
Yes No
Have any o f  your family had any type o f  arthritis? □  □
I f  YES then p lease describe which relation had the arthritis and what type o f  arthritis they had.
Relation
.g. Parental grandfather, mother, brother Psoriatic Rheumatic Unknown type
Psoriasis arthritis Osteoarthritis Arthritis of arthritis□ □ □ □ □
2 . □ □ □ □ □
3. □ □ □ □ □
4. □ □ □ □ □
□ □ □ □ □
6 . □ □ □ □ □
7. □ □ □ □ □
□ □ □ □ □
□ □ □ □ □
10. □ □ □ □ □
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Section 7 - Previous Hospital Admissions
(Please provide details below o f any hospital admissions you have had which were related to your arthritis)
Section 8 - M edications
Have you been prescribed any o f the following drugs. I f  yes please provide details about when you started and 
finished them and why you stopped taking the medication.





Anti -  TNF drugs












I / I I / I
I I  I I
1 1 1 1 1 1
We are interested in learning how your illness affects your ability to function in daily life. Please feel 
free to add any comments at the end of this form.
PLEASE TICK THE ONE RESPONSE WHICH BEST DESCRIBES YOUR USUAL ABILITIES 
OVER THE PAST WEEK.









Are you able to:
- D ress yourself including shoelaces and doing buttons? d l □ □ □
- Shampoo your hair? □ □ □ □
2) Rising
Are you able to:
- Stand up from an armless straight chair? □ □ □ □
- Get in and out o f  bed? □ □ □ □
3) Eating
Are you able to:
- Cut your meat? □ □ □ □
- Lift a full cup or glass to your mouth? □ □ □ □
- Open a new  carton o f milk (or soap powder)? □ □ □ □
4) Walking
Are you able to:
- W alk outdoors on flat ground? □ □ □ □
- Climb up 5 steps? □ □ □ □
PLEASE TICK ANY ADDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE ACTIVITIES
□  Walking stick
□  Walking frame
□  Crutches
□  Wheelchair
□  Devices used for dressing (button hook, zipper pull, long handled shoe hom etc)
□  Built -up or special utensils 
I I Special or built-up chair
I | Other (specify)
PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE ACTIVITIES
I I Dressing and Grooming I I Rising O  Eating I I Walking
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Please turn over
PLEASE TICK THE ONE RESPONSE WHICH BEST DESCRIBES YOUR USUAL ABILITIES 














Are you able to:
- Wash and dry your entire body? □ □ □ □
- Take a bath? □ □ □ □
- Get on and off the toilet? □ □ □ □
Reach
Are you able to:
- Reach and get down a 51b object (e.g. bag of □ □ □ □
potatoes) from just above your head?
- Bend down to pick clothing from the floor? □ □ □ □
Grip
Are you able to:
- Open car doors? □ □ □ □
- Open jars which have previously opened? □ □ □ □
- Turn taps on and off? □ □ □ □
Activities
Are you able to:
- Run errands and shop? □ □ □ □
- Get in and out o f a car? □ □ □ □
- Do chores such as vacuuming, housework or light Q □ □ □
gardening?
PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE 
ACTIVITIES
| | Raised toilet seat
□  Bath seat 
|—| Jar opener (for j ars 
Previously opened)
I I Bath Rail 
□  Long-handled appliances for reach 
I I Other (specify)
PLEASE TICK ANY ACTIVITIES OR AREAS THAT YOU USUALLY NEED HELP FROM 
ANOTHER PERSON
I I Hygiene Q  Reach Q  Gripping and opening things Q  Errands and housework
HOW STRONG HAS THE PAIN IN YOUR JOINTS BEEN IN THE PAST WEEK?
Please mark on the line to indicate the severity of the pain
No p a in ___________________________________________________________  Pain as bad as it could be
HOW ACTIVE HAS YOUR ARTHRITIS BEEN IN THE PAST WEEK?
Please mark on the line to indicate your level of activity 301
Not active at a ll   Extremely active
Appendix 7




T e l : 01225 465941
Fax: 01225 473435
INFORMATION SHEET FOR PATIENTS WITH PSORIASIS 
Name of research project: Markers of outcome in psoriatic 
arthritis
Introduction
This information sheet is for people who have psoriasis. We would like you to help with a 
research project. This is absolutely voluntary and if  you would prefer not to take part you 
would not have to give a reason and your future care would not be affected in any way.
What is the purpose of the study ?
Psoriasis is a very common skin condition which affects approximately one in fifty o f the 
population. The majority o f people with psoriasis never have problems with their joints but 
unfortunately about one in ten people with psoriasis develops arthritis. This can present 
problems with pain, stiffness and swelling in the joints or pain and stiffness in the spine.. 
Arthritis associated with psoriasis is a very variable condition and affects patients in different 
ways. We are interested in finding out what factors influence why some people with psoriasis 
develop arthritis and why some people get more severe arthritis than others. We have already 
studied a group o f our patients who have psoriasis and arthritis and we would now like to 
study people who have psoriasis but not arthritis. In order to do this we would like to take a 
small sample o f your blood to test for the presence particular genes and a new antibody in the 
blood which may help us to understand why some people with psoriasis develop arthritis and, 
if  they do, how severely.
Why have you been chosen ?
You have been asked to participate because you have psoriasis.
Who is organising the study ?
Dr McHugh, Dr Korendowych and Dr Ravindran are Rheumatologists working at the Royal 
National Hospital for Rheumatic Diseases in Bath. They have a particular interest in arthritis 
associated with psoriasis. They are organising a study to try to find out why some people with 
psoriasis develop arthritis and why the majority do not.
What will happen if you take part ?
We would ask you to see either Dr Ravindran/ Dr Korendowych or our specialist therapist to 
discuss the study with you and give you an opportunity to ask any questions. This will be in 
the Dermatology unit at the Royal United Hospital after your normal appointment or if  your 
GP looks after your psoriasis we could also see you at the Royal National Hospital for 
Rheumatic diseases in Bath or at the GP practice. We would ask you to give one small blood 
sample (approximately 15mls or 3 teaspoons) on one occasion only. We would also ask that 
you take a minute or two to fill in a short questionnaire and allow us to briefly examine your 
joints and skin. If there is any evidence o f inflammation in your joints we may ask you to have
X-rays of those joints. Studies have also suggested that some patients with psoriasis may also 
have arthritis in the spine and in some this may occur in the absence of symptoms. We would 
also like to investigate this further and would ask you to have an x-ray of your lower spine.
What are the possible benefits of taking part ?
The results of this study will not be of benefit directly to you but may eventually benefit others 
by increasing our understanding of psoriasis and arthritis.
What are the possible risks of taking part ?
The insertion of a needle into a vein for collection of blood may produce minor pain, bmising 
or bleeding at the insertion site. There is a small risk of an infection at the site.
What will happen to my blood sample ?
Your sample will be kept in secure storage at the Bath Institute for Rheumatic diseases. The 
sample will be used to test for the genes we are interested in for this project. Some of this 
project involves working closely with a laboratory in Australia which has specialist facilities to 
look at these genes. Dr Korendowych has been awarded a fellowship to travel to Australia to 
use their facilities to complete this work. In order to do this a small amount of your blood 
sample will be transported to Australia where storage will be similarly rigorous to Bath and the 
sample will only be used by Dr Korendowych and then destroyed. The remainder of the 
sample will be kept in Bath for a further 10 years and then destroyed. The sample will only be 
used for the purposes of the tests described in this sheet. If any further tests are required within 
10 years, you will be asked to give your permission before these could be carried out.
Confidentiality -  who will know you are taking part ?
Data collected for this research will be treated as confidential information. Your blood sample 
will be allocated a study number and your name will not be on the sample. Only Dr McHugh, 
Dr Korendowych and Dr Ravindran will know that your study number applies to you. The 
results of the study on your blood will not be given to you. The overall results of the many 
patients who take part in the study will increase our understanding of psoriatic arthritis as a 
whole but will not be of benefit for individual patients. Summary results of this research may 
be published in the scientific literature but you will never be individually identified in any 
publication.
Will anybody benefit financially from the study ?
No
Ethics Approval
This study has been approved by the Bath Local Research Ethics Committee.
What happens now ?
You are free to choose whether you would like to take part. If you do not it will not affect your 
usual care. Thank you for reading this information sheet. If you have any questions about the 
study please ask the doctor or nurse who sees you in the clinic or Dr Ravindran/ Dr 
Korendowych who can be contacted in the clinic or at the Royal National Hospital for 
Rheumatic Diseases on telephone 01225 465941. Please keep this information sheet.
Thank you very much
Dr Ellie Korendowych and Dr Jaya Ravindran 
Research Fellows to Dr McHugh
Appendix 8.
RECRUITMENT FOR PSORIASIS AND ARTHRITIS STUDY
Dear Patient
You are invited to take part in a research project involving patients with psoriasis taking place 
at the Royal National Hospital for Rheumatic Diseases (RNHRD). About one in ien patients 
with psoriasis develop arthritis, although it is not clear why some do and others do not. The 
Research Team at the RNHRD think that genes may play an important role. Therefore, we 
are looking for people with psoriasis to assist us in investigating this area. This is purely 
voluntary and if you would prefer not to take part you do not have to give a reason and your 
future care will not be affected in any way.
The study takes place at the RNHRD, in Bath. In a one off appointment, at a time to suit you, 
a Doctor or Clinical Research Therapist will ask some questions about your psoriasis, 
examine your joints, nails and skin, and ask you to provide a blood sample and an X-Ray of 
your lower spine. The appointment is likely to take about an hour and reasonable transport 
costs can be reimbursed.
Further details are given in the information sheet provided.
If you are interested in taking part and would be happy for us to contact you, please fill in the 
detachable section at the bottom of this letter and return it in the stamped envelope provided. 
Alternatively, please contact Dr Ravindran or Jenny Lewis, members of the research team at 
the RNHRD on 01225 465941 extension 432 or extension 267.
Thank-you for taking the time to read this letter
Yours sincerely
Dr Linda McHugh 
General Practioner
I am / am not interested in taking part in the psoriasis and arthritis study












INFORMED CONSENT FORM FOR PATIENTS WITH PSORIASIS 
Name of research project: Markers of outcome in psoriatic arthritis
Have you read the patient information sheet ? Yes / No
Have you had an opportunity to ask questions and discuss this study ? Yes / No
Have you received satisfactory answers to all your questions ? Yes / No
Have you received enough information about the study ? Yes / No
Who have you spoken to ?
Do you understand that you are free to withdraw from the study :
• At any time
• Without having to give a reason
• Without affecting your future care Yes /No
Do you agree to take part in this study ? Yes/No
Signed Date
Name in block capitals
Signed ( Researcher) ____________  Date
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Appendix 10
SCREENING QUESTIONNAIRE FOR PATIENTS WITH PSORIASIS
1. How old were you when you first developed psoriasis ? ........................................
2. Are you under the care of a dermatologist ? Yes / No
If yes, who? .........................................
3. Does anyone else in your family have psoriasis ? Yes / No
If yes, who ? (please include brothers, sisters, parents, grandparents and children)
4. Does anyone in your family have arthritis ? Yes / No
If yes, who ? ..............................................................................................................
What type of arthritis do they have and do they have psoriasis ?................................
5. Have you ever had psoriasis affecting your nails (eg thickened yellow ridged nails, 
pitting of nails) Yes / No
6. Have you had any of the following problems with your joints that have lasted for more 
than a week? :
Swollen Joints Yes / No
Painful Joints Yes / No
Stiff Joints Yes / No
Back problems Yes / No
Neck problems Yes / No
If yes, tell us more..............................................................................................................
7. Have you ever seen your GP due to problems with your joints?
Yes / No
If yes, please tell us m ore...................................................................................................
8. Have you ever needed to take medication for your joints for longer than a week ?
Yes / No
If yes, please tell us m ore...................................................................................................
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